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Abstract 
 
Cord blood transplantation (CBT) for high-risk hematologic cancers is limited by 
the low numbers of immune cells in a single CB unit, leading to diminished 
graft-versus-leukemia effect. Although natural killer (NK) cells can mediate 
potent graft-versus-leukemia effect, and are the first reconstituting lymphocytes 
after transplantation, the receptor-ligand interactions mediating their cytotoxicity 
are not well understood.   
 
I first studied killer-cell immunoglobulin-like receptor (KIR) and HLA genotypes, 
NK phenotype and function for 110 CBT recipients to identify specific patterns of 
KIR-HLA interaction that might predict for CBT effectiveness.  I found that the 
donor genotype of HLA-C1-KIR2DL2/3 combined with KIR2DS2/3 to be an 
important predictor of disease control after CBT in patients with an HLA-C1/C1 
or HLA-C1/C2 background.  These findings suggest means to improve the 
clinical efficacy of NK cells in HLA-defined patient subgroups, especially those 
with HLA-C2 homozygosity. 
 
I then extended my studies to investigate the role of NK cells in the control of 
CMV reactivation, as cord blood grafts are known to be more susceptible to 
latent virus infection from lack of transfer of adaptive subsets unlike other graft 
sources.  I found that CB grafts expressing a NKG2C deletion allele possessed 
higher risk of CMV reactivation post CBT, with the risk significantly reduced with 
the presence of the wild type allele.  Results collectively suggested that the 
susceptibility of CBT recipients to CMV reactivation is determined by the NKG2C 
content of the infused CB units.  
 
Based on the current understanding of NK licensing/education, the most critical 
developmental process required for functional competence, I attempted to 
identify markers that distinguish between ‘licensed/educated’ and 
‘unlicensed/hyporesponsive’ NK cells.  I discovered differential adhesive 
properties between the two functionally distinct subsets, and also report the 
possible contribution of the adaptor protein CrkL in NK licensing/education. 
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Chapter 1 Introduction 
 
1.1.1 Natural killer cells 
               Natural killer (NK) cells are large granular lymphocytes which 
play a crucial role in the early innate immune response.  NK cells have potent 
effector function, and are capable of directly lysing malignant cells through 
release proinflammatory cytokines such as interferon (IFN)γ and tumor necrosis 
factor (TNF)α(1).  NK cells can also lyse target cells through the release of 
cytotoxic granules containing perforin and granzyme B disrupting the target cell 
membrane and inducing apoptosis, as through Fas-FasL and TRAIL-death 
receptor pathway as illustrated in (Fig. 1.1)(2).  Characterized by the 
expression of CD56 and absence of CD3, NK cells  are the first line of defense 
against virally-infected and malignant cells.  All NK cells express the 
intermediate-affinity heterodimeric IL-2 receptor (IL-2Rβγ) but only CD56 bright 
constitutively express the high affinity heterotrimeric IL-2 receptor (IL-2Rαβγ).  
Differential expression of CD56 can assign different roles to NK cells (Fig. 
1.2)(3).  For example, the CD56 bright subset responds better to soluble factors, 
whereas CD56 dim cells respond better to receptors that bind to ligands 
anchored on other cells.  CD56 dim and bright subsets differ in their expression 
profiles of chemokine, cytokine and homing receptors.  CD56 bright NK cells 
reside in secondary lymphoid organs, tonsils and inflammation sites and are 
equipped to rapidly respond to the cytokine milieu and relay the amplification of 
type 1 inflammatory response to the adaptive arm (4).  CD56 dim NK cells are 
specialized in the surveillance of the peripheral sites, and regarded as more 
mature and capable of responding to cellular targets without prior sensitization 
(5). 
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Fig. 1.1 Mechanism of NK cytotoxicity.  The process of NK cell mediated cell 
lysis resembles that of CD8+ cytotoxic T cells, and involves discrete regulated 
steps namely adhesion, immune synapse formation, granule polarization and 
exocytosis.  Upon the detection of a susceptible target, NK cells directly 
engage with the target by establishing an immune synapse.   Once 
successfully conjugated, NK cells redirect the cytotoxic granules towards the 
tumour cell release the contents into the intercellular cleft.  Cytotoxic granules 
consist of perforin which disrupts the target cell membrane and allows entry of 
granzymes A and B.  These serine proteases induces apoptosis of target cells 
through both caspase-dependent and-independent pathways.  Some NK cells 
particularly the CD56bright subsets can mediate Fas-Fas Ligand interaction, 
where ligation of Fas (member of TNF receptor family) with an intracytoplasmic 
“death domain” on the target cell can indirectly activate the caspase enzymatic 
cascade and ultimately lead to apoptosis.  Immature NK cells do not possess 
either of these mechanisms and instead mediate TRAIL-dependent cytotoxicity, 
where TRAIL receptors such as DR4 and DR5 similarly are ligated and induce 
apoptosis similarly to Fas. 
 
       Adapted from Smyth et al., 2002(2) 
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Fig. 1.2 Distinct subsets of Natural killer cells  NK cells are classified into 
two main subsets based on the intensity of CD56 expression on their surface, 
with each subset displaying opposing functions.  CD56dim NK cells represent 
the more mature subset, capable of efficient surveillance through release of 
cytotoxic granules.  CD56bright cells reside within the secondary lymphoid 
organs and can efficiently migrate to sites of inflammation.  Once activated 
CD56bright NK cells are capable of producing a wide array of cytokines, making 
them efficient regulators of the immune response. 
 
      Adapted from Orange et al., 2012(6) 
1.1.2 NK cell activation : “missing self” 
                   NK cells are constantly modulated by an array of 
inhibitory and activating signals transduced from a variety of receptors.  A key 
component which ensures the tolerance and safety of the host from NK cell 
activity, is the engagement of inhibitory receptors by the MHC class I molecules 
(7).  Engagement of these receptors provide antagonistic signals, allowing the 
autologous cells to be spared from NK cell attack.  The main inhibitory 
receptors include the killer cell immunoglobulin-like receptors (KIRs) which 
recognizes specific groups of HLA-A, B and C alleles.  Specifically, KIR2DL2 
and KIR2DL3 recognizes the HLA-C1 group, KIR2DL1 and KIR2DL2/3 (with 
lower affinity) recognize the HLA-C2 group, and KIR3DL1 recognizes several 
HLA-A and HLA-B with the Bw4 motif (8).  Other inhibitory receptors which 
recognize MHC class I molecules include the CD94 –NKG2A, which recognize 
 21 
the HLA-E group.  When MHC class I expression is down regulated as a result 
of stress e.g. from virus infection or tumour transformation, the inhibitory balance 
or tolerance is broken and the NK cell will subsequently exhibit cytotoxicity (9).  
This is the basis of “missing self” (Fig.3).  In addition, stimulatory ligands could 
be induced during events such as transformation or infection. Engagement of 
these ‘stress’ by activating receptors on NK cells, known as the induced-self 
recognition,  can overcome the constitutive inhibitory self signals.  provide NK 
cells with the maximal ability to discriminate between normal cells and 
transformed or infected target cells.  
 
Fig. 1.3 Concept of Missing-self recognition by NK cells.  The interaction of 
inhibitory receptors wih their cognate ligands including MHC class I proteins 
suppress NK cell responses under normal conditions. When interacting with 
target cells expressing ligands for both inhibitory and activating receptors, the 
outcome is determined by the cumulative balance of signals. The amount of 
activating and inhibitory ligands on the target cell, as well as the qualitative 
differences in the signals transduced, are modulated during immune responses 
by down-regulating inhibitory signals or up-regulating activating signals.  These 
qualitative changes in inhibitory and activating signals are detected by the 
combination of missing-self and induced-self recognition by the NK cells. 
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      Adapted from Lanier et al., 2005(10)  
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1.1.3 NK licensing 
                Inhibitory KIRs have activating counterparts with extensive 
homology in extracellular domains.  In order to ensure inhibitory dominance, 
the affinity of the inhibitory receptor for a ligand is often higher than that of its 
activating counterparts.  Hence the functional outcome of NK cells is 
determined by the ultimate imbalance between these inhibitory and activating 
signals. Other activating receptors include CD16, CD94/NKG2C, NKG2D, and 
the natural cytotoxicity receptors NKp30, NKp44, and NK46 (11).  However, 
missing self and engagement of activating receptors alone does not guarantee 
NK activation.  NK cells remain non-functional until they encounter and interact 
with their cognate HLA-ligands, and hence become “licensed”(12-14).  Once 
qualitatively calibrated with this tolerance threshold during development, NK 
cells acquire functional competence and are capable of monitoring other cells for 
the quality and quantity of HLA-class I expression.  As the KIR receptors and 
their cognate HLA-class I ligands are variable and segregated on different 
chromosomes, not all KIR expressing NK cell are subject to a functional 
ligand-receptor interaction (around 60%) (15).  Unlicensed NK cells remain 
hyporesponsive, and thus NK licensing is a fundamental process for the 
acquisition of functionality and also a checkpoint for self-tolerance (16).  The 
precise role of the pool of unlicensed NK cells is not known.  Several other 
models have been proposed to explain how NK cells may achieve tolerance, 
such as the dis-arming model.  In contrast to the proposed arming theory of 
initially hyporesponsive NK cells acquiring tolerance, the dis-arming models 
proposes that the function of autoaggressive NK cells is calibrated through 
cognate KIR-HLA class I interactions at the point of egress. NK cells that do not 
encounter their cognate ligand on targets will enter hyporesponsiveness, in a 
manner similar to B and T-cell anergy.  The tunable rheostat-model is the most 
recently proposed concept, which proposes that the arming and disarming 
models are not mutually exclusive. Instead, they suggest that NK cells can apply 
a combination of both models throughout their developmental stages and can 
modify their responsiveness according to their HLA-class I environment in a 
tunable manner (17, 18).  Currently the HLA-class I expressing cell types that 
interact with NK cell that are responsible for licensing are unknown, and they are 
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likely to be of both hematopoietic and non-hematopoietic origins.  In addition to 
this, it is now becoming apparent that NK cells can be licensed through 
interactions of HLA-class I on both neighboring cells (trans-binding) and on NK 
cells themselves (cis-interaction)(19, 20). 
 
Fig. 1.4 Current perspectives of NK licensing/education  NK cell licensing 
resembles T cell central selection and is presumed to occur in the bone marrow.  
NK cells expressing inhibitory receptors (KIR or NKG2A) that recognize self-HLA 
class I molecules acquire functional competence, and functional potential will 
increase in a qualitative manner with the number of interaction during 
development.  The greater the variety of self-recognizing inhibitory receptor 
expressed, the greater the functional output.  Despite the different proposed 
licensing models, they all agree that self KIR-expressing NK cells are functional 
whilst KIR negative or non-self KIR expressing NK cells are unresponsive. NK 
cells that do not express any self-recognizing inhibitory receptors, or expressing 
irrelevant KIRs for which the cognate ligand is not expressed in the individual, 
NK cells remain hyporesponsive and referred as anergic.  Even if these cells 
expressed activating receptors and were appropriately ligated, they will not 
respond due to the lack of licensing/education process.  The inhibitory 
receptors known to contribute to licensing are KIR2DL1, KIR2DL2/3, KIR3DL1, 
which recognizes HLA-C2, C1 and Bw4 respectively. 
 
                Adapted from Sun et al., 2011(21) 
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1.1.4 NK development  
                  NK cells originate primarily in the bone marrow (Fig. 1.5).  
The initial development pathways of NK and T cells are shared through the 
common lymphoid progenitor cells (CLP), initially with the expression of c-kit, 
IL-7 (CD127) receptors then committing to the NK cell lineage with the 
expression of IL-2 receptor (CD122)(22).  NK specific receptors are gradually 
and sequentially upregulated, namely CD94/NKG2A molecules whilst progenitor 
markers such as CD34, CD117 are gradually down regulated.  It was 
conventionally presumed that NK cells derived from hematopoietic precursors in 
the bone marrow circulate to distal sites and complete their maturation process 
in a uniform manner in secondary lymphoid organs.  However, recently it is 
becoming apparent that NK cell development is not necessarily a linear process 
and it is in fact much more sophisticated.  NK cells at various developmental 
stages can transit between tissues/organs via peripheral blood, and the 
developmental programming is greatly influenced by the unique 
microenvironments provided by the tissues/organs, leading to developmental 
heterogeneity and plasticity (1).  In addition to the lymph node which is 
considered as the predominant site of NK maturation, several other tissue type 
and organs have been reported to support NK cell differentiation.  Early NK 
progenitors have been observed to be seeding the liver once egress from the 
bone marrow, and fully complete their differentiation along the NK cell lineage.  
Hepatic NK cells which emerge are found to be more cytotoxic than peripheral 
blood NK cells, and also appear to comprise 30-40% of the hepatic lymphocytes.  
The uterus and decidua have also been shown to be abundant in NK cells during 
the first trimmest of pregnancy, where they show distinct characteristics (referred 
as uterine NK and decidual NK respectively) from peripheral blood NK cells and 
are specialized in tissue remodeling, neoangiogenesis, placental vascularization.  
NK precursors found in the uterus only differentiate into uNK cells and CD34+ 
precurors have also lost its multipotent phenotype, strongly suggesting the 
specificity of the uterus to support maturation of NK precursors into uNK cells.  
Hence although not all events are understood definitively, it must be recognized 
that NK cell lineage commitment and differentiation are not necessarily a linear 
process. 
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Fig. 1.5 Developmental intermediates of NK cell 
                 The traditional view of NK cell development is represented by 
a linear pathway from haematopoetic stem cells (HSCs) in the bone marrow to 
fully functional NK cells in the periphery. a) depicting the expression pattern of 
several molecular markers throughout the stages of NK cell maturation in 
humans and mice. NK cell precursors (NKPs) lack typical NK cell markers but 
give rise to NK cells. Immature NK cells express CD161 and natural killer group 
2, member D (NKG2D), as well as receptors required for growth and survival. 
NK cell education via self MHC class I molecules probably begins at the 
immature NK cell stage. b) Pseudo-mature and mature NK cells can traffic out of 
the bone marrow and populate the peripheral lymphoid organs (spleen, liver and 
lymph nodes) establishing tissue specific NK cells with distinct functional 
properties. NK cells can be activated following detection of missing or altered 
self MHC class I molecules or by an inflammatory environment.   
a) 
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          Adapted from Huntington et al., 2007(23) 
b) 
 
      Adapted from Yu et al., 2013(24) 
1.1.5 Inhibitory and activating KIR  
                The major class of self inhibitory receptors highlighted in the 
licensing section, such as killer cell immunoglobulin-like receptors (KIRs) and 
leukocyte immunoglobulin-like receptors (LILRs), are monomeric type I 
glycoproteins of the immunoglobulin superfamily, whereas others such as the 
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mouse Ly49 and human CD94-NKG2A receptors, are type II glycoproteins with 
a C-type lectin–like scaffold.   The KIR family or CD158 are members of the 
immunoglobulin superfamily that comprise 15 expressed receptors which can be 
either inhibitory or activating (Table.1.1)(25).  All KIR are type I transmembrane 
glycoproteins consisting of either two (KIR2D) or three (KIR3D) extracellular 
Ig-like domains, a stem region, a transmembrane region and a cytoplasmic tail. 
Depending on the length of the cytoplasmic tail, KIR can be subdivided into 
long-tailed and short-tailed receptors.  Generally long-tailed KIRs represent 
inhibitory and short-tailed KIRs are activating.   An exception is KIR2DL4, 
which has a long intracytoplasmic tail but also displays activating property, 
stimulating potent cytokine production.  Although diverse in their extracellular 
domains, these inhibitory NK receptors share a common signalling motif in their 
cytoplasmic regions called ITIM (immunoreceptor tyrosine-based inhibitory 
motifs)(26).  These ITIMs have a conserved V/I/LxYxxL/V sequence, which 
execute NK cell inhibition via recruitment of the protein tyrosine phosphatases 
SHP-1 and SHP-2, which prevents the phosphorylation of key activating adaptor 
protein Vav1 and terminates further activation down stream (fig. 1.6) (27).    
 
Fig. 1.6 Inhibitory signaling by KIR/NKG2A in NK cells. The model of 
Inhibitory signaling in NK cells is depicted. Binding of 	 -arrestin 2 to 
phosphorylated ITIM enhances the recruitment of SHP-1 and SHP-2 to 
phosphorylated ITIMs. The dephosphorylation of Vav1 by SHP-1 blocks its GEF 
activity and activation of Rac1. Phosphorylation of the adapter Crk by Abl, which 
is induced by inhibitory receptor engagement, results in disassembly of the Cbl–
Crk–C3G complex. Inhibition is dominant over activation because it occurs 
upstream of the actin-dependent clustering and phosphorylation of co-activation 
receptors. 
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       Adapted from Watzl et al. 2010,(28) 
 
Activating KIRs possess positively charged residues (mostly arginine) in the 
transmembrane region, facilitating the association with accessory molecules 
such as DAP12 or FcεRIγ (KIR2DL4) to induce NK cell activation. The exception, 
KIR2DL4 contains both ITIMs and a positively charged residue (lysine), which 
facilitates the association with FcεRIγ and the induction of activating signals.  
Many of the ligands for these activating KIRs remain unknown (Table. 1.1) 
Table.1.1 KIR nomenclature and their corresponding ligands 
 
 Adapted from IPD-KIR Database 
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1.1.6 KIR haplotypes and allelic polymorphisms 
               KIR genes are defined into two haplotypes, with the functionally 
relevant distinction being the difference in the number of activating receptors 
(Fig. 1.7).  Group A haplotype displays a fixed organization of mostly inhibitory 
KIR genes which recognizes HLA class I molecules as their ligands, with the 
exception of KIR2DS4 being the only activating KIR gene.  In contrast, group B 
haplotype is characterized by significantly more variable gene contents with a 
large proportion occupied by activating KIR with lower binding to HLA class I 
molecules or unknown ligands (29).  KIR genes can be subdivided into 
telomeric or centromeric depending on the locus, and sequence analysis reveals 
that allelic diversity of the centromeric region is predominantly found in 
haplotype A whilst the telomeric region is mostly in haplotype B (Fig. 1.7).  In 
addition to these haplotypic variations, KIR genes are further diversified by point 
mutations and homologous recombination which generates allelic 
polymorphisms.  Such allelic variability can greatly influence the ligand affinity 
and cell surface expression of the KIRs and hence contribute in providing 
phenotypic and functional diversity (30).  KIR3DL1, a well characterized and 
one of the most polymorphic KIR genes, has several allotype variants with 
distinct binding levels ranging over an order of magnitude with the following 
hierarchy; 3DL1*005<*007*<*001<*020*01502 (31).   
                Genetic and mapping studies reveal that despite all human 
population retaining both KIR A and B haplotypes, the distribution and relative 
frequencies widely vary between distinct ethnic groups and populations, 
implicating that a particular haplotype clearly evolves to become specialized for 
distinct and complementary functions under selective pressure such as 
encounter with pathogens (32).  In the Japanese population for instance, 
haplotype A dominates with approximately 80% frequency, whilst in the 
Caucasian population the distribution is relatively even (31).  KIR diversity 
appears to have been influenced by the driving force of reproduction, where 
haplotype B has been shown to give an evolutionary advantage such as 
improved placentation and lower risk of pre-eclampsia (33).    
                Recent studies have correlated KIR gene content with the risk 
of infection, autoimmunity, cancer and pregnancy-associated disorders (34).  
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Most importantly, KIR gene contents have also been implicated with clinical 
outcomes in the transplant setting, where the presence of activating haplotype B 
genes in the graft was shown to confer reduced rate of relapse in the allogeneic 
transplant settings (35).  
 
Fig. 1.7 KIR genomic region – haplotypes and allelic polymorphism 
                Human killer cell immunoglobulin-like receptor (KIR) genes 
are evenly distributed between the centromeric and telomeric regions of the KIR 
locus. Both regions have distinctive gene-content motifs.  The combination of 
the centromeric A1 and telomeric A1 motifs forms the KIR A haplotypes, which 
encodes inhibitory receptors for HLA-C1 (KIR2DL3) and HLA-C2 (KIR2DL1) in 
the centromeric region and inhibitory receptors for HLA-Bw4 (KIR3DL1) and 
HLA-A3/11 (KIR3DL2) in the telomeric region. KIR2DS4, which recognizes 
HLA-A3/11 and some C1- and C2-containing HLA-C molecules, is the activating 
receptor for the A haplotypes. The different A haplotypes all have an identical 
KIR gene content, but they vary by allelic polymorphisms. For each gene, the 
colours denote different alleles: the most frequent allele is shown in red, the next 
most frequent in yellow, and so on to green, blue and purple. 
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             Adapted from Parham et al., 2013(29) 
1.1.7 NK receptors  
NK cells do not respond through a single dominant antigen receptor as seen in T 
and B cells, but are instead tightly regulated through a vast array of germline 
encoded activating and inhibitory receptors collectively known as the NK 
receptors.  The majority of these NK cell receptor genes are found colocalized 
in the common region on human chromosome 12 called the NK complex (NKC), 
and do not demonstrate extensive polymorphism, as their corresponding ligands 
also show minimal allelic variation (11).  In addition to this, NK cells lack the 
ability to undergo DNA rearrangement to create receptor diversity.  However, 
the fact NK cell receptors are invariant and constitutively expressed on the 
majority of the cell population provides NK cells with greater flexibility in sensing 
and responding quickly to changes in the environment.  A limitation for the 
study of NK cell receptors has been that the ligands for several of the NK 
activation receptors have yet to be identified, particularly the NCR families.  
Previously regarded as NK cell-specific, NK receptors seem critical for 
recognition and deployment of the cytotoxic program, which has recently been 
reported in other innate lymphoid subsets such as CD8+ gamma-delta T cells 
(36).  It is now becoming apparent that in T cells, the expression of NK 
receptors is often confined to the effector or to ‘primed’ subset, e.g. CD8+ T cells 
(and some CD4+) strictly after conversion to effector or memory phenotype (37, 
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38).  In NK cells on the other hand, both in vivo and in vitro differentiation 
experiments have illustrated NK receptors to be expressed at an earlier stage 
than KIR expression, hence they are presumed not to be correlated with a 
licensed signature (22, 39).   
 
Fig. 1.8 NK cell receptors and ligand recognition.  The overview of the 
structurally characterized activating and inhibitory human NK receptors and their 
respective ligands, and the central activating receptors found on human NK cells 
is illustrated.  A schematic representation of the homodimer NKG2D, the 
natural cytotoxicity receptors, NKp30, NKp44, and NKp46, NKp80, NKp65, 
activating receptors 2B4, NTB-A, CRACC, DNAM-1, and the Fc receptor CD16 
with their corresponding ligands are listed. The associated cytoplasmic signaling 
molecules for these activating receptors which include DAP12, DAP10, and CD3
/FcRI and the specific transmembrane residues which facilitate their 
interaction are also shown. 
 
               Adapted from Watzl et al., 2012 (40)  
1.1.8 NK signaling 
                NK cells express a wide array of germ-line encoded activating 
receptors aimed to respondly rapidly towards a variety of targets, however 
ligation of a single activating receptor is insufficicient to induce a potent effector 
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response even in the absence of inhibitory signals (41).   With the exception of 
CD16, NK receptors require to or more simultaneous engagement of 
costimulatory or activating receptors in order to achieve an activation threshold 
(42).  Bryceson et al demonstrated the induction of potent cytotoxicity upon 
co-engagement of appropriate pair-wise antibody combinations observed 
simultaneously with a rise in intracellular Ca2+, but, with a significantly lower 
kinetics and slower responses compared to that elicited by CD16 (43).  
Perhaps this is a safety measure as this ensures that opsonized targets are 
processed through innate phagocytic activities.  Indeed CD16 is only acquired 
at very late stages of NK development, similar to the KIR.  Whereas single 
ligation of other receptors only induces minor elevations in Ca2+ and low target 
cell lysis, CD16 is the only receptor capable of inducing a response by itself.  
However, even when multiple co-receptors are simultaneously ligated, not all 
combination leads to induction of synergy or activation.  This requirement for 
specific synergistic combinations of activation receptors may serve as a 
safeguard to prevent unrestrained activation of NK cells and only intended 
targets are eliminated (28); i.e, the more potent the response, the less common 
the ligand.  In conjunction with this safeguard hypothesis, ligands for DNAM-1, 
CD2, NKG2D which are only capable of inducing a low response in 
combinations, are widely expressed.  Expression for ligands for 2B4 and 
NKp46 which induces a potent effector response upon co-engagement, are very 
restricted.  Initially NK activation and cytotoxic response was considered 
non-specific upon encounter with transformed or virus-infected cells, through the 
lack of self inhibitory receptors, but it is now clear that each activation receptor 
activates a defined distinct signaling pathway down stream despite the same 
outcomes (44). 
 
1.1.9 Haematopoietic Stem Cell Transplantation and impact of NK 
alloreactivity 
               Haematopoietic Stem Cell Transplantation (HSCT) is the only 
curative treatment for a number of haematological malignancies and bone 
marrow disorders.  Whilst potent graft-versus-leukemia (GVL) effects have led 
to the successful eradication of recipient malignant cells, the obstacle to the 
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success of this procedure has been the associated severe graft versus host 
disease (GvHD) caused by T cells in the graft (45).  When T cells are 
extensively depleted to prevent such outcome, NK cells are the first lymphocyte 
subset to reconstitute and can be detected in the peripheral blood as early as 30 
days post HSCT (46).  With potent effector functions of direct cell lysis and 
inflammatory cytokine production, donor NK cells are considered to be the 
crucial players in mediating a successful long-term GVL effect post HSCT (47).   
The pioneering work of Velardi et al (48) demonstrated donor-versus-recipient 
NK-cell alloreactivity to be capable of eliminating leukaemia relapse without 
increasing the risk of GVHD in HLA mismatched recipients, resulting in a new 
era in the exploitation of NK cells for cancer immunotherapy.  In these studies 
the authors compared the outcome of patients based on the NK-alloreactivity of 
the donors.  In patients with AML, transplantation from NK-alloreactive donors 
was associated with significantly lower relapse rate compared to 
non-NK-alloreactive donor (5 year relapse rate 0% vs. 75%; P=0.0008). These 
data ultimately led to several retrospective analyses of KIR ligand mismatch 
effect on outcome in the HLA-matched unrelated and matched sibling transplant 
settings. Whilst there were several large registry studies failing to show an 
increased GvL effect (49-51), others supported a GvL effect associated with a 
survival advantage (52-55). The conflicting data may be related to differences in 
the transplant conditioning protocols, patient populations, underlying diseases, 
graft composition, and post-transplant immunosuppressive regimens (56). 
Subsequent studies have shown that the accuracy of the prediction of relapse 
could be improved by taking into consideration the presence of inhibitory KIRs 
on the donor’s NK cells and the absence of corresponding KIR ligand in the 
recipient’s HLA repertoire (a receptor-ligand model) (57). 
More recently, specific activating KIR genes in donors were found to predict the 
risk of relapse following allogeneic transplantation for AML.  Patients with AML 
who received allografts from donors who were positive for KIR2DS1 had a lower 
risk of relapse (26.5%) than those with allografts from donors who were negative 
for KIR2DS1 (32.5%); P=0.02 (58).  Similar results have also been reported in 
the setting of matched sibling donor transplants; Patients with AML who received 
allografts from donors who were positive for KIR2DS1 had 4 times lower risk of 
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relapse than those who received a graft from KIR2DS1 negative donors (59).   
A limitation of many of these studies is that they do not take into account the 
effects of KIR licensing on NK function following allogeneic stem cell 
transplantation.  Although it is presumed that the acquisition of NK cell function 
is influenced by the HLA-Class I environment of the donor, murine studies 
suggest a greater degree of plasticity and indicate that NK cell responsiveness 
can also be influenced by the inhibitory input from the recipient (18, 60, 61).  
 
Fig. 1.9 Concept of NK alloreactivity in HSCT and infusion.  NK cells have 
been a promising target for immunotherapy in the treatment of cancer.  NK cells 
can be transferred into the patient through HSCT where donor HSC progenitors 
develop into alloreactive NK cells in the patient (above), or alternatively donor 
NK can be expanded ex vivo and infused directly into the patient (below).  Both 
approach anticipate in a potent GvL response by enhancing the “missing-self” 
effect, by deliberately creating a partial mismatch of the donor inhibitory KIR and 
patient HLA-ligand.  Despite healthy patient cells lacking the compatible HLA 
molecules to inhibit the donor NK cells, they also lack the ligands for activating 
receptors and hence maintain tolerance.  However, whilst residual tumour cells 
also lack the compatible HLA they express the activating receptor ligands (often 
a signature of transformed cells, e.g. MIC-A/B).  This leads to selective 
elimination and activation towards only patient tumour cells. 
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            Adapted from Vivier et al., 2012(62) 
 
Fig. 1.10 Roles of NK cells in HSCT.  Donor NK cells mediate a potent GvL 
response towards patient tumour cells through direct cell lysis, but in a strictly 
regulated and selective manner without inducing GvHD.  Donor NK cells does 
not induce GvHD due to their strict requirement of inhibitory and activating signal 
imbalance, which even in a KIR-HLA mismatch setting will not harm normal 
tissues.  As the earlier subset to occupy the bone marrow, NK cells play a 
crucial role in preparing the hematopoietic niche for the reconstitution of the 
donor hematopoietic cells.  They do so by providing a milieu of supportive 
cytokines, whilst also selectively killing recipient hematopoietic cells to prevent 
graft rejection.  In addition, NK cells selectively kill reactive recipient T cells and 
recipient APCs to prevent further T-cell priming, which collectively leads to the 
suppression of GvHD.    
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                Adapted from Moretta et al., 2002(63) 
1.2.1  Umbilical cord blood as an emerging graft source 
                Cord blood (CB) is a rich source of hematopoietic stem and 
progenitor cells and is being increasingly used as graft source for hematopoietic 
stem cell transplantation (HSCT).(64)  Despite the naïve nature of CB 
T-lymphocytes,(65, 66) the risk of relapse is lower after CB transplantation 
(CBT) compared with other donor sources.(67-70) As NK cells are the first 
lymphocytes to reconstitute after HSCT(71-77) and their role in both innate and 
adaptive immunity is well characterized,(3, 78, 79)  it is likely that they play a 
crucial role in protection against early disease relapse.  Cord blood offers 
unique advantages, many of which are directly applicable to NK cell directed 
alloreactivity. The ease of collection of CB and cryopreservation make them 
readily available as off-the-shelf source for NK cell immunotherapy.(80, 81) 
Besides, a greater degree of HLA mismatch is well tolerated after CBT resulting 
in less than expected risk GVHD with comparable outcomes in contrast to other 
graft sources.(70, 82-87) Also, due to almost a log less T-cells in CB than other 
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graft sources, (82, 84, 88-90) most of which are naïve,(91-93) minimizes the risk 
of GVHD.(82, 84, 87) More importantly, NK cell reconstitution after CBT is faster 
and superior than that after PB HSCT.(45, 94) One study showed that the 
absolute numbers of CD56+CD16+ NK cells were significantly higher after 
double unit CBT (DCBT) for up to two years compared with filgrastim-mobilized 
unrelated donor PB HSCT.(74) Moreover, CB contains certain unique cell 
populations, which may be NK-cell progenitors and are either absent or present 
in minute numbers in PB.(95-101) These cells have a potential to differentiate 
into NK cells after ex vivo stimulation with cytokines, including IL-2, (100) IL-15 
and/or FLT-3 ligand.(95, 99, 100) Data also suggest that CB CD56bright NK cells 
(but not CB T-cells) produce significantly more IFN-ϒ after stimulation with IL-12 
and IL-18 compared with PB NK cells.(93) This may compensate for functionally 
naïve CB T-cells – thus also contributing to lower risk of GVHD while maintaining 
the crucial GVL effect. The expression of CD69 (an activation marker), is 
increased appreciably in CB NK cells, but not in PB NK cells, after stimulation 
with IL-12 and IL-18.(93) What’s more, the expression of CXCR4, which is a 
bone marrow homing receptor on NK cells, is significantly higher in CB CD56bright 
and CD56dim NK cells compared with their PB counterparts.(102) Therefore, 
infused CB NK cells may have better bone marrow homing potential, which is 
the principle site of many hematological diseases. 
In addition to the role of NK cells in CBT, the use of ex vivo purified and activated 
CB NK cells is also being explored for adoptive immunotherapy. Although 
numerous studies have been conducted using autologous or allogeneic (PB or 
BM) NK cells infusions (103-105), no clinical study to date has report on the use 
CB NK cells. A handful of clinical trials to evaluate the feasibility, safety and 
efficacy of CB NK cell adoptive immunotherapy in transplant and non-transplant 
settings are currently underway 
 
Fig. 1.11 Concept of cord blood transplantation 
Cord blood transplant (CBT) has extended access to hematopoietic stem cell 
transplantation (HSCT) for many patients who lack an HLA-matched donor, 
especially those from racial and ethnic minorities. Despite its many advantages, 
including immediate availability and ease of access, transplantation with a single 
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unit of umbilical cord blood (UCB) is often associated with delayed engraftment 
and immune reconstitution due to a limited number of haematopoietic stem cells 
(HSCs) in a single CB unit. Engraftment can be enhanced by the addition of a 
second unit of UCB, or by the addition of ex vivo-expanded HSCs from another 
unit of UCB or from a haploidentical adult haematopoietic donor graft.  From the 
perspective of NK cell development, the potential three way KIR-L interactions 
among the recipient and the two CB grafts further complicates the outcome.  It 
is hypothesized that NK cells from the “dominant” CB unit contribute to the 
beneficial NK alloreactivity, but the role of NK cells in the non-dominant CB unit 
and their influence in mediating donor-vs-recipient and graft-vs-graft 
alloreactivity is not clear. 
 
Adapted from Li et al, 2012 (106) 
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1.2.2 Umbilical cord blood licensing 
Although the context of licensing has been studied in the setting of HSCT, many 
questions remain unanswered and in particular there are minimal data on cord 
blood NK cell licensing.  The study by Schönberg et al, demonstrating a biased 
functional enhancement in self-HLA class I recognition by NK cells in neonates 
is the only publication to date to examine the licensing status of cord blood NK 
cells (107).  Currently there are no established in vitro functional assays to 
study KIR-dependent regulation of NK cells and their licensing status in cord 
blood.  Phenotypically, cord blood NK cells represent an immature phenotype, 
very closely resembling the developmental intermediate stage 4 NK cells with a 
high proportion of the CD56bright bright population, along with higher 
expression of inhibitory receptors associated with an early developmental stage 
such as NKG2A (102, 108).   
 
1.3.1  Adaptive memory features of NK cells 
               Originally NK cells were considered as a short-lived, innate 
immune subset capable of inducing rapid responses against virally infected or 
malignant cells.  Recent studies have introduced the concept of immunological 
memory by NK cells, defined by three main observations: (i) antigen-specific NK 
memory cells induced by MCMV infection; (ii) NK memory cells induced by 
exposure to cytokines alone; and (iii) liver-restricted NK memory cells with highly 
antigen-specific recall responses e.g. hapten.(109). 
 
Fig. 1.12 Adaptive memory pathway of NK cells.   
NK cells can take one of three paths towards becoming a memory cell. In the 
mouse, murine cytomegalovirus (MCMV)-induced NK memory cells are 
generated after the cognate recognition of the m157 MCMV protein on infected 
cells by the activating Ly49H receptor. Memory generation requires interleukin 
(IL)-12 and NK cell signaling through the IL-12 receptor. Additional 
co-stimulatory signals by other cytokines and/or adhesion molecules might also 
be required.  The human equivalent of m157 mouse protein has not yet been 
identified. However, the observation that the expression of the activating NKG2C 
receptor is increased in HSCT patients following CMV reactivation supports the 
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existence of memory NK cells in human.  Exposure to IL-12, IL-15, and IL-18 
can result in the generation of cytokine- induced memory NK cells. Sensitization 
with antigen is not required in this model. Liver-restricted memory NK cells are 
presumed to be sensitized with haptens or specific antigens, in conjunction with 
chemokine CXC ligand (CXCL)16, generating liver-restricted memory NK cells. 
The precursors might be selected by the cognate recognition of hapten-modified 
self-proteins or foreign antigens, and develop into memory NK cells. Receptors 
responsible for the antigen specificity have not been identified. 
 
Adapted from Trends Immunol 2013, Lanier 
 
The most extensively studied of NK memory has been in the context of CMV 
reactivation (110).  CMV reactivation is a significant cause for morbidity and 
mortality in patients after hematopoietic cell transplantation (111).  With 
advancements in detection and strict graft selection criteria, the incidence of 
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CMV disease post HSCT has significantly reduced; however, many 
infection-related complications remain and CMV-related mortality is not 
uncommon.  Interestingly, a number of studies have reported an association 
between CMV reactivation and improved relapse-free survival in patients with 
AML, suggesting that under certain conditions, CMV reactivation may actually 
be beneficial to the patient.  The established perception to date has been that 
any antiviral activity post transplants is derived from the donor T cell repertoire 
(112), but the detailed mechanism on the unexpected beneficial effect of CMV 
reactivation on clinical outcome remains unclear.  Anti-leukemic effect 
mediated by CMV reactivation was mostly confirmed in myeloblative 
conditioning and particularly profound effects observed in AML patients, of which 
known to be particularly susceptible to alloreactive NK cells in a partial KIR 
mismatch setting (113).  Positive clinical outcomes have also been reported in 
cohorts of other diseases such as chronic myeloid leukemia, acute 
lymphoblastic leukemia and lymphoma where T –cell depleted grafts have been 
used (114).  Collectively these data highlights the possible importance of NK 
cells in this unexpected protective effect post CMV reactivation, rather than the 
conventional graft-T cell mediated protection. 
                A unique phenomenon reported within the CMV reactivated 
patient group is the robust expansion of NK cells expressing the activating 
NKG2C receptor (115).  Compared to healthy controls, NKG2C+ NK cells are 
also found at a higher frequency in CMV-seropositive individuals (116).  
Together with demonstration that NKG2C+ NK cells expand when co-cultured 
with CMV-infected fibroblasts in vitro (117), and identical observations reported 
in patients infected with other virus studies such as hantavirus (118) and 
chikungya virus (119), there is growing evidence that NKG2C+ NK cells may be 
virus-specific.  Reconstituting NKG2C+ NK cells post HCT have been detected 
as early as 2 weeks post transplant and also possess enhanced effector 
functions along with a mature differentiated phenotype, as well as potentially 
transferable adaptive properties (115, 120, 121).  Interestingly, several studies 
have also reported the association between CMV reactivation and protection 
against  disease relapse after cord blood transplant patients (122).  Cord 
blood being very rich in hematopoietic stem cell progenitors are increasing being 
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used as a promising alternative graft source.  The fact that CMV-associated 
protection against relapse is also seen in cord blood recipients eliminates the 
possibility of passive immunity provided solely by CMV-specific T cells since 
cord blood T cells are immunologically naïve.  As the first lymphocyte subset to 
be detected post transplant, it is likely that NK cells are important candidates in 
mediating anti-tumour response in CMV reactivated patients, although the 
detailed mechanism has not been investigated to date.  A major obstacle for 
such investigations is related to the fact that the viral ligands for NKG2C possibly 
are not known.   Based on structural studies, it has been revealed that HLA-E, 
a MHC class I molecule ubiquitously expressed on most peripheral cell types to 
be a stimulating ligand for NKG2C.  HLA-E is one of many stress-induced NK 
receptor ligands that is upregulated on virus-infected cells. HLA-E is also 
upregulated on cancerous cells in many haematological malignancies, as 
upregulation of HLA-E by leukemic cells is an efficient mechanism for evasion of 
T cell mediated cytotoxicity (123).  It is conceivable that NKG2C+ NK cells 
provide a strong GvL effect through the specific elimination of HLA-E+ leukemic 
cells.  Others have suggested a role for CMV infection in relapse protection that 
is independent of NKG2C.  Moretta et al reported that CMV reactivation is 
associated with acceleration in NK development and reconstitution (124).   As 
CMV infection accelerates the maturation of reconstituting NK cells, the earlier 
emergence of highly differentiated effector NK cells could be responsible for the 
prevention of relapse and lower incidence of infection. 
 
In summary, post-DUCBT patients provide a unique model to study the 
development and reconstitution of NK cells in vivo, whilst also allowing the 
evaluation of emerging memory NK cells against CMV. 
Thus, to exploit the immunological reactivity of NK cells to improve the response 
to CBT, we will need to have a better understanding of the biologic mechanisms 
involved in the observed effects of KIR-HLA interactions.  
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I hypothesize that NK cells play a significant role in protection against relapse 
after cord blood transplantation and that specific patterns of KIR-HLA interaction 
will determine the risk of relapse and the status of NK licensing post CBT. 
 
1.4 Thesis Aims; 
 
1. To determine donor and recipient KIR-HLA ligand interactions with 
prognostic importance in the post-CBT setting and their effect on the 
reconstituting KIR repertoire. 
 
2. To determine the role of NK cells in protection against CMV reactivation 
after cord blood transplantation. 
 
3. To understand the mechanisms of cord blood NK licensing. 
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Chapter 2    Materials and Methods 
 
2.1 Processing, freezing and thawing PBMC 
 
2.1.1 Isolation of PBMC from healthy donors and patients with 
haematological malignancies undergoing cord blood transplantation 
Fresh whole blood from healthy volunteers and patients with haematological 
malignancies undergoing cord blood transplantation were collected in K2 
EDTA-treated 10ml BD vacutainer blood collection tubes (BD Hemogard, 
cat#366643). In some experiments requiring large numbers of mononuclear 
cells, buffy coat was purchased from the Gulf Coast Regional Blood Center 
(Houston, TX, USA).  All samples were processed within 2 hours of 
collection/receipt and peripheral blood mononuclear cells (PBMCs) isolated 
using density gradient technique (Lymphoprep).   Briefly, blood samples were 
diluted 1:1 with 1x PBS medium (Fisher Scientific, cat# SH3025601) to make a 
homogenous solution and  30ml of this diluted blood was gently layered over 
15ml of Lymphoprep solution (Axis-shields, cat# 1114544), achieving a 2:1 
sample to lymphoprep ratio.  Without disturbing the layers the samples were 
immediately transferred to a centrifuge where they were spun for 30 minutes at 
1800rpm at 21Co on medium acceleration/0 or minimum brake settings.  Once 
completed, the mononuclear cell layer was carefully collected with a sterile 
transfer pipette and washed twice in PBS solution for 10 minutes at 1400rpm at 
21Co.  The cell pellet was then treated with 1x BD lysing buffer (BD Biosciences, 
cat#555899) for 7 minutes in the dark at room temperature to remove any 
residual erythrocytes.  After the incubation was completed the sample was 
briefly centrifuged at 1400rpm for 3 minutes to aspirate the lysing buffer, which 
was then further washed twice in PBS for 10 minutes at 1400 rpm.  The 
mononuclear cells were resuspended in 10ml complete SCGM medium (Cell 
Genix, cat#20802) supplemented with 10% heat inactivated FBS (Fisher 
scientific, cat# SH3007103HI), 1% Pen Strep (Life Technologies, 
cat#15140-122) and counted for viability. 
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2.1.2 Isolation of cord blood mononuclear cells (CBMC)  
Cord blood units for research were provided by the M. D. Anderson Cord Blood 
Bank and obtained under an institutional review board (IRB)-approved protocol.  
The density gradient technique was used to isolate CBMC following the  same 
protocol as that described in the previous section for PBMCs. The only 
difference was the use of Histopaque solution (Sigma-Aldrich, cat#10771) 
instead of Lymphoprep as the density gradient media. Centrifuge settings, 
subsequent washes, lysis treatments and dilutions were performed exactly as 
described for PBMC processing. 
 
2.1.3 Cell Viability and counting 
Viability assessment and cell counting were performed by trypan blue 
immediately after isolation of mononuclear cells (Sigma Aldrich, cat# T8154) 
exclusion.  Cell volume was diluted 1:1 with trypan blue solution and a viable 
cell count was performed on a standard haemocytometer.  Sufficient number of 
cells required for immediate analysis was removed, whilst any remaining cells 
were cryopreserved and stored for later use. 
2.1.4 Freezing:  PBMCs/CBMCs were resuspended in cell freezing media 
DMSO x1 (Sigma-Aldrich, cat#C6164) on ice at a concentration of 5x106 cells/ml.  
The cell suspension was quickly aliquoted into cryovials on ice and transferred 
into a pre-chilled controlled freezing-rate Nalgene box (Fisher Scientific, 
cat#5100-0001), which was stored in -80Co overnight.  Cryovials were then 
transferred into liquid nitrogen. 
2.1.5 Thawing: Cell vials were removed from liquid nitrogen or -80Co freezer 
and placed on ice.  Vials were quick-thawed in a 37ºC water-bath and 
immediately transferred to 15ml of pre-warmed complete SCGM medium 
supplemented with 10% heat inactivated FBS, 1% Pen Strep and 50,000 unit 
DNase I (EMD Millipore, cat#260913).   Cells were washed at 1400 rpm for 10 
minutes and resuspended in 10 ml complete media for counting and viability 
assessment.  Following freeze-thaw procedure, the yield of viable cells ranged 
between 80-95%.  Cells were then adjusted to a concentration of 2 x106/ml 
before being plated out in 24 well plates and rested overnight at 37ºC, 5% CO2 
prior to experiments.   
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2.2 Target cell lines for NK cell functional studies : maintenance and 
culture conditions 
K562 is an erythroleukaemia cell line obtained from a chronic myeloid leukaemia 
patient in blast crisis (125).  It is useful as a target for NK cell functional studies 
as it does not express HLA class I molecules and therefore has no ligands for 
the inhibitory killer immunoglobulin receptors (KIRs).  
721.221 is an EBV-transformed B lymphoblastoid cell line which also is 
commonly used for NK cell functional assays due to its HLA-class I-deficient 
properties (126).  In addition to the wild type my study utilized the following 
clonal HLA class I transfected variants (bold indicating the HLA-Class I molecule 
being expressed); 721.221-AEH (HLA-E), 721.221-Cw*0702 (C1), 
721.221-Cw*0401(C2), 721.221-B*5801(Bw4)(127).  The cell lines were a kind 
gift from Dr. CJ Denman of MD Anderson Cancer Center.  
All cell lines were cultured in RPMI, supplemented with 10% heat inactivated 
FBS, 1% Penstrep, 1% L-Glutamine at 37Co / 5% CO2.  New cultures were 
initiated at 1 x106 viable cells/ml in T25 cm3 flasks and scaled up to T75 cm3 
flasks depending on cell count with medium renewal every 2 days.  No cell lines 
were cultured for more than 2 weeks from a single batch regardless of quality (to 
prevent HLA class I up regulation following prolonged culture). 
The surface expression of HLA class I on the cultured cell lines was assessed 
prior to functional assays by flow-cytometry.  Briefly, cells were surface-stained 
for 15 minutes in the dark with either 5µl PE HLA-E (Biolegend, clone 3D12) or 
5µl APC HLA-ABC (BD biosciences, clone DX17).  Transfected variants were 
confirmed to have >95% expression of the relevant HLA class I, whilst the 
expression of HLA class I on the parental 721.221 and K562 cell lines was 
confirmed to be < 5%  
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2.3 Flow cytometry  
All data acquisition for multicolour flow cytometry assays were performed on a 
BD LSR Fortessa analyser equipped with 4 lasers capable of detecting up to 17 
fluorescent signals.  Detailed configurations are as follows; Violet 405nm laser 
(7 colours), Blue 488nm laser (2 colours), Yellow-Green 561nm laser (5 colours) 
and Red 640nm laser (3 colours).   
A minimum event of 2,000,000 (or the entire sample if the count did not suffice) 
NK cells was acquired.  Data were analysed using FlowJoTM software (Treestar, 
San Carlos, CA). 
 
2.3.1 Development of a functional NK assay 
In order to dissect the developmental differences in functional competence 
(licensing/education) of NK cells, a reliable and reproducible assay to evaluate 
NK function was required.  Flow cytometry is a powerful tool capable of 
providing detection of multiple parameters, both phenotypic and functional, and 
hence was selected as the main component of this study.  The panel initially 
consisted of 5 colours, CD56-BV605 and CD3-APC-Cy7 for NK cell identification 
within bulk PBMC populations, and CD107a-PE-CF594, IFNγ-V450 and 
TNFα-PE-Cy7 as the parameters to assess effector function.  NK cells showed 
a potent response to cellular targets lacking self HLA-class I, as illustrated in Fig. 
2.1.  K562, a HLA class I deficient leukemia cell line, is a highly reliable cell line 
for NK functional assays due to this reason.  In addition to cellular targets, PMA 
and ionomycin were used as a positive control in all assays.  
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Fig. 2.1   Functional evaluation of NK cells towards HLA class I deficient 
K562 targets.  Co-culturing K562 cell lines in bulk PBMC assays induced 
functional response specifically in NK cells whilst CD3+ T cells remained 
unresponsive, demonstrating the suitability of K562 in NK cell functional assays. 
 
In contrast, PMA and ionomycin, a potent PKC activator and inducer Ca2+ influx 
is capable of activating both NK cells and T cells, as they bypass any surface 
receptor engagement requirements and activate the common MAP Kinase 
pathway associated with effector function. 
 
2.3.2 Immunophenotyping : Standard NK receptor functional assay       
                As a means to familiarize further with the techniques of flow 
cytometry and to explore the differential expression of various NK receptors, I 
designed a 13-colour panel capable of simultaneously detecting surface 
receptor expression and functional properties of NK cells.   PBMC or purified 
NK cells were resuspended in culture media at a concentration of 1x106/ml and 
distributed into a 96 well flat bottom plate, in a volume of 200µl per well.  To 
assess NK cell effector function, 1x105 target K562 cells were added to each wel 
l (final E:T ratio of 10:1). Cells were stimulated with 0.05µg/ml PMA and 
1.25µg/ml ionomycin (positive control) or cultured alone (negative control).   To 
each well the followings were added: 10 µl BFA, 5 µL diluted monensin (BD 
GolgiStopTM Cat#554724; 700 µL per vial) (diluted 1:10, ie  5µl stock : 45µl 
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PBS) and 2µl CD107a PE-CF594 (clone H4A3, BD Biosciences).  The plates 
were then incubated for 5 hours at 37C°.  Cells were then harvested and 
transferred to FACS tubes and washed twice in PBS.  Detailed measurements 
of antibodies to be used are summarized in Table. 2.1.  Cells were stained with 
live/dead aqua marker (Invitrogen) in the dark at RT for 20-30mins and washed 
with PBS.  Surface staining was performed using an antibody cocktail including 
the following mAbs; CD3-APC-Cy7 (clone SK7), CD56- BV605 (clone HCD56), 
CD16-BV650 (clone 3G8), NKG2D-PE (clone 1D11), NKp30-Biotin (clone 
P30-15) (Biolegend), NKG2C-APC (clone 134591) PAN KIR- FITC (clone 
180704)(R&D), NKG2A-PE-Cy7 (clone Z199, Beckman coulter), 
NKp44-PerCP-eflour710 (clone  44.189,  eBioscience), NKp46-BV711 (clone 
9E2/Nkp46, BD Bioscience).  Cells were incubated for 20 min at RT in the dark, 
washed with 2 mL PBS then stained with secondary antibody Qdot800 
Streptavidin (Invitrogen) in the dark for a further 20 minutes.  Upon completion 
of the incubation period, cells were washed with 2 mL PBS and fixed and 
permeabilized using the BD FACS lysing solution Cat# 349202 [diluted 1:10 in 
dH20].  After incubation for 10 minutes, cells were washed and stained with 
IFNγ-V450 (clone B27) and TNFa-A700 (clone Mab11), for 30 min in the dark.   
Cells were washed in 2ml PBS at 2000 rpm and analysed on the flow cytometer. 
All wash settings for flow experiments (FACS tubes) were set at 2000 rpm for 5 
minutes unless stated otherwise. 
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Table. 2.1  Antibody description and full product details included in 
standard NK receptor panel 
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD56 Brilliant Violet 605 HCD56 Biolegend 1.25 
CD3 APC-Cy7 SK7 Biolegend 1.25 
CD16 Brilliant Violet 650 3G8 Biolegend 0.5 
NKG2A PE-Cy7 Z199 Beckman Coulter 5 
NKG2D PE 1D11 eBioscience 1.25 
NKG2C APC 134591 R&D 20 
NKp30 Biotin/ 
Streptavidin- 
Qdot800 
P30-15 Biolegend/ 
Life Technologies 
10 / 0.25 
NKp44 PerCP-efluor 710 44.189 eBioscience 1.25 
NKp46 Brilliant Violet 711 9E2/Nkp46 BD Bioscience 1.25 
PAN KIR FITC 180704 FAB1848F 5 
CD107a PE-CF594 H4A3 BD Bioscience 0.5 
IFNγ V450 B27 BD Bioscience 1.25 
TNFα Alexa Fluor 700 MAb11 Biolegend 1.25 
Live/Dead 
stain 
Aqua NA Life Technologies 0.5 
 
2.3.3 Functional Assessment: NK licensing panel    
              Previous studies have reported that there no single surface 
marker is capable of distinguishing between licensed and unlicensed NK 
subsets(128).  The licensing status of NK cells can only be determined post 
activation through their differential functional capacity.   Hence an 11-colour 
licensing panel as described in Table. 2.2 was designed to evaluate and identify 
the licensed and unlicensed NK cell subsets.  This included functional readouts 
in parallel with 3 main KIRs associated with licensing (KIR2DL1, KIR2DL2/3 and 
KIR3DL1), the self-HLA class I recognizing inhibitory receptors.   In addition to 
the K562 cell line, the 721.221 wild type cell line and 721.221-HLA class I 
expressing variants were also used as targets, an approach adapted from Yu et 
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al(129).  Briefly, PBMC or purified NK cells were resuspended in culture media 
at a concentration of 1x106/ml and distributed into a 96 well flat bottom plate, in a 
volume of 200µl per well.  A total of 8 conditions were prepared as follows;  
 
1) Unstimulated (negative control/cultured alone/no target)  
2) K562 (HLA class I deficient)  
3) 721.221 (HLA class I deficient) 
4) 721.221-AEH (HLA-E-expressing),  
5) 721.221-Cw*0702 (C1-expressing)  
6) 721.221-Cw*0401(C2-expressing)  
7) 721.221-B*5801(Bw4-expressing)  
8) PMA/Ionomycin (positive control).   
 
Target cell lines were distributed at 1x105 per well, and positive control wells 
were stimulated with 0.05µg/ml PMA and 1.25µg/ml ionomycin (positive control).   
To each well the followings were added: 10 µl BFA, 5 µL diluted monensin (BD 
GolgiStopTM Cat#554724; 700 µL per vial) (diluted 1:10, ie  5µl stock : 45µl 
PBS) and 2µl CD107a PE-CF594 (clone H4A3, BD Biosciences).  The plates 
were then incubated for 5 hours at 37C°.  Cells were then harvested and 
transferred to FACS tubes and washed twice in PBS.  Detailed measurements 
of antibodies to be used are summarized in Table. 2.2.  Cells were stained with 
live/dead aqua marker (Invitrogen) in the dark at RT for 20-30 mins and washed 
with PBS.  Surface staining was performed using an antibody cocktail including 
the following mAbs; CD3-APC-Cy7 (clone SK7), CD56- BV605 (clone HCD56), 
KIR3DL1-AlexaFluor700 (clone DX9, Biolegend), NKG2A-PE (clone REA110), 
PAN-KIR-APC (clone NKVSF1, Miltenyi Biotec), KIR2DL2/2DL3/2DS2-FITC 
(clone CH-L, BD Biosciences) and KIR2DL1/2DS1/2DS3/2DS5-PerCP-CY5.5 
(clone HP-MA4, eBioscience).  Upon completion of the incubation period of 20 
minutes in the dark, cells were washed with 2 mL PBS once and fixed and 
permeabilized using the BD FACS lysing solution Cat# 349202 [diluted 1:10 in 
dH20].  After incubation for 10 minutes, cells were washed and stained with 
IFNγ-V450 (clone B27) and TNFa-A700 (clone Mab11), for 30 min in the dark.   
Cells were washed in 2ml PBS at 2000 rpm and analysed on the flow cytometer. 
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All wash settings for flow experiments (FACS tubes) were set at 2000 rpm for 5 
minutes unless stated otherwise. 
 
Table. 2.2 Antibody description and full product details included in NK 
licensing panel 
 
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD56 Brilliant Violet 605 HCD56 Biolegend 1.25 
CD3 APC-Cy7 SK7 Biolegend 1.25 
NKG2A PE REA110 Miltenyi Biotec 5 
KIR2DL1/2DS1/
2DS3/2DS5 
PerCP-Cy5.5 HP-MA4 eBioscience 1.25 
KIR2DL2/2DL3/
2DS2 
FITC CH-L BD Bioscience 5 
KIR3DL1 Alexa Fluor 700 DX9 Biolegend 0.5 
KIR2D APC NKVSF1 Miltenyi Biotec 2.5 
CD107a PE-CF594 H4A3 BD Bioscience 0.5 
IFNγ V450 B27 BD Bioscience 1.25 
TNFα PE-Cy7 MAb11 BD Bioscience 1.25 
Live/Dead stain Aqua NA Life Technologies 0.5 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
Fig. 2.2  Gating strategy of NK licensing panel. Exclusion gating of 
single-cell flow cytometric analysis to study the functional capacity if NK cells 
expressing inhibitory KIR for self HLA class I. PBMCs were incubated with no 
target or K562, 721.221 cells and stained for KIRs, including KIR2DL2/DL3, 
KIR2DL1 and KIR3DL1. The effector function of NK cells, including CD107a 
degranulation, IFN-γ and TNF-α production is measured in single KIR 
expressing NK cells following 6-hour coculture with targets. Directed analysis of 
NK cells exclusively expressing inhibitory KIRs was performed as illustrated for 
KIR2L1, KIR2DL2/3 and KIR3DL1. For instance, to analyze single 
KIR2DL1-expressing NK cells, gating for CD3-CD56+ NK cells was followed by 
the exclusion of KIR3DL1+ and KIR2DL2/DL3+ cells. CD107a degranulation, 
IFN-γ and TNF-α production were then measured in single KIR2DL1-expressing 
NK cell population following coincubation with 721.221 cells. Gating ancestry; 
Lymphocyte gate (SSC-A vs FSC-A) -> Singlet (SSC-A vs SSC-H) -> Viable 
cells (SSC v Viable dye –ve) - > CD56+CD3- > KIR2DL1+ -> 
KIR2FL2/3-veKIR3DL1-ve -> NKG2A-ve -> CD107a +ve or IFN + or TNF+. 
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By individually gating on the single KIRs as described in Fig. 2.2, NK cells could 
be broken down into several subsets where the licensing status could be 
predicted based on the KIR expression and HLA genotyping of the individual.  
Whilst K562 and 721.221 are classical NK functional targets activating the cells 
through ‘missing-self’ mechanisms, the HLA class I expressing variants silenced 
the NK subsets expressing the corresponding inhibitory KIRs, but responded to 
NK cells expressing non-self HLA class I.  By using an exclusion gating 
strategy as illustrated in Fig. 2.2, characterization of NK cells with an “exclusive 
KIR expression” allowed segregation and simultaneous analysis of NK subsets 
with different inhibitory receptor repertoires, which provided information on how 
this could affect functional output (Fig. 2.3a).   Such use of the HLA class I 
expressing variants demonstrated the specificity of the receptor ligand 
interaction of inhibitory KIRs, resulting in differential functional output for each 
cell line targets (Fig. 2.3b).  Challenging NK cells towards self and non-self 
HLA-class I expressing cell lines recapitulates the various outcomes in HSC 
transplant recipients, where NK cells could become alloreactive and responsive 
(due to HLA mismatch) or inhibited (HLA match).   
 
Fig. 2.3. Functional assay of NK cell licensing.  PBMC preparations from 
four C2/C2 and Bw4/Bw6 donors were incubated with no target, K562, 721.221 
and 721.221 transfected with the HLA-Cw3 (C1), HLA-Cw4 (C2), HLA-Bw4, or 
HLA-E epitopes, and stained for KIR and intracellular IFN-γ. NK cell subsets with 
exclusive expression of the indicated inhibitory KIR demonstrate higher 
response among NK cells expressing the self (licensed)-KIR 2DL1 and KIR3DL1 
as compared with the unlicensed KIR 2DL2/3 or KIR negative groups, and the 
response is nearly completely inhibited upon challenge with the cognate class I 
ligand. a) Representative FACs plots for responsive and unresponsive subset. 
b) Functional hierarchy histogram illustrating  differential functional response 
towards various target cell lines.  
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a) 
 
                          Illustrations adapted from Raulet et al., 2006 (130) 
 
b)    HLA type C2/C2, Bw4 
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Functional readouts were collectively presented in a hierarchy histogram based 
on single KIR expression and various stimulation conditions displayed on the x 
axis, as illustrated above in Fig. 2.3b.   Each coloured bar represents NK cell 
subsets exclusively expressing the highlighted KIR (or no KIR expression at all; 
hyporesponsive KIR-).  Combined with the HLA-typing data as determined in 
Fig. 2.10, the licensed NK subsets are identified as those exclusively expressing 
the KIR matching the individual’s HLA-type.  In the example above, a HLA 
C2/C2, Bw4/Bw6 individual would have NK cells expressing KIR2DL1 (red) and 
KIR3DL1(green) as the licensed subsets.  When looking at the HLA-class I 
deficient target conditions (K562 and 721.221), the licensed (red and green) NK 
cells are superior in their ability to produce IFNγ compared to the unlicensed 
(blue and white) subsets.   In the conditions encountering HLA-class I 
expressing variants, KIR2DL1 licensed NK cells (red) are significantly inhibited 
upon encounter with the target expressing the cognate HLA-class I ligand 
(HLA-C2), likewise with the licensed KIR3DL1 NK cells (green) significantly 
inhibited by the condition HLA-Bw4.  However, both KIR2DL1 and KIR3DL1 
expressing NK cells respond at a comparable level to the wild type, as the ligand 
expressed does not correspond to either of the KIRs expressed.   The 
differential functional readouts were pooled together accordingly to C1/C1 or 
C2/C2 homozygous, or C1/C2 heterozygous genotype. 
 
2.3.4 Development of a flow panel to study reconstitution of NK cells in 
cryopreserved PBMC collected from patient with haematological 
malignancies undergoing cord blood transplantation (CBT) 
 
The licensing panel successfully demonstrated the differences in the functional 
capacity of licensed vs. unlicensed NK cells at the single-KIR level.  This panel 
was modified to include activating KIRs (where mAbs were commercially 
available) and NKG2C.  Activating KIRs are associated with functional 
competence (131) and NKG2C were also recently suggested to show biased 
coexpression in licensed/educated  subsets (115, 132).  Details of antibodies 
used in these studies are included in Table. 2.3.  NK cell cytotoxicity and 
cytokine production was assessed by pre-incubating PBMCs alone (negative 
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control) or with target cells (ET ratio of 10:1) for 5 hours at 37C¹ in the presence 
of anti-CD107a-PE-CF594 (clone H4A3), GolgiStop/monensin (both from BD 
Biosciences) and Brefeldin A (Sigma-alrich, USA).  PMA/ionomycin stimuli 
were used as positive controls.  After the incubation period, cells were stained 
with live/dead aqua viability marker (Life technologies, Paisley, UK), then 
surface stained in a 2 step procedure with a cocktail of mouse anti-human 
antibodies.  Cells were first stained with anti-CD56-BV605 (clone HCD56), 
anti-CD3-PECy5 (clone UCHT1), anti-CD16-BV650 (clone 3G8), 
anti-KIR3DL1-AlexaFluor700 (clone DX9) (Biolegend), anti-KIR2DL1-APC 
(clone REA284), anti-KIR2DL3-Biotin (clone REA147) (Miltenyi Biotec), 
anti-NKG2A-PECy7 (Clone Z199) (Beckman Coulter) and 
anti-NKG2C-AlexaFluor488 (clone 134591) (R&D Systems).   
Samples were left to stain for 20minutes, followed by secondary staining with the 
following and incubated for a further 20 minutes; anti-KIR2DS1/L1-PE (clone 
EB6B), anti-KIR2DS2/L2/L3-PECy5 (clone GL183), anti-KIR3DS1/L1 (clone 
Z27.3.7, self conjugated with Life technologies Qdot705 antibody labelling kit) 
(Beckman Coulter), and anti-streptavidin-APC-Cy7 (Biolegend). 
Once surface staining was completed, cells were treated with BD FACS lysing 
solution, then fixed and permeablized with BD FACS Permeablizing solution 2 
(both from BD Biosciences).  Finally, cytokine production was detected by 
subsequent intracellular staining with anti-IFNγ-V450 (clone B27) and 
anti-TNFα-PerCPCy5.5 (clone MAB11) (BD Biosciences).   Cells were washed 
in 2 ml PBS at 2000 rpm and analysed on the flow cytometer.  The gates for 
true functional population (CD107a, IFNγ and TNFα positive) were set using the 
negative controls as the baseline. 
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Table. 2.3 Antibody description and full product details included in CBT 
reconstitution panel  
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD56 Brilliant Violet 605 HCD56 Biolegend 1.25 
CD3 PE-Cy5 UCHT1 Biolegend 0.5 
CD16 Brilliant Violet 650 3G8 Biolegend 0.5 
NKG2A PE-Cy7 Z199 Beckman 
Coulter 
5 
NKG2C Alexa Fluor 488 134591 R&D 
systems 
5 
KIR2DL1 APC REA284 Miltenyi 
Biotec 
10 
KIR2DL1/S1 PE EB6.B Beckman 
Coulter 
10 
KIR2DL2/L3/ 
S2 
PE-Cy5.5 GL183 Beckman 
Coulter 
20 
KIR2DL3 Biotin/ 
Streptavidin- 
APC-Cy7 
REA147 Miltenyi 
Biotec/ 
Biolegend 
5 / 0.25 
KIR3DL1 Alexa Fluor 700 DX9 Biolegend 0.5 
KIR3DL1/S1 Purified Antibody 
Self-conjugated 
with Qdot 705 
Z27.3.7 Beckman 
Coulter 
Life 
Technologies  
10 
CD107a PE-CF594 H4A3 BD 
Bioscience 
0.5 
IFNγ V450 B27 BD 
Bioscience 
1.25 
TNFα PerCP-Cy5.5 MAb11 Biolegend 1.25 
Live /Dead 
Stain 
Aqua NA Life 
Technologies 
0.5 
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Table. 2.4 Antibody description and full product details included in the 
HLA class I phenoytping panel 
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD13 PE WM15 Biolegend 1.25 
CD33 PE-Cy7 P67.6 BD Biosceinces 2.5 
CD34 PerCP 8G12 BD Biosciences 2.5 
HLA-ABC APC G46-2.6 BD Biosciences 2.5 
 
2.3.5 Surface phenotyping : CMV memory phenotype panel   
In addition to the NK reconstitution panel aimed to detect the quantitative 
difference in functional licensed and developmentally immature unlicensed NK 
cells, a memory panel was established consisting of NKG2C and other surface 
molecules associated with NK memory phenotype (116, 124, 132).  Detailed 
units of antibodies to be used are described in Table. 2.5.  Cells were stained 
with live/dead aqua viability marker (Life technologies, Paisley, UK), then 
surface stained in a 2 step procedure with a cocktail of  mouse anti-human 
antibodies.  Cells were first stained with anti-CD56-BV605 (clone HCD56), 
anti-CD3-PECy5 (clone UCHT1), anti-CD16-BV650 (clone 3G8), 
anti-4-1BB-AlexaFluor700 (clone 4B4-1), anti-DNAM-1-APC (clone 11A8), 
anti-2B4-PerCP-CY5.5 (clone C1.7) (Biolegend), anti-NTB-A-Qdot705 (clone 
292811), anti-NKG2C-AlexaFluor488 (clone 134591) (R&D Systems), 
anti-Siglec7 Pacific Blue (clone REA214), anti-PAN KIR-Biotin (clone 
NKVSF1)(Miltenyi Biotec), anti-ILT2-PE (clone HP-F1), anti-NKG2A-PECy7 
(clone Z199) (Beckman Coulter) and, anti-CD57-PE-CF594 (clone NK-1, BD 
Biosciences). 
Samples were left to stain for 20 minutes, then stained with secondary antibody 
anti-streptavidin-APC-Cy7(Biolegend) and incubated for a further 20 minutes.  
Cells were washed in 2ml PBS and immediately analysed on a flow cytometer. 
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Table 2.5 Antibody description and full product details included in CMV 
memory phenotype panel 
Antibody Fluorochrome Clone Vendor Concentration 
(g/ml) 
CD56 Brilliant Violet 605 HCD56 Biolegend 1.25 
CD3 PE-Cy5 UCHT1 Biolegend 0.5 
CD16 Brilliant Violet 650 3G8 Biolegend 0.5 
NKG2A PE-Cy7 Z199 Beckman Coulter 5 
NKG2C Alexa Fluor 488 13451 R&D systems 5 
KIR2D Biotin/ 
Streptavidin-APC-Cy7 
NKVSF1 Miltenyi Biotec/ 
Biolegend 
5 / 2 
 
ILT2 PE HP-F1 Beckman Coulter 10 
DNAM-1 APC 11A8 Biolegend 0.5 
2B4 PerCP-Cy5.5 C1.7 Biolegend 0.5 
NTB-A Purified Antibody 
(self-conjugated with 
Qdot 705) 
292811 R&D systems 
(Life 
Technologies) 
20  
4-1BB Alexa Fluor 700 4B4-1 Biolegend 0.5 
CD57 PE-CF594 NK-1 BD Bioscience 0.25 
Siglec-7 Pacific Blue REA214 Miltenyi Biotec 5 
Live 
/Dead 
Stain 
Aqua NA Life 
Technologies 
0.5 
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2.4 ADCC assay (plate bound CD16 stimulation) 
In addition to missing-self detection, NK cells are also activated through 
antibody-dependent cellular cytotoxicity (ADCC).  The assay for functional 
response of NK cells to ADCC-triggering was optimized using CD16 mAb-coated 
plates.  Purified CD16 antibody (Clone 3G8, BD Bioscience) or isotype control 
IgG1 (Clone MOPC-21) were reconstituted at a concentration of 10µg/ml in PBS 
and distributed into 96-well non-tissue culture treated plates (30µl per well).  
The plate was gently tapped to ensure that the entire surface of the well is 
covered, then sealed with parafilm and incubated overnight at 4C°.  The 
mAb-coated plates were gently washed 3 times with PBS, and NK cells or 
PBMCs were plated out at 2x105 cells per well in the presence of CD107a mAb, 
BFA and Golgi-stop (as per the protocol for K562 stimulation described above).  
After 5 hours of incubation, cytokine production by NK cells was assessed using 
intracellular staining as described above.  
 
Fig. 2.4 Representative example of ADCC-activation in NK cells.  Plates 
were coated with either CD16 mAb or isotype control and used to stimulate 
NK/PBMCs in a similar manner as with the cell line targets.  Functional 
readouts were observed specifically in the CD56dim subset in which CD16 are 
co-expressed.    
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2.5 Analysis of the expression of the active form of LFA-1 and the 
transcription factors T-bet and Eomesodermin 
Thomas et al. (133) shed light to the possibility of differential adhesive properties 
between licensed and unlicensed NK cells.   NK cells are capable of producing 
an autonomous inside-out signal which induces the conformational change of 
the LFA-1 adhesive molecule to an active form, allowing efficient target cell 
contact and hence, the ability to perform their cytotoxic roles.  The authors 
speculated that licensed NK cells are capable of inducing this active form more 
readily than unlicensed cell subsets, contributing to the enhanced functional 
output upon encounter with a tumour cell target.  In my study, I adapted the 
protocol developed by Thomas et al’s study and expanded it to a panel including 
all 3 inhibitory KIRs, allowing for the detailed assessment and comparison of the 
adhesive properties of licensed vs. unlicensed NK cells at the single KIR subset 
level. Of note, Thomas et al only defined licensed and unlicensed NK cells 
looking at bulk KIR+ vs KIR- populations.  In addition to this, Eomesodermin 
and T-bet, which are transcription factors regulating the differentiation and 
function of cytotoxic lymphocytes (134, 135), were also included in the panel.  
Purified LFA-1 antibody (MEM-83) was conjugated with the Alexa Fluor 647 
Antibody labelling kit (Life Technologies) accordingly to the manufacturers 
instructions.  Staining was performed as follows; 
PBMCs were pre-incubated either alone (negative control) or with K562 target 
cells (ET ratio of 10:1) for 20 mins in a 37C° waterbath.  After the incubation 
period, cells were washed and stained with live/dead aqua viability marker, then 
surface stained with CD56-BV605 (clone HCD56), CD3-APC-Cy7 (clone SK7), 
KIR3DL1-AlexaFluor700 (clone DX9)( Biolegend), KIR2DL1/S1-PE (clone 
EB6.B), KIR2DL2/L3/S2-PE-CY5.5 (clone GL183), NKG2A-PECy7 (Clone Z199) 
(Beckman Coulter) and LFA-1-Alexa Fluor 647 (clone MEM-83) (Abcam) for 20 
minutes in the dark at RT.  Once surface staining was completed, cells were 
treated with BD FACS lysing solution, then fixed and permeablized with BD 
FACS Permeablizing solution 2 (both from BD Biosciences).  Finally, the 
expression of the transcription factors was measured by staining with 
Eomesodermin-PerCP-eFluor 710 (clone WD1928) and T-bet PE-CF594 (clone 
04-46).   Cells were washed in 2 ml PBS at 2000 rpm and analysed on the flow 
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cytometer.  The gates for active LFA-1 positive population were set using the 
LFA-1 expression in negative controls as the baseline.  Transcription factors 
were gated by establishing an FMO. 
 
Table. 2.6   Antibody description and full product details included in the 
active LFA-1 panel 
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD56 Brilliant Violet 605 HCD56 Biolegend 1.25 
CD3 APC-Cy7 SK7 Biolegend 1.25 
NKG2A PE-Cy7 Z199 Beckman Coulter 5 
KIR2DL1/S1 PE EB6.B Beckman Coulter 10 
KIR2DL2/L3/S2 PE-Cy5.5 GL183 Beckman Coulter 20 
KIR3DL1 Alexa Fluor 700 DX9 Biolegend 0.5 
LFA-1 Purified Antibody 
(self-conjugated 
with Alexa Fluor 
647)  
MEM-83 Abcam  
(Life  
Technologies) 
1  
Eomesodermin PerCP-eFluor 710 WD1928 eBioscience 0.5 
T-bet PE-CF594 04-46 BD Bioscience 2.5 
 
2.6 NK receptor synergy experiment 
As revealed by the studies by Bryceson et al.(43), most NK cell receptors are 
unable to function independently and require the engagement of synergistic 
receptors to mediate natural cytotoxicity in order to achieve an activation 
threshold.  In order to assess whether there are differential signalling properties 
between the licensed and unlicensed subsets at the synergistic signal level, the 
activation of resting NK cells were tested by antibody cross-linking activating 
receptor NKp46 and 2B4 co receptor combination similar to the approach taken 
by Bryceson et al.   Monoclonal antibodies for the isotype control, activating 
receptor NKp46, costimulatory receptor 2B4 were used either alone or in 
combination (Table. 2.7).  The concentration of the mAbs were adjusted to a 
concentration of 10µg/ml in PBS and distributed into 96-well non-tissue culture 
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treated plates (30µl per well).  The plate was gently tapped to ensure that the 
entire surface of the well is covered, then sealed with parafilm and incubated 
overnight at 4C°.  The mAb-coated plates were gently washed 3 times with 
PBS, and NK cells or PBMCs were plated out at 2x105 cells per well in the 
presence of CD107a mAb, BFA and Golgi-stop (as per the protocol for K562 
stimulation described above).  After 5 hours of incubation, cytokine production 
by NK cells was assessed using intracellular staining as described previously. 
 
Table. 2.7  Antibody combinations included in the initial screening of 
synergy signalling 
Condition Antibody Clone Vendor Signal Type 
1 IgG1 κ/IgG2B κ MOPC-1 BD 
Biosciences 
Isotype Control 
2 2B4 eBioC1.7 eBioscience Costimulatory  
3 NKp46 MAB1850 R&D Activating  
4 2B4+NKp46 NA NA Costimulatory  
+Activating  
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Fig. 2.5 Representative example of activating receptor synergy assay.   
Stimulating NK/PBMCs with a single activating receptor or co-receptor induced 
very poor functional readouts, however when used in combination NK cell 
functional response were significantly enhanced.  Demonstrating the concept of 
synergy of activation signalling in certain receptor combinations. 
 
 
2.7 Chromium-51 (51Cr) release assay 
Chromium based cytotoxicity assay was performed in parallel to intracellular 
staining assays in the early assay development stage of the study for accurate 
quantification of target cell cytolysis by NK cells.  The following procedures for 
handling radioisotope chromium-51 (51Cr) were done under a secure lead brick 
shielded environment. 
K562 or 721.221-AEH target cells (5x105) were resuspended in 1ml of culture 
media.  51Cr (PerkinElmer, cat#NEZ020001MC) was added at a 10% volume 
ratio (100µl /ml of target cells) and gently mixed using a pipette before incubating 
for 2 hours at 37Co 5% CO2.  Once complete, cells were washed twice in PBS 
and resuspended in 10 ml culture media to achieve a concentration of 5x104 /ml.  
Target cells were then distributed into V-bottomed 96 well plates at 50µl/well 
(2500 cells/well).  Purified NK cells were suspended in culture medium at 
concentrations ranging from 1x106/ml, 5x105/ml, 2.5x105/ml, and 5x104/ml;  
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50µl of each NK cell preparation was added to the target cells for an effector: 
target (E:T) ratio of 20:1, 10:1, 5:1 and 1:1.  Controls for spontaneous release 
and maximum release included culture medium alone or target cells cultured 
with 0.1%, respectively.  Reaction volumes were maintained at 100µl /well and 
all conditions were done in triplicates.  Plates were briefly centrifuged to ensure 
cell contact at the bottom of the wells, then incubated at 37Co 5% CO2 for 4 
hours.  After incubation, plates were spun down and supernatants were 
carefully collected without disrupting the pellet.  Supernatants were transferred 
onto a LumaPlateTM (Perkin Elmer, cat#6005630) and left to dry overnight.  
Plates were then read on a microplate scintillation/luminescence counter 
(Packard, C991200 TopCount NXT).  Percentage of specific lysis by NK cells 
were calculated using the standard formula;  
 
[(Experimental readout – Spontaneous lysis)/(Maximum lysis)] x 100 
 
Calculated values were plotted to create a lysis curve. 
 
In order to prevent poor target cell labeling from radioactive decay of the 51Cr 
stock, 51Cr was used in all experiments within one week of purchase (half-life of 
51Cr being 27.7 days). 
 
Fig. 2.6 Representative example of 51Cr lysis curve against K562 target.  
Chromium release assay was initially performed in parallel to the flow cytometry 
bassed functional assay, in order to provide quantitative readouts of direct cell 
killing and thus combine with the flow based functional readouts.      
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2.8  Purification of NK cells using the Miltenyi bead selection method 
NK selection was performed using the human NK cell isolation kit from Miltenyi 
Biotec (cat# 130-092-657) according to manufacturer’s instructions.   Fresh 
PBMCs were washed in pre-chilled CliniMACS buffer (Miltenyi Biotech) 
containing 0.5% human serum albumin (Baxter Healthcare) and resuspended in 
40µl of the same buffer per 107 total cells.  10µl of NK Cell Biotin-Antibody 
Cocktail was added to the suspension per 107 total cells and incubated in the 
refrigerator (2-8℃) for 5 minutes after mixing thoroughly.  A further 30 µl  of 
buffer per 107 total cells was added to the suspension along with 20µl  of NK 
Cell MicroBead Cocktail per 107 total cells, which was mixed thoroughly and 
incubated for an additional 10 minutes in the refrigerator (2-8°C).  After the 
incubation period the final volume was adjusted to 500 µl of buffer per 108 cells 
or scaled up accordingly for higher cell numbers.   Immediately prior to 
proceeding to magnetic separation,  appropriate number of LS MACS 
Separator Columns were prepared by rinsing with 3ml of buffer (3 x 1ml).   The 
columns were then fitted with 30µm pre-separation filters and placed in the 
magnetic field.  Cell suspension was applied to the column at a ratio of 2x108 
cells per column and the flow-through containing the unlabelled NK cells were 
collected in a suitable collection tube. Purity of the selected NK cells was 
evaluated by flow cytometry; cells were surface stained with anti-CD56-BV605 
(clone HCD56) and anti-CD3-APC-Cy7 (clone SK7) for 15 minutes in the dark 
before analysis.  Purity was ensured to be >95% for all experiments.  
Negative selection was chosen for the separation strategy to avoid any down 
stream interference that could occur from direct labelling of surface molecules  
(e.g, activation). 
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Fig. 2.7    Representative example plot of purity evaluation.  NK 
selection were performed on freshly isolated PBMCs for in vitro 
differentiation/expansion assays.  Purity and viability checks were performed 
after each selection to ensure high quality purity of  >95%.   
Enrichment of CD56+CD3-ve NK cells to a high purity (>95%) 
 
2.9 Proliferation assay – CFSE labelling 
The degree of NK proliferation was detected by CFSE staining where each peak 
created by the dilution/loss of the CFSE stain indicates a cycle of proliferation. 
Magnetically enriched NK cells were labelled with 1µM carboxyfluorescein 
diacetate succinimidyl ester (CFSE)(Life Technologies, cat#C34554) in PBS for 
5 minutes at 37°C. The reaction was then quenched by the addition of cold 
SCGM supplemented with 10% FBS, followed by 3 washes to remove excess 
CFSE.  CFSE-labelled NK cells were then cultured in 10% FCS supplemented 
SCGM with 1000 U IL-2/ml, demi-depleted and medium exchanged with fresh 
cytokines every other day.  NK cells were first plated in 24-well plates at a 
concentration of 5x105/ ml and transferred to 6-well plates after 4-5 days at 1x 
106/ml.   Controls included unstimulated CFSE-labelled NK cells (negative 
control) and unlabelled NK cells.   
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Fig. 2.8 Representative example of CFSE assay depicting NK cell 
proliferation.  Selected NK cells were stimulated with IL-2 for a period of upto 
9-14 days, and was monitored every other day upon medium exchange and 
cytokine replenishment.  Successful expansion were confirmed by the increase 
in cell size determined by SSC and FSC (a), and most importantly the dilution of 
CFSE with cell division (b). 
a) SSC vs FSC 
  
b) CFSE labeling  
 
2.10 DNA extraction from whole blood samples 
Genomic DNA was extracted from frozen CB and PB samples using the Qiagen 
column-based method (Qiamp midi kit, Qiagen, Gaithersburg, MD, USA). Briefly, 
thawed PBMC were mixed with 100 µl protease and 1.2 ml of lyzing buffer and 
vortexed vigorously for 1 min. Lysed cells were then incubated for 10 min in a 
water-bath at 70 ºC. To optimise DNA binding to the silica membrane, 1ml 
ethanol was added, the sample was mixed and then vigorously vortexed for 
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1minute before being passed through the Qiamp midi column.  The column was 
then spun at 1850g (3000rpm) for 3 minutes, washed with 2ml AW1 buffer, spun, 
and washed again with 2 ml AW2 buffer.  DNA was then eluted from the column 
into a new tube by adding 150 µl low-salt buffer, incubating at room temperature 
for 5 minutes and then spinning down at 4500 g for 2 mins. DNA concentration 
and purity were measured using a nanodrop machine. The optimal cell number 
to achieve a DNA purity of >90% with a DNA concentration of 50-200 ng/µl was 
5 x106 cells. 
 
2.11 KIR genotyping 
KIR genotyping was performed using the Invitrogen KIR Genotyping SSP kit 
(Invitrogen, CA, cat. 78930-30). This identifies the presence or absence of each 
of the 15 known KIR genes and 2 pseudo genes as well as the common variants 
of 2DL5, 2DS4, and 3DP1. Briefly, 0.92 µg of DNA was added to the kit buffer 
mixed with 1.4 µl taq polymerase (Invitrogen, CA,USA) and purified water. 8µl of 
this solution was added to each well, containing a different set of 
sequence-specific primers for each KIR gene. Plates were loaded onto the 
thermocycler (Gene amp PCR system 9700) and polymerase chain reaction was 
performed. This involved initialising for 1 minute at 95 °C followed by 30 cycles 
of denaturation at 94 °C for 20 seconds, annealing at 63 °C for 20 seconds and 
elongation at 72 °C for 90 seconds before the sample was cooled to 4°C. Each 
KIR gene was identified by the presence or absence of a band on 1.5% agarose 
electrophoresis gel stained with ethidium bromide (in USA) or SYBR safe DNA 
gel stain (in London) (Invitrogen, CA,USA).   
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Table. 2.8  PCR cycling parameters for KIR Genotyping SSP typing kit 
No. of cycles Temperature Duration Step name 
1 cycle 95°C 60 sec. Denaturation 
30 cycles 94°C  
63°C  
72°C  
20 sec. 
20 sec. 
90 sec. 
Denaturation 
Annealing 
Extension 
∞ 4°C  ∞ End - hold 
 
Fig. 2.9   Representative example of KIR genotyping analysis – gel 
picture.  Presence or absence of a specific KIR gene or allele were indicated 
by the corresponding bands with reference to the molecular weights provided by 
the worksheet (Table. 2.9). 
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Table. 2.9     KIR genotyping analysis work sheet – Gene  well 
correspondence  chart   
 
        Adapted from Invitrogen KIR Genotyping SSP kit 
 
2.12 KIR-ligand typing 
The OlerupKIR-HLA Ligand SSP typing kit (Olerup, cat# 104.201-12) qualitative 
diagnostic kit allows the detection of KIR ligands HLA-C1, HLA-C2, and Bw4 
molecules using PCR-SSP technique.  Briefly, 0.42µg of genomic DNA was 
mixed with 21 µl of PCR master mix which was further diluted with 35 µl dH20.  
After thorough mixing, 10 µl of this DNA-PCR master mix-H20 mixture was 
distributed into each of the 5 wells of the provided PCR plate.  The plate was 
then covered with adhesive seals to ensure that all reaction wells were 
completely covered to prevent evaporation during PCR amplification.  
Following brief centrifugation, the plate was loaded onto a 96 well thermocycler 
(Bio-Rad, iCycler) to initiate PCR.  The PCR cycling parameters used were as 
follows; 
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Table. 2.10 PCR cycling parameters for OlerupKIR-HLA Ligand SSP typing 
kit 
No. of cycles Temperature Duration Step name 
1 cycle 94°C 2 min Denaturation 
10 cycles 94°C  
65°C  
10 sec. 
60 sec. 
Denaturation 
Annealing and 
extension 
20 cycles 94°C 
61°C  
72°C  
10 sec. 
50 sec. 
30 sec. 
Denaturation 
Annealing 
Extension 
∞ 4°C  ∞ End - hold 
 
Each KIR HLA ligand was identified by the presence or absence of a band 
product on a 0.8% agarose electrophoresis gel stained with ethidium bromide 
(Bio-Rad, cat#161-0433).  A Lamda DNA ladder (Promega, cat# G3011) was 
run in parallel for band size distinction.   Before implementing this HLA typing 
kit into the experiments, quality assurance and quality control were initially 
performed by confirming the results with the HLA laboratory at MD Anderson 
cancer center. 
 
 
Fig.2.10    Representative example of HLA typing analysis – gel.   Each 
lane corresponds to a HLA epitope or allele variation, hence the kit allows 
determination of HLA type by the presence or absence of a positive band.    
 
 
 
1. HLA-C1 
2. HLA-C2 
3. HLA-Bw4 Threonine 
80 
4. HLA-Bw4 Isoleucine 
 76 
2.13 CMV quantitation/Viral Load detection in Patients 
Genomic DNA and patient HLA status were provided by the MDACC HLA 
Typing Laboratory in support with the BMT program.  At the time of sample 
collection CMV levels were measured using CMV antigenemia testing by the 
microbiology laboratory at MDACC.  
 
2.14 NKG2C genotyping 
NKG2C genotyping was performed by PCR amplification with sequence-specific 
primers (PCR-SSP) by the MDACC HLA Typing laboratory.  Copy number 
variation of the NKG2C genes were genotyped and assessed by PCR-SSP 
method using a set of primer pairs described previously(136, 137).  Two pairs 
of primers are used to detect the NKG2C genotypes. Primer NKG2C/F 
(5’-CAGTGTGGATCTTCAATG-3’) and NKG2C/R 
(5’-TTTAGTAATTGTGTGCATCCTA-3’) amplify a 201 bp fragment from NKG2C 
wild type (wt) carrier. Primer NKG2Cdel/F 
(5’-ACTCGGATTTCTATTTGATGC-3’) and NKG2Cdel/R 
(5’-ACAAGTGATGTATAAGAAAAAG-3’) amplify a 411 bp fragment from 
NKG2C deletion (del) carrier. A single-tube PCR-SSP genotyping strategy 
combining the two sets of primers was validated and modified from Moraru M, 
etc (137).  Briefly, genomic DNA sample was mixed with the two sets of primers 
in a final concentration of 1 µM for NKGC2/F and NKGC2/R, and 0.5 µM for 
NKG2Cdel/F and NKG2Cdel/R, dNTPs, PCR buffer, Taq polymerase, and PCR 
amplified under the following thermal cycling conditions: 1 cycle of 2 min at 95¹C, 
then 10 cycles of 20 sec at 95¹C, 30 sec at 60¹C and 40 sec at 72¹C, and 20 
cycles of 20 sec at 95¹C, 30 sec at 56¹C and 40 sec at 72¹C. The last extension 
cycle of 3 min at 72¹C was followed. The PCR product was visualized using gel 
electrophoresis and UV exposure. 
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Fig. 2.11  Representative gel picture of NKG2C genotyping  Upper 
band of 411 bp fragment is observed only in carriers of NKG2C deletion (del), 
and the lower band of 201 bp only in carriers of NKG2C gene (wt). From left to 
right, lane 1 – lane 5, 5 DNA samples of donors with different genotypes: wt/del, 
del/del, wt/wt, wt/del, wt/wt, respectively; lane 6, homozygote control for NKG2C 
(wt/wt); lane 7, heterozygote control (wt/del); lane 8, homozygote control for 
NKG2C deletion (del/del); lane 9, H2O contamination control; and lane 10, 
molecular weight marker, 150 bp ladder. 
         
 
 
 
2.15 Development and optimization of Phosflow assay to study NK cell 
signalling 
The phosflow assay is a flow cytometry based assay which enables the precise 
detection of phosphor-proteins at the single cell level in combination with other 
surface and intracellular markers.  The precise increase (phosphorylation) or 
decrease (dephosphorylation) of the phosphor-proteins within the cell in 
response to a stimulus allows one to dissect and interpret the signalling cascade 
in vitro.  However there are difficulties, as many cell surface antigens are 
sensitive to fixation/permeablization procedures resulting in a loss of recognition 
by their respective antibodies. Limited information  is available on the 
compatibility of the commercially available antibodies for the phosflow assay 
protocol..  Hence the major challenge in establishing a phosflow protocol for 
this study was to identify the compatible phosflow kit and surface antibodies for 
analysis.  Initial studies were performed using the phosflow kit manufactured by 
BD Biosciences.  However, this system had a number of disadvantages, 
including limited compatibility with the surface mAbs required to distinguish 
1 
wt/del  
2 
del/del  
3 
wt/wt 
4 
wt/del  
5 
wt/wt 
6 
wt/wt  
7 
wt/del  
8 
del/del  
9 
H2O  
Size 
Marker  
411 bp 
(del) 
201 bp 
(wt) 
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licensed subsets detailed in Table 2.2, long procedure time  which made it 
difficult to maintain the strict timing when large numbers of samples were 
assayed concurrently.  Also the permeablizing/fixation steps resulted in 
interfering with surface antigens of interest.  A number of steps were 
undertaken to try and optimize the protocol with modest improvement in the 
results; however, we were unable  to optimize the co-staining protocol  for a 
number of phenotypic markers.  The Beckman PerFix Expose was then tested 
as an alternative and found to be superior to BD Bioscience kit, with shorter  
assay time (1 hour) and stability of surface epitope expression during treatment. 
 
Fig. 2.12    Evaluating the various commercially available phosflow kits  
Representative FACs plots of PBMCs treated with various phosflow kit reagents 
and timing of antibody staining reflecting on the quality of CD56-ECD 
CD3-Pacific Blue surface staining.  Far left; PBMCs treated with BD phosflow 
kit stained with antibodies prior to the fix-perm treatment shows good resolution.   
Middle left; showing the same BD phosflow kit but fix reagent applied before the 
surface staining, resulting in a poor resolution due to severe damage to the 
surface epitopes.  Middle right; showing the same BD phosflow kit with staining 
performed after both fix and perm treatment, showing improved staining 
compared to fix-stain-perm results but nevertheless uninterpretable staining with 
many false positive populations.  Far right;  Beckman Coulter PerFix EXPOSE 
kit, surface staining applied after fix and perm procedure yet showing distinct 
and clear population subsets.     
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As a novel panel determining the differential signalling in licensed and 
unlicensed cells, the phosflow antibody panel required the inclusion of a 
sophisticated repertoire of inhibitory KIRs and NKG2A receptors.  Clones from 
Beckman coulter were the only compatible antibodies, which provided me with a 
full repertoire of the receptors of interest, whilst proving to withstand the harsh 
phosflow treatment maintaining high distinct populations as illustrated in Fig. 
2.13. 
 
Fig. 2.13 Evaluating the compatibility of selected surface antibodies with 
the Phosflow assay.  In order to investigate the association of p-CrkL with NK 
licensing, the ideal panel must include CD56, CD3 (NK markers), KIR2DL1/S1, 
KIR2DL2/L3/S2, KIR3DL1 (self HLA I-inhibitory receptors), NKG2A 
(non-classical self HLA I-inhibitory receptor) and p-CrkL.  As the critical 
receptor known to  phosphorylate CrkL upon ligation, NKG2A antibodies from 
Miltenyi Biotec, R&D systems and Beckman Coulter were evaluated.  Below 
are the representative examples of the staining on CD56+CD3-gated NK cells.  
Far left; Clone REA110 from Miltenyi Biotec shows no successful binding, 
suggesting the corresponding epitope is damaged after the treatment or the 
binding affinity is too weak.  Middle; Clone 131411 R&D shows a fair specificity, 
as the NKG2A+ NK cells could be barely but possible to distinguish based on the 
CD56 bright subset (All C56bright subsets should be NKG2A+).  Far right; 
Clone Z199 Beckman Coulter shows excellent resolution, with clear distinct 
subsets of NKG2A- and NKG2A+ NK subsets.   
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H202 is a potent member of the reactive oxygen species (ROS) and a strong 
inducer of phosphorylation (138).  It is commonly used as a positive control in 
many cellular signalling assays.  However, H202 is capable of activating many 
signalling pathways simultaneously.  The ultimate aim of this signaling assay 
was to identify potential signaling pathways and candidate signaling molecules 
involved in the licensing process of NK cells, in particular the signaling events 
which occurs downstream of ITIM phosphorylation after inhibitory KIR ligation 
with its cognate HLA class I ligands.   As inhibitory KIR ligation leads to the 
phosphorylation of ITIM domains and the recruitment of tyrosine phosphatases 
such as SHP-1 and SHP-2 (139), licensing also was initially suspected to be 
involving these tyrosine phosphatase-dependent dephosphorylation events.  
However, it was demonstrated in 2005 using the SHP1-defective 
motheaten-viable mice experiments that although ITIM is crucial for licensing, 
SHP-1 was dispensable (140).  Hence an alternative candidate and the 
corresponding signaling cascade have been questioned ever since.  Recent 
work revealed that ITIM bearing receptors can signal independently through a 
novel mechanism involving the small adaptor molecule Crk .(141).  This study 
performed by Peterson et al elegantly demonstrated that during NK inhibition 
through CD94/NKG2A and inhibitory KIR ligation, Crk becomes phosphorylated 
by the constitutively active tyrosine kinase c-Abl and dissociates from its active 
complex c-Cbl-Crk-C3G and p130CAS-Crk-C3G, losing the property as a GEF for 
the GTPase Rap1 and ultimately promotes inhibition (142).  As all inhibitory 
KIRs associated with licensing share the ITIM domain, I hypothesized that 
perhaps Crk could be the determinant of licensing signals and hence I adapted 
the concept from Long’s study to screen for any differential phosphorylation 
capacity between self and non-self inhibitory KIRs.  However, conventional 
signaling approach using western blots to identify phosphorylated proteins was 
not going to suffice, as I needed to analyze NK cells at the single KIR expression 
level to observe any potential differential phosphorylation between the licensed 
and unlicensed subsets, hence the choice of phosflow.  To assess the 
signalling response to ligation of individual NK receptors, individuals receptors 
were crosslinked and phosphorylation of p-CrkL examined by phosflow.  To test 
that this theory is practical, cross linking of NKG2A receptor was attempted with 
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a fragment specific anti-mouse IgG F(ab’)2 post Z199 staining, which displayed a 
strong phosphorylation detectable by FACS analysis.  Briefly, PBMCs were 
rested overnight, harvested the next day and placed on ice.  Cells were surface 
stained as previously described with anti-NKG2A-PE-Cy7 (Z199) for  
20minutes on ice, then stimulated with  fragment specific anti-mouse IgG 
F(ab’)2  at 37°C for 10 minutes.  Cells were fixed immediately, followed by 
intracellular phospho-CrkL-Alexa488 (pY207) was added along with remaining 
surface markers (CD56, CD3, KIRs).   Once the assay was  validated with the 
NKG2A (Z199) antibody, I applied it the protocol to antibodies for inhibitory KIRs 
(KIR2DL1/S1 (EB6.8), KIR2DL2/L3/S2 (GL183), KIR3DL1/S1 (Z27.3.7)).  The 
advantage of the cross-linking method was that the target receptor could be 
stimulated with ease, providing that the compatible antibody is available, rather 
than specifically produce a cell line expressing the target ligand.  The other 
advantage of antibody cross-linking was that any signalling event which occurs 
could be distinguished by gating on the specific subset expressing the receptor 
of interest.   For example, when stimulating the KIR2DL1+NK cells with the 
anti-KIR2DL1/S1 antibody, single KIR2DL1+NK cells could be identified by 
gating on the total CD56+CD3- ! KIR2DL1+ !KIR2DL2/3-KIR3DL1- (double 
negative), as with the exclusion gating applied for the functional assessments in 
Fig. 2.2.  Once KIR2DL1+ was successfully identified by gating, pCrkL levels 
were compared to the unstimulated. 
 
Fig. 2.14  Determining the optimal physiological stimulus for the NK 
phosflow assay.  Representative FACs plots of PBMCs stimulated with 
various stimulants, gated on CD56+CD3- NK cells.  Top row left:  pCrkL level 
in resting NK cells.  Top row right: Significant increase in pCrkL level in NK cells 
post 5 minutes H202 stimulation (blue histogram) relative to baseline pCrkL (red 
lhistogram).  Bottom row far left: pCrkL increase in NK cells post 15minutes 
co-incubation with HLA-E(NKG2A ligand) expressing 721.221 cell line (blue 
histogram) relative to baseline (red histogram).   Increase in pCrkL post 
cross-linking of functional grade NKG2A antibody in NK cells.  pCrkL increase 
was observed strictly in the NKG2A+gated NK subset (bottom row far right, blue 
histogram), whilst in the NKG2A- gated NK cells (bottom row middle, blue 
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histogram)  the increase is minimal and almost comparable to the base line (red 
histogram). 
 
After careful evaluation and kinetics studies performed on a combination of  
various kits, antibodies and stimulus, the following protocol was established.  
Detailed units of antibodies to be used are described in Table. 2.11.      
  
Table. 2.11  Antibody description and full product details included in NK 
licensing Phosflow panel 
 
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD56 ECD N901 Beckman Coulter 10 
CD3 Pacific Blue UCHT1 Biolegend 2.5 
NKG2A PE-Cy7 Z199 Beckman Coulter 5 
KIR2DL1/S1 PE EB6.B Beckman Coulter 10 
KIR2DL2/L3/S2 PE-Cy5.5 GL183 Beckman Coulter 20 
KIR3DL1/S1 APC Z27.3.7 Beckman Coulter 10 
pCrkL Alexa Fluor488 K30-391.50.80 BD Bioscience 1.25 
Live /Dead Aqua NA Life Technologies 0.5 
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Freshly isolated PBMCs were resuspended in cold PBS at 106/ml and distributed 
into FACS tubes at 1x105 cells per tube.  Cells were washed once with 2 ml 
PBS at 1500 rpm for 5 minutes and excess PBS was gently aspirated without 
disrupting the cell pellet.  Cells were resuspended in 500 µl PBS and stained 
with 0.5µl live/dead aqua reagent (diluted in 50µl DMSO) and incubated at RT in 
dark for 30 minutes.  At the end of the incubation period cells were washed with 
2 ml cold PBS at 1500 rpm for 5 minutes, and excess PBS was gently aspirated 
down to 200 µl staining volume without disrupting the cell pellet.  The tubes 
were then surface stained with the following antibodies and incubated on ice 
(4°C) for 20 minutes; 
 
Table. 2.12 Primary surface staining conditions for Phosflow assay. 
Tube/Condition Antibody Concentration 
(µg/ml) 
1.FMO NA NA 
2.Unstimulated Purified 
IgG1/IgG2 iso 
10 
3.NKG2A (CD159a) PE-Cy7 5 
4.KIR2DS1/L1 (CD158a,h) APC 10 
5.KIR2DS2/L2/L3(CD158b1,b2,j) PE-Cy5.5 20 
6.KIR3DS1/L1 (CD158e1,e2) PE 10 
7.H202  (positive control) NA NA 
 
Tubes were washed, spun down for 5 minutes at 2000 rpm with cold PBS and 
aspirated down to 200µl staining volume.  1 µl of anti-mouse IgG F(ab’)2 Cross 
linker was added to all tubes (except H202 positive control tube) and immediately 
transferred to 37°C water bath for a 10 minute incubation.   For the H202 
positive control tube, 200µl of pre-warmed 100uM H202 was added and 
immediately transferred to 37°C water bath for a 5 minute incubation.  Cells 
were washed for 3 min with PBS at 2000 rpm and the supernatant was aspirated 
down to 200µl staining volume.   The processing of the positive control tube 
was done within the incubation period allowing synchronization with the other 
tubes before proceeding to the permeablization step.  Upon completion of the 
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10 minute incubation period, 25µl of fix solution no.1 (Beckman PerFix 
EXPOSE) was added to all tubes and incubated in the dark/RT for 10minutes.  
1ml of 1x Perm solution no.2 (comprising of 500µl stock solution+ 500µl  FBS) 
was then added to all tubes and incubated in a 37°C water bath for 5 minutes.  
Tubes were immediately centrifuged at 2000 rpm for 5 minutes and excess PBS 
was aspirated as much as possible without disrupting the cell pellet.  50µl of 
Stain Buffer no.3 was then added to all tubes, along with the different antibody 
combination to each tube as follows;  
 
Table. 2.13 Secondary and intracellular staining combinations for 
Phosflow assay. 
Tube/Condition Antibody with ref to 
table.    
Volume 
1.FMO All antibody except 
pCrkL 
3µl 
2.Unstimulated All antibody 3µl 
3.NKG2A (CD159a) All antibody except 
NKG2A 
3µl 
4.KIR2DS1/L1 (CD158a,h) All antibody except 
KIR2DS1/L1 
3µl 
5.KIR2DS2/L2/L3(CD158b1,b2,j) All antibody except 
KIR2DS2/L2/L3 
3µl 
6.KIR3DS1/L1 (CD158e1,e2) All antibody except 
KIR3DS1/L1 
3µl 
7.H202  (positive control) All antibody 3µl 
 
Tubes were vortexed thoroughly and incubated in the dark/RT for 40 minutes.  
Finally, all tubes were washed in 2 ml of 1xWash buffer no.4 at 2000 rpm for 
5minutes, the buffer was discarded and cells were prepared for immediate 
FACS analysis. 
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2.16 In vitro cell NK differentiation from CB CD34+ progenitors  
This protocol was adapted from studies of Ni Fang et al (143).   Isolated CD34+ 
cells from CBMCs were cultured in SCGM supplemented with 100 U/ml 
Penicillin/Streptomycin and 10% FBS in the presence of recombinant human 
SCF (30 ng/ml), Flt3-L (50 ng/ml), IL-15 (50 ng/ml) and IGF-1 (100 ng/ml).  
Depending on the cell number/yield of the starting population (5×104 cells or 
1×105 cells per culture), cultures were grown in 0.1 or 1.0 ml medium in 96- or 
24-well culture plates, respectively.   The cultures were incubated at 37°C in a 
humidified atmosphere with 5% CO2 for 4 weeks.   Every 3–4 days, half of the 
medium volume was replaced with fresh medium containing the same 
concentration of freshly added cytokines. Cell density was thereby adjusted to 
1×106 cells/ ml in 6-well culture plates.  Surface phenotype of the differentiating 
cells were regularly phenotyped with the antibody cocktail described in Table. 
2.14 to monitor correct NK lineage progression as described previously(22).   
The assay was terminated at day 28, when cells were collected and NK cells 
were assessed for their KIR expression using the panel described previously in 
Table. 2.3 (Fig. 2.15). 
 
Table. 2.14  Antibody description and full product details included in 
CD34+ progenitor cell differentiation panel 
Antibody Fluorochrome Clone Vendor Concentration 
(µg/ml) 
CD34 FITC 561 Biolegend 1.25 
CD117 PerCP-Cy5.5 104D2 BD Biosciences 1.25 
CD161 APC 191B8 Miltenyi Biotec 5 
CD56 BV605 HCD56 Biolegend 1.25 
CD3 PE-Cy5 UCHT1 Biolegend 0.5 
NKG2A PE-Cy7 Z199 Beckman Coulter 5 
CD94 PE HP-3D9 BD Biosciences 1.25 
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Fig. 2.15 In vitro NK differentiation from CB CD34+ HPCs and monitoring 
of KIR reconstitution. NK cells were differentiated from cord blood derived 
CD34+ HPCs in order to recapitulate the reconstitution of NK cells post cord 
blood transplant and the sequential acquisition of KIR receptors in vitro.  
Delayed acquisition of C2-specific KIR2DL1 during NK cell differentiation. 
Induced acquisition of KIRs from NKG2A+KIR- NK subsets is achieved in a 
sequential manner: the C1-specific KIR2DL2/3 is expressed earlier and at higher 
frequency than the C2-specific KIR2DL1. 
 
    Illustration adapted from Fischer et al. 2007(144) 
 
2.17 Patients consent and recruitment 
All patients who received CBT at MD Anderson Cancer Center (MDACC) 
between July 2005 and December 2012 under standardized protocols for the 
treatment of different hematologic malignancies were eligible for this analysis. 
HLA genotypes were provided by the HLA Typing Laboratory at MDACC. For 
the discovery and validation studies, patients were selected sequentially, and no 
patient was included in both studies.  
The discovery cohort included 110 patients who had undergone CBT and had 
available genomic DNA from both the recipient and the CB graft (Table 3.1). The 
median follow-up for surviving patients at the time of analysis was 14 months 
 87 
(range, 2-64 months). An independent cohort of 94 consecutive patients with 
features similar to those of the study group was used to validate our results.  
This study was performed in accord with the Declaration of Helsinki following 
informed consent and was approved by the local institutional review board.  
Patient PBMC samples were grouped into 3 time point accordingly to their time 
of sample collection post transplant (T1 = 1-3 months post transplant, T2 = 3-6 
months, T3 = >6months). 
 
2.18 Statistical Analysis 
For analysis used in chapter 3 and 4, the probability of overall survival (OS) and 
risk of CMV reactivation was calculated by the Kaplan-Meier method, with the 
cumulative incidence procedure used to estimate the risk of disease relapse and 
transplant related mortality (TRM). Univariate analysis was performed with 
standard statistical methodology. Variables found to be significant at the p<0.10 
level were included in the multivariate analysis, where OS was examined with a 
Cox regression model and relapse by Fine-Gray regression analysis. 
Categorical data were compared with Fisher’s exact test, and quantitative data 
with the Mann-Whitney or the Kruskal-Wallis test. Hazard ratios (HR) are 
reported with 95% confidence intervals (CI).  
For chapter 5, Mann–Whitney tests were performed for individual comparisons 
of two independent groups. Paired T-tests were performed for comparisons of 
paired groups.  Statistical analysis was performed using GraphPad Prism 6 
software, with significance defined at P <0.05 with a 2-tailed test.   
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Chapter 3 Specific HLA-KIR Genotype Combinations Predict 
Leukemia/Lymphoma Control by NK Cells after Cord Blood 
Transplantation 
 
3.1 Introduction 
Allogeneic hematopoietic stem cell transplantation (HSCT) is the sole curative 
treatment for many hematologic cancers. Yet, only 30% to 40% of patients who 
require an allograft have a human leukocyte antigen (HLA)-identical sibling 
donor (145).  The less stringent requirements for HLA matching made possible 
by umbilical cord blood (CB) has greatly extended access to HSCT,(89, 146) 
although this option has a number of disadvantages, including delayed 
hematopoietic recovery, that impose higher risks of life-threatening infections 
and the progression of residual disease.  Thus, strategies that could eliminate 
minimal residual disease after CB transplantation (CBT), would be instrumental 
in promoting CBT as a clinically efficacious procedure.  As the first lymphocyte 
subset to reconstitute the peripheral blood after CBT,(147, 148) NK cells play an 
important role in mediating the GVL effect (48, 149, 150) and therefore offer 
attractive options for improving the outcome of CBT. In the allogeneic transplant 
setting, the ability of an NK cell to recognize and kill transformed cells is 
governed by complex interactions between killer immunoglobulin-like receptors 
(KIRs) and their HLA class I ligands(48, 149, 151) that are currently poorly 
understood. Thus, identifying specific combinations of activating and inhibitory 
KIRs and their HLA ligands, and relating them to transplantation outcome, has 
assumed increasing importance in efforts to exploit NK cell alloreactivity in CBT. 
This is a complex task, as early reports linked haploidentical transplants from 
KIR-HLA mismatched donors to a marked reduction in relapse rates,(48, 53) 
while later analyses failed to demonstrate a clinical benefit from KIR-ligand 
incompatibility (50, 51).  Moreover, the ‘education’ or ‘licensing’ of NK cells 
governs their functional maturation, enabling their discrimination of self from 
missing-self. This is not an all-or-nothing process, but instead takes place over 
time as the donor NK cells adapt to their new surroundings in the recipient, 
resulting in a continuum of NK cell responsiveness (16).  
Based on these considerations, I hypothesized that the recipient’s HLA group C 
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environment for inhibitory KIRs, together with donor NK cell licensing and 
activating KIRs, exerts the greatest influence on NK cell function against residual 
leukemia and other hematologic cancers after CBT.  This concept was pursued 
by analyzing recipient HLA genotypes and donor HLA and KIR genotypes for 
110 patients who had undergone CBT at a single center..  Inhibitory KIR 
phenotypes and functional data of the reconstituting NK cells at the single cell 
level were achieved through multicolour flow cytometry. 
 
3.2 Results 
3.2.1 Recipient HLA-C genotypes are associated with distinct 
transplantation outcomes  
HLA group C molecules were initially selected as the factor of interest due to 
their importance in NK cell licensing and hence the functional competence of 
donor NK cells (14).  When grouped according to the presence or absence of 
genes encoding recipient HLA-C ligands for donor inhibitory KIRs, 24 of the 110 
patients had alleles belonging only to the HLA-C2/C2 group, 53 had alleles 
belonging to both groups (HLA-C1/C2) and 33 patients had alleles belonging 
only to the HLA-C1/C1 group. Patients with an HLA-C2/C2 genotype had a 
significantly higher risk of progression than those with C1/C1 or C1/C2 
genotypes (HR 4.46 [95% CI 2.04-9.74] vs. 1.00 vs. 1.96 [0.51-2.76], P<0.001 
and P=0.001 respectively), as well as a significantly worse overall survival (HR 
2.35 [1.34-4.13] vs. 1.00 vs. 0.77 [0.42-1.34], P=0.0002 and P=0.004 
respectively) (Fig. 3.1a,b). The transplant-related mortality (TRM) among the 
three cohorts were nearly identical (Fig. 3.1c). Notably, the adverse impact of the 
HLA-C2/C2 genotype on the risk of progression and overall survival was 
independent of the myeloid or lymphoid origin of the underlying malignancy.  
Moreover, in contrast to previous reports in the setting of HLA-matched HSCT, 
there was no demonstrable impact of a donor B/x haplotype(152) or a combined 
KIR2DS1 and HLA-C1/x genotype(153) on the risk of disease progression or 
overall survival.  Given their nearly identical outcomes and similar clinical 
features (Table 3.1), we combined patients classified as C1/C1 or C1/C2 into the 
C1/x group for all remaining time-to-event analyses.  
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Table 3.1 Patient characteristics and outcomes in the learning cohort 
(n=110) 
 n 2-year overall 
survival 
2-year CI 
progression 
Age  I 
≤40 yr 
>40 yr 
 
59 
51 
p=0.09 
37.9 
23.0 
p=0.64 
31.7 
36.7 
Sex 
Male 
Female 
 
48 
62 
p=0.34 
29.0 
31.4 
p=0.83 
34.1 
34.0 
Diagnosis 
Acute lymphoblastic leukemia 
Acute myeloid leukemia 
Myelodysplastic syndromes 
Others 
 
24 
44 
19 
23 
p=0.77 
31.1 
32.4 
39.2 
39.2 
p=0.68 
24.8 
35.9 
43.2 
34.4 
Disease status at transplant 
Complete remission 
Refractory/relapsed disease  
 
67 
43 
p=0.01 
45.0 
29.4 
p=0.02 
25.6 
46.6 
Conditioning regimen 
Myeloablative 
Non-myeloablative 
 
79 
31 
p=0.59 
27.4 
37.0 
p=0.59 
35.3 
30.5 
Graft 
Single cord  
Double cord 
 
5 
105 
p=0.56 
31.3 
20.0 
p=0.79 
49.4 
40.0 
CMV status II 
Seropositive 
Seronegative 
 
97 
11 
p=0.63 
33.1 
14.1 
p=0.41 
31.9 
51.5 
HLA match between recipient and 
dominant cord unit III 
≤4/6 
5/6 
6/6 
 
 
40 
43 
13 
p=0.48 
 
35.9 
25.5 
49.1 
p=0.36 
 
31.2 
43.1 
20.5 
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Patient HLA class C group 
C1/C1 
C1/C2 
C2/C2 
 
33 
53 
24 
p=0.001 
38.0 
36.3 
10.0 
p<0.0001 
31.4 
27.8 
75.9 
Patient HLA class C group 
C1/x 
C2/C2 
 
86 
24 
p<0.001 
41.5 
10.0 
p<0.001 
29.3 
75.9 
 
Patients receiving CB grafts with 
combined HLA-C1-KIR2DL2/L3/S2 
genotype IV  
             Yes  
       No 
 
 
 
 
67 
37 
p=0.003 
 
 
 
50.1 
26.5 
p=0.01 
 
 
 
20.2 
49.1 
Patients receiving CB grafts with 
combined HLA-C2-KIR2DL1/S1 
genotype IV  
             Yes  
             No 
 
 
 
47 
57 
p=0.18 
 
 
40.6 
30.6 
p=0.75 
 
 
36.6 
36.6 
Number of haplotype B in the graft IV 
2 CB units 
1 CB units 
0 CB units 
 
88 
14 
2 
p=0.63 
34.6 
29.3 
50.0 
p=0.51 
30.5 
26.7 
0 
HLA-C1/x patients receiving CB grafts 
with combined 
HLA-C1-KIR2DL2/L3/S2 genotype IV  
            Yes  
            No 
 
 
 
31 
49 
p=0.01 
 
 
57.4 
33.8 
p=0.002 
 
 
6.7 
42.8 
I  The median age was 38 (range 2-73) 
II Two patients had missing data 
III The identity of the dominant CB unit could not be ascertained in 14 cases  
IV Six patients had missing data 
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Figure. 3.1 Effect of recipient HLA-C genotype on clinical outcome after 
CBT. The 2-year cumulative incidence rates of progression (Panel A), overall 
survival (Panel B) and treatment-related mortality (TRM; Panel C) are shown for 
110 patients stratified according to the results of HLA-C genotyping. Patients 
with HLA-C2/C2 genotype had a significantly higher cumulative risk of 
progression (100%) compared to those with an HLA-C1/C1 (32%) or C1/C2 
(24%) genotype (P<0.001).   HR denotes hazard ratio. Patients still at risk are 
indicated by tick marks on the curves.  
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To confirm the clinical relevance of HLA-C ligands, we validated our findings with 
an independent cohort of 116 consecutive patients who underwent CBT 
between 2005 and 2009 at MDACC (Table 3.2).  For the discovery and 
validation studies, patients were selected sequentially, and no patient was 
included in both studies. High-resolution HLA genotyping results were available 
in all cases, enabling us to substantiate the lower survival rate and higher risk of 
progression associated with HLA-C2/C2 alleles versus the presence of at least 
one HLA-C1 allele (Fig. 3.2).   
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Table. 3.2 Patient characteristics and outcomes in the validation cohort 
(n=116)
Age- yr  
Median 
Range  
 
41.0 
1-73 
Sex- no. (%) 
Male 
Female 
 
69 (59.6) 
47 (40.4) 
Diagnosis, no. (%) 
Acute lymphoblastic leukemia 
Acute myeloid leukemia 
Myelodysplastic syndromes 
Chronic myeloid leukemia 
Chronic lymphocytic leukemia 
Hodking lymphoma 
Non Hodking lymphoma 
Other 
 
25 (21.4) 
42 (36.7) 
5 (4.3) 
7 (6.0) 
11 (9.4) 
7 (6.0) 
12 (10.3) 
7 (5.9) 
Disease status at transplant- no. (%) 
Complete remission 
Active disease  
 
66 (57.3) 
50 (42.7) 
Conditioning regimen- no. (%): 
Myeloablative 
Non-myeloablative 
 
85 (73.5) 
31 (26.5) 
Graft 
Single cord  
Double cord  
 
9 (7.7) 
107 (92.3) 
CMV status- no. (%) * 
Seropositive 
Seronegative 
 
104 (89.7) 
12 (10.3) 
Degree of HLA match by CB unit  
Unit 1 
≤4/6 
 
 
52 (44.8) 
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5/6 
6/6 
Unit 2 
≤4/6 
5/6 
6/6 
44 (37.9) 
13 (17.3) 
 
58 (54.2) 
43 (40.2) 
6 (5.6) 
 
Fig 3.2. Validation of results in learning cohort with an independent cohort 
of 116 patients who underwent CBT at this center from 2006 to 2009. 
Panels A and B show the 2-year cumulative progression and overall survival 
estimates for 116 consecutive patients stratified by HLA-C group (C1/x 
combines C1/C1 and C1/C2). Patients still at risk are indicated by tick marks on 
the curves. 
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Similar to the multivariate analysis in the discovery cohort, the variables 
“refractory/relapsed disease”, “CB graft negative for HLA-C1-KIR2DL2/L3/S2 
genotype” and “patient HLA-C2 homozygosity” were the only independent 
predictors for relapse and OS, and the interaction term “CB graft negative for 
HLA-C1-KIR2DL2/L3/S2 genotype” and “patient HLA-C2 homozygosity” was 
found to be significant in both analyses. Following the same methodology 
employed in the discovery cohort, patients were classified into three categories: 
HLA-C1/x patients who received an HLA-C1-KIR2DL2/L3/S2 graft (n=40, red 
line), HLA-C1/x patients who did not receive an HLA-C1-KIR2DL2/L3/S2 graft 
(n=38, green line) and HLA-C2 homozygous patients (n=16, purple line).  The 
adjusted hazard ratios for relapse for the three groups were 1.00, 6.4 (CI 
1.53-28.75; p=0.01) and 20.7 (CI 45.7-93/90; p<0.001) respectively.  The 
adjusted hazard ratios for OS were 1.00, 2.19 (CI 1.15$4.18;(p=0.02) and 5.36 (CI(
2.54$11.32;( p<0.001).( ( Patients with relapsed/refractory disease at CBT had 
higher relapse and worse OS: adjusted HR 2.37 (CI 1.09-5.82; p=0.004) and 
adjusted HR 1.42 (1.01-3.84; p=0.04) (Fig. 3.1.3)  
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Figure 3.3. Multivariate analysis for relapse and OS in the validation 
cohort. Panels A and B show the 2-year cumulative incidence of relapse and 
OS for the 3 groups described above. Vertical lines indicate censored patients.    
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3.2.2 Single KIR2DL2/3-expressing NK cells emerge as the dominant NK 
cell subset after CBT regardless of recipient HLA-C ligands  
The effect of HLA-C genotypes on outcome might have been related to biased 
expression of their cognate receptors during NK cell development. Thus, we 
allowed CB-derived CD34+CD38- hematopoietic progenitor cells from eight CB 
units to differentiate to CD3-CD56+ NK cells in vitro(143), and then determined 
the order of KIR acquisition.  Typically, the surface expression of KIRs was 
detectable after 2 to 3 weeks of culture. KIR expression on differentiating NK 
cells was characterized by the earlier appearance and higher expression of 
C1-specific KIR2DL2/3 compared to C2-specific KIR2DL1/S1 (P<0.001), 
irrespective of whether the sample was from an HLA-C1/C1, C1/C2 or C2/C2 
donor (Fig. 3.4).  These data suggest a model in which the sequential order of 
HLA-C-specific KIR acquisition on recovering NK cells after CBT is 
epigenetically programmed and biased toward a functional repertoire dominated 
by C1-specific NK cells.  
 
 
Figure. 3.4 Flow cytometric analysis of the emergence and frequency of 
CD56+CD3- NK cells. Defined by surface KIR expression both in vitro 
(differentiation from CD34+CD38- hematopoietic progenitor cells from eight CB 
donors; Panels A and B) and in vivo (peripheral blood samples from seven 
HLA-C1/C1, nine C1/C2 and four C2/C2 patients; Panel C), collected at different 
post-CBT intervals (median 50.0 [T1], 97.5 [T2] and 189.5 [T3] days). Panel D 
shows the frequency of KIR2DL2/3 vs. KIR2DL1/S1-expressing single NK cells 
at the T1-T3 intervals. Box plots represent median values (lines inside boxes) 
and the first and third quartiles; whiskers extend to 1.5 times the interquartile 
range. 
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Using 14-color multiparameter flow cytometry, KIR expression was studied on 
single-cells in peripheral blood samples from 20 patients (seven C1/C1, nine 
C1/C2 and four C2/C2) at three post-CBT intervals (median 50.0, 97.5 and 
189.5 days; designated T1, T2 and T3, respectively). As shown in Fig. 3.2c, 
single KIR2DL2/3-expressing NK cells dominated the NK cell repertoire, 
regardless of the recipient’s HLA-C group. At T1, T2 and T3, the median 
frequencies of KIR2DL2/3-expressing NK cells were significantly higher than 
those for KIR2DL1/S1-expressing NK cells (23.0% vs. 2.9%, P<0.001;  21.6% 
vs. 3.5%, P<0.001 and   27.6% vs. 4.0%, P<0.001, respectively) (Fig 3.4d). 
These findings support our in vitro model favouring the generation of C1-specific 
NK cells early after CBT. 
 
The function of recovering KIR-expressing NK cell subsets in the context of 
different HLA-C ligand environments were then evaluated. When NK effector 
function was determined in C1/x vs. C2/C2 recipients, the frequency of 
IFN-γ+KIR2DL2/L3+ NK cells was 26.7% (interquartile range 23.6-30.6%) 
compared to 12.9% (10.4-19.3%) (P<0.001). For TNFα+KIR2DL2/L3+ NK cells, 
it was 14.5% (12.4-18.7%) compared to 11.6% (range 8.3-13.7%) (P=0.02), and 
for CD107a+KIR2DL2/L3+ NK cells, it was 16.6% (13.1-21.7%) compared to 
11.5% (9.4-18.4%) (P=0.06). Representative FACS plots are presented in (Fig. 
3.5). These results suggest that the HLA-C2/C2 background of the recipient can 
specifically inhibit the effector function of regenerating NK cells. 
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Fig. 3.5 Reconstituting single KIR2DL2/3-expressing NK cells shows 
differential effect accordingly to host HLA type: KIR2DL2/3+ NK cells have 
reduced effector function in HLA-C2/C2 recipients compared to HLA-C1/C1 or 
HLA-C1/C2 recipients.  A) Representative FACS plots B) Cummulative data 
A) 
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3.2.3 Combined HLA-C1-KIR2DL2/3 and KIR2DS2/3 genotype in the CB 
graft is associated with a lower risk of progression in C1/x recipients  
To account for the more favorable outcome in the C1/x group, we first assessed 
the contribution of the activating homolog of the C1-specific inhibitory KIR 
receptor, KIR2DS2/3 (154).  KIR gene of interest was considered to be positive 
if it was present in at least one CB unit. This analysis showed that the 
KIR2DS2/3 genotype of the donor lacked a significant impact on disease 
progression (HR 0.97 [95% CI 0.48-1.97], P=0.95).  
 
Because mature licensed NK cells respond more vigorously than their 
unlicensed counterparts through their activating receptors (128, 140, 155), it was  
hypothesized that any association between the donor KIR2DS2/3 genotype and 
protection from progression in HLA-C1/x recipients would be more pronounced if 
the donor NK cells were licensed.  Using KIR and HLA data available for 80 of 
86 patients to predict the KIR licensing status of CB units, we identified three 
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distinct groups among patients. Group A included the 34 patients who were 
transplanted with at least one CB unit possessing the combined donor genotype 
of HLA-C1-KIR2DL2/3 and KIR2DS2/3; group B, the 31 patients who received at 
least one CB unit with the genotype of HLA-C1-KIR2DL2/3, with neither unit 
being positive for KIR2DS2/3; and group C, the remaining 15 patients who 
received units that were negative for the combined HLA-C1-KIR2DL2/3 
genotype, with 9 cases positive for KIR2DL2/3 in an HLA-C2/C2 CB unit (three 
cases were negative for KIR2DL2/3). Patients in group B and C had a 
significantly higher risk of progression than patients in group A, namely HR 3.38 
(95%CI 1.07-10.68, p=0.03) and HR 6.60 (95% CI 2.19-19.87, p=0.001) 
respectively, while the risks in groups B and C were similar (Fig. 3.6a). These 
data, together with those in Fig. 3.4B,C, underscore the importance of the 
combination of licensed KIR2DL2/3- and KIR2DS2/3-positive NK cells in 
conferring protection from disease progression in HLA-C1/x recipients.  The 
presence of additional activating KIR genes, such as KIR2DS1, lacked any 
discernible impact on outcome in any of the three groups studied (data not 
shown), pointing to the requirement for receptor expression on recovering NK 
cells in order for the NK cells to exert their protective effect. 
By 6 months after transplantation with two CB units, one dominates as the main 
source of hematopoiesis (147).  Therefore, a 6-month landmark analysis of the 
influence of the KIR-HLA genotype on disease progression was performed. The 
10 C1/x patients in whom the dominant CB unit was positive for the combined 
genotype of HLA-C1-KIR2DL2/3 and KIR2DS2/3 had a significantly lower 2-year 
cumulative incidence of progression than did the 37 C1/x patients, in whom the 
dominant unit was negative for HLA-C1, KIR2DL2/3 or KIR2DS2/3 (0% vs. 
37.5%; HR 31.25 [1.96-0.61.7], P= 0.01). 
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Figure. 3.6 Effect of NK cell licensing status and activating KIR genes on 
protection from relapse after CBT. Incidence rates of disease progression are 
shown for HLA group C1/x patients who received at least one CB unit predicted 
to be licensed (combined genotype of KIR2DL2/3-HLA-C1) and positive for 
KIR2DS2/3 (optimal combination, Group A) compared to those receiving at least 
one CB unit predicted to be licensed for KIR2DL2/3 but with neither unit positive 
for KIR2DS2/3 (suboptimal combination, Group B) or both CB units negative for 
KIR2DL2/3-HLA group C1 (suboptimal combination, Group C) (Panel A).  
Panels B and C show outcome for HLA-C1/x patients receiving at least one CB 
unit with an optimal or suboptimal KIR2DL2/3-HLA-C1 and KIR2DS2/3 
combination versus the entire HLA-C2/C2 group (Panel B). HR denotes hazard 
ratio with a 95% confidence interval. Tick marks on the curves denote patients 
still at risk. 
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3.2.4 Combined HLA-C1-KIR2DL2/3 and KIR2DS2/3 genotype in the CB 
graft, recipient homozygosity for HLA-C2 and disease status at transplant 
are major factors associated with progression  
In a univariate analysis of selected variables, disease status at transplant, 
HLA-C2 homozygosity in the recipient, and graft positivity for licensed 
HLA-C1-KIR2DL2/3 and KIR2DS2/3 attained significance (P<0.01). By 
multivariate analysis, recipient C2/C2 genotype (HR 2.48 [95% CI 1.16-5.32], 
P=0.024), active disease at the time of transplant (HR=2.51, [1.22-5.16], 
P=0.012) and the infusion of at least one CB unit positive for licensed 
HLA-C1-KIR2L2/3 and KIR2DS2/3 (HR 0.32, [0.11-0.97], P=0.027) were 
independent predictors of disease progression, whereas recipient C2-C2 
genotype (HR 1.99 [1.13-3.52], P=0.013) and active disease at the time of 
transplant (HR 2.12 [1.27-3.53], P=0.004) were the only variables independently 
associated with overall survival.  Independent predictors of disease progression 
were then used to identify patients who might derive the greatest benefit from 
CBT.  The 23 HLA-C1 patients who received at least one CB unit with the 
combined genotype of HLA-C1-KIR2DL2/3 and KIR2DS2/3, and were in 
remission at the time of transplant, had an excellent outcome compared with 
results for the remaining 82 patients: 2-year cumulative incidence of relapse, 
13.5% vs. 65.8% (HR 1 vs 4.54 [1.35-14.28], P=0.003). This result translated to 
a 2-year survival rate of 72% vs. 17.6% (HR 1 vs 4.17 [1.75-9.09], P=0.001).  
 
3.2.5 Regenerating single KIR2DL2/3-expressing NK cells from CB units 
with the combined HLA-C1-KIR2L2/3 and KIR2DS2/3 genotype possess 
enhanced effector function in HLA-C1/x recipients  
Next it was considered that licensed NK cells expressing KIR2DL2/3 together 
with KIR2DS2/3 are optimal in C1/x recipients because they likely possess 
enhanced effector function. This hypothesis was tested by analyzing effector 
function post-transplant against K562 targets compared to that of reconstituting 
NK cells in recipients of CB units with a ‘suboptimal KIR-HLA’ combination 
(unlicensed NK cells expressing KIR2DL2/3 or NK cells negative for KIR2DS2/3).   
Patients receiving optimal CB units had significantly higher frequencies of 
KIR2DL2/3+ KIR2S2/3+CD107a+ NK cells (median 18.1% [interquartile range 
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16.8-19.5%]. vs. 13.4% [11.9-14.9%], P=0.01), KIR2DL2/3+ KIR2S2/3+IFN-γ+ 
NK cells (28.7% [25.7-31.7%]  vs. 17.0% [14-19.5%], P=0.002) and 
KIR2DL2/L3+KIR2S2/3+TNF-α+ NK cells 16.4% [14.6%-18.2%] vs. 12.3% 
[11.0%-13.6%], P=0.02) (Fig. 3.5).  These findings suggest that NK cells 
expressing licensed KIR2DL2/3 may recognize reduced HLA class I expression 
on leukemic cells (Fig. 3.7), which respond more vigorously when triggered 
through their activating receptors (KIR2DS2/3), ultimately leading to a superior 
outcome for HLA-C1-positive patients after CBT. 
 
Figure. 3.7  NK cells from CB units with the optimal KIR2DL2/3-HLA-C1 
and KIR2DS2/3 combination display enhanced effector function compared 
to CB units with the suboptimal combination; Representative FACs plots for 
Optimal a) and Suboptimal b) CB units c) cumulative data 
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3.2.6 Leukemic blasts down modulate HLA-Class I as an immune evasion 
mechanism. 
NK cells require encounter with self cognate HLA-class I in order to acquire 
functional competence during early stages of development, however the same 
HLA-class I ligand will inhibit functional response of functionally competent NK 
cells.  This raises questions as to how KIR2DL2/3+ CB NK cells reconstituting 
in HLA-C1/x recipients can kill HLA-C1 expressing tumour cells.    Although 
leukemic cells express HLA class I, they have been reported to downregulate 
these molecules to evade immune recognition by T cells (156, 157). Primary 
blasts from 10 patients with AML at diagnosis were defined as 
CD34+CD33+CD13+ and had significantly lower expression of HLA class I when 
compared to CD13+CD33+ myeloid cells (monocytes, granulocytes) from 
healthy donor bone marrow samples (P<0.0001) (Fig. 3.8). 
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Fig. 3.8  HLA class I molecules are downregulated on the surface of leukemic 
blasts. (A) Gating strategy is presented for phenotyping of AML blasts and 
healthy control myeloid cells. Cells are gated on the myeloid lineage based on 
co-expression of CD13 and CD33. CD34 coexpression is included for AML 
blasts. (B) HLA class I expression was analysed on the surface of myeloid cells 
from 10 healthy control bone marrow and 10 AML patient samples collected at 
diagnosis. The HLA class I expression per cell, measured by MFI (mean 
fluorescence intensity), is significantly lower on the surface of AML blasts 
compared to healthy control myeloid lineage cells.  
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3.3 Discussion 
            Specific combinations of KIR receptors and HLA ligands were 
studied within the reconstituting NK cell repertoire of CB recipients to identify 
those most closely linked to the clinical outcome of CBT.  First of all, I have 
shown that recipients homozygous for HLA group C2 have a significantly higher 
rate of progression within the first 180 days post-CBT than do patients positive 
for HLA-C1/x. This finding was confirmed in an independent cohort of 116 
consecutive patients and agrees with studies of patients homozygous for HLA 
group C2 in a non-transplant settings,(158) as well as those undergoing 
unrelated donor HSCT (159, 160).  The results represent an advance over 
previous efforts to define the role of KIR-HLA genetics in CBT outcome,(161, 
162) which have focused on KIR-HLA ligand incompatibility with only limited 
attention paid to functional correlates and mechanisms of NK cell activity. 
             These data collectively suggest that the adverse impact of 
HLA-C2 homozygosity on treatment outcome resides in the order in which KIRs 
are acquired during NK cell regeneration, which many believe is a stochastic 
process (163). Indeed, it is shown here that NK cells generated in vitro from 
CB-derived CD34+ cells express KIRs in a sequential manner, characterized by 
the earlier appearance and higher expression level of C1-specific KIR2DL2/3 
receptors, compared to C2-specific KIR2DL1 receptors. This result parallels flow 
cytometric evidence of the lagging recovery and hypofunctionality of 
KIR2DL1-expressing NK cells in the first 6 months post-CBT, contrasted with the 
high frequency of KIR2DL2/3-expressing NK cells, observed as early as 1 month 
post-CBT. Others have shown that KIR2DL1 has a much stronger binding 
affinity for HLA-C2 ligands than does either KIR2DL2 or KIR2DL3,(164, 165) 
predicting a stronger inhibitory signal from KIR2DL1 and HLA-C2 interactions in 
vivo.  Thus, the model suggested by our findings -- rapidly recovering subsets 
of functional KIR2DL2/3-expressing NK cells with restricted populations of 
KIR2DL1-expressing NK cells -- would be expected to render NK cells 
hyporesponsive in C2/C2 recipients, diminishing the graft-versus-leukemia effect 
and predisposing to an increased risk of progression. Nonetheless, some 
protection against disease progression could be expected from the early 
reconstituting KIR2DL2/3-expressing NK cells,(166) although this scenario loses 
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traction given the poor effector function of reconstituting KIR2DL2/3-positive NK 
cells in C2/C2 recipients. These data are consistent with previous work in the 
setting of haploidentical HSCT, which demonstrates marked inhibition of 
KIR2DL2/3-expressing NK cells by C2-expressing target cells.(167)   
           The presence of activating KIR genes in the donor plays an 
important role in protection against leukemic relapse and cytomegalovirus 
reactivation (58, 152, 168, 169). Recipients of grafts from donors with KIR B 
haplotype-defining genes have a decreased incidence of relapse(170) as do 
those whose NK cells express certain activating KIRs, such as KIR2DS1.(58) 
However, in studies in both humans and murine models, unlicensed NK cells are 
hyporesponsive to activating stimuli, and the expression of an activating 
receptor by itself only partially reverses such impairment(14, 140). Unfortunately, 
the rules governing NK cell licensing in the human allogeneic transplant 
environment are largely undefined. In a murine model of cytomegalovirus, NK 
cell licensing behaviour was shown to correspond to the HLA genotype of the 
donor (not the recipient)(171), and recent evidence from patients undergoing 
allogeneic HSCT suggests a larger role in licensing for the donor as opposed to 
host HLA molecules.(172) These observations support findings of the present 
study, in which the CB graft appeared to shape NK cell functionality after CBT. 
That is, patients with a C1/C1 or C1/C2 genotype fared significantly better when 
they received CB grafts positive for licensed KIR2DL2/3-expressing NK cells and 
the gene for activating KIR2DS2/3. These observations emphasize the 
contributions of NK licensing and activating KIRs, as opposed to KIR-ligand 
mismatch exclusively, to alloreactivity in the post-CBT setting.  I did not find an 
impact of a donor B/x haplotype(152) or KIR2DS1 on the risk of disease 
progression after CBT.  This is likely related to delayed expression of the 
corresponding activating receptors on recovering NK cells after CBT (Fig 3.2c).   
Combined with the down expression of HLA-Class I observed on AML blasts 
(Fig.3.6), collectively my data suggest that licensed KIR2DL2/3-expressing NK 
cells can recognize reduced HLA class I expression on leukemic cells more 
readily than unlicensed NK cells, leading in turn to more robust triggering of NK 
cells through their activating receptors, such as KIR2DS2/3.  
             CB units for transplantation are typically selected on the basis of 
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cell dose and a minimum of 4/6 matching with the recipient at HLA-A, B and DR 
alleles.(89, 146, 150) The insights into KIR-HLA interactions provided by this 
study suggest that CBT patients in the C2/C2 group would benefit from the 
infusion of mature NK cells expressing KIR2DL1/S1 immediately after 
transplantation.  Indeed, CB-derived NK cells have been shown to be readily 
expandable by a robust, GMP-compliant procedure,(173) yielding sufficient 
numbers of cells to elicit an early GVL response in C2/C2 recipients. Guided by 
these data on C1/x recipients, I now propose that the selection of at least one 
CB unit licensed for KIR2DL2/3 and positive for the activating KIR2DS2/3 gene 
may result in an improved outcome after CBT in this group of patients.  The 
current study may have limitations regarding the C1/C2 heterozygous cohort 
group being relatively small, and further investigation should validate the 
findings.  A clinical trial testing these two strategies is currently underway at the 
MD Anderson Cancer Center. 
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Chapter 4 Impact of Donor NKG2C Genotype on the Incidence of CMV 
Reactivation after Cord Blood Transplantation 
 
4.1 Introduction 
 
Following the findings in chapter 3 which identified the potential of specific 
HLA-KIR genotype combinations to improve clinical outcome on cord blood 
transplantation by a mechanism mediated by reconstituting NK cells, this 
chapter aims to investigate the potential of NK cells to control transplant 
associated complications, namely cytomegalovirus infection. Cytomegalovirus 
(CMV) reactivation is a major cause of morbidity and mortality post cord blood 
transplantation (111, 174-176).  With less stringent HLA matching requirements 
allowing higher rate of engraftments cord blood has become a promising 
alternative to bone marrow and peripheral blood stem cells grafts (81, 177, 178), 
but on the downside has been associated with a higher risk to latent virus 
infections (179, 180).  Despite low risk of transmission directly from the donor 
CB grafts after thorough screening plus low rate of reported congenital infection, 
CMV is highly prevalent in the global population (50-100%) and reactivation of 
residual latent virus in seropositive recipients are close to inevitable, exposing 
cord blood recipients at particular risk(181).  CMV viral infection is primarily 
controlled by CD8+ memory T cells with CMV antigen specificity (182), however 
unlike in bone marrow grafts such transfer of adaptive immune subsets are 
absent due to the naïve content of cord blood leaving viral clearance entirely 
dependent on the innate arm (183).  Anti-viral therapy will often resolve the viral 
load to an acceptable level, although the toxicities and sometimes adverse side 
effects emphasizes on the need for a less invasive control measure (184).  NK 
cells are the first lymphocyte subsets to inhabit the bone marrow post cord blood 
transplantation and have been shown to play a pivotal role in the control of 
herpes virus family in the absence of T cell population (185).  In particular are 
the activating receptor NKG2C+ NK cells, which are implicated in the control of 
CMV and speculated to be the memory subset capable of providing potent 
antiviral response (116).  NK cells have been reported to undergo clonal 
expansion in a NKG2C mediated manner in the presence of CMV (117, 186) 
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displaying conceptual resemblance to a memory CD8+ T cell response to a 
foreign antigen.  Preferential expansion of NKG2C+ NK cells have also been 
observed in several other acute and chronic infectious diseases systematically 
associated with CMV co-infection, including infection with hantavirus, 
chikungunya virus, HIV, HBV and HCV (118, 119, 132, 187).  Due to the high 
variability of NKG2C frequency among the population it was investigated 
whether any genetic background was predisposing such outcome.  After 
identification of a homozygous deletion of the NKG2C gene in upto 4% and 
heterozygous deletion in upto 34% of Japanese and European population, 
molecular studies further revealed that NKG2C is in fact expressed in a 
gene-dose dependent manner (136, 188).  As the total absence of NKG2C did 
not result in overt disease susceptibility in healthy individuals (189, 190) it was 
initially posed dispensable for survival and reproduction.  However it was later 
revealed to be a definitive risk for HIV disease progression (191) and current 
data on the active involvement of NKG2C gene-copy number variations on the 
outcome of transplant setting is limited to one study within an extremely small 
cohort size(192).  Here I aim to provide novel insights into the influence of 
Donor CB NKG2C zygosity on CMV reactivation outcome under double cord 
blood transplant setting and to identify any potential clinical implications. 
 
4.2 Results 
 
4.2.1 NKG2C gene dose of CB graft predicts for risk of CMV reactivation 
after CBT 
Conventionally NKG2C-expressing NK cells have been linked to efficient 
recognition and subsequent elimination of CMV infected cells (112, 186, 193).  
This observation, combined with studies reporting that the frequencies and 
regulation of NKG2C receptor expression is dependent on the gene copy 
number (136, 188), suggests that the outcome of CMV reactivation could be 
directly influenced by the NKG2C gene dose of the CB grafts.  The study group 
amongst which I investigated consisted of 72 DUCBT CMV sero-positive 
recipients, all of whom achieved donor engraftment.  42 (58%) of these 
developed evidence of CMV reactivation which occurred at a median time of 
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51.9 days (range 27.3-76.8).  High-resolution NKG2C genotyping data for 
recipients and corresponding cord blood grafts were available in all cases.   
Characteristics of these patients are summarized in (Table.4.1).  NRM was 
defined as death after transplant that was not preceded by recurrent or 
progressive malignancy. 
 
Table. 4.1 Patient Characteristics  
 
 
Patient characteristics Total patient 
Incidence of CMV reactivation  42/72 
Time to CMV reactivation (days) 51.9 (27.3-76.8) 
Sex  (Male) 35 
Age (years) 40.5 (7-73) 
Diagnosis 
AML/MDS 
ALL 
Lymphoma (NHL; HL) 
 
37 
18 
17 
Remission status at transplant 
CR 
Active disease 
 
42 
31 
Conditioning 
Myeloablative / Non-myeloablative 
 
52 / 20 
Type of conditioning 
Busulfan/clofarabine/thiotepa or 
TBI/ATG 
Fludarabine/Cyclophosphamide/TBI 
Melphalan/Thiotepa/Fludarabine/ATG 
 
1412 
46 
GVHD prophylaxis Tacrolimus + MMF 
CB1-HLA match 
4/6 
5/6 
6/6 
 
31 
35 
6 
CB2-HLA match 
4/6 
5/6 
6/6 
 
36 
30 
6 
NRM Death after transplant – not 
preceded by recurrent or 
progressive malignancy 
2-year OS 34% (95% CI 23.0-47.0) 
2-year NRM 47.9% (95% CI 34.1-62.0) 
2-year relapse 34.7% (95% CI 23.1-48.5) 
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As double cord blood transplantation is characterized by one cord dominating 
the main source of hematopoiesis by the 6 months landmark, the cord blood 
grafts were further stratified into dominant and losing in addition to their NKG2C 
gene content.  Six patients showed evidence of mixed chimerism and hence 
were were unable to assign them into dominant/losing groups.  Of the 66 
dominant CB units 43 (65%) had the NKG2C genotype wild type/wild type 
(designated NKG2C w/w) and 23 (35%) had the NKG2C genotype wild 
type/delete (NKG2C w/d).  Comparisons of key features between the NKG2C 
genotype recipients, both in dominant and losing CB unit scenarios, revealed no 
differences that might bias further analysis (Table. 4.2). Of note, NKG2C gene 
content did not impact on the propbability of the CB graft to dominate 
engraftment.  
 
Table. 4.2 Patient pre-transplant characteristics compared according to 
CB genotype (w/w or w/d) and engraftment category (dominant or losing) 
of CB. 
Patient 
characteristics 
W/W 
(dominant) 
(%) 
W/D 
(dominant
) 
(%) 
P WW 
(losing) 
(%) 
W/D 
(losing) 
(%) 
P 
Sex   
Male 
female 
 
19 (44.2) 
24 (55.8) 
 
13 (56.5) 
10 (43.5) 
 
0.44 
 
19 (45.2) 
23 (54.8) 
 
13 (54.2) 
11 (45.8) 
0.61 
Age (years) 
<40 
>40 
 
24 (55.8) 
19 (44.2) 
 
11 (47.8) 
12 (52.2) 
 
0.61 
 
25 (59.5) 
17 (50.5) 
 
10 (41.7) 
14 (58.3) 
 
0.21 
Diagnosis 
AML/MDS 
ALL 
Lymphoma 
(NHL; HL) 
 
19 (44.2) 
13 (30.2) 
11 (25.6) 
 
15 965.2) 
4 (17.14) 
4 (17.4) 
 
0.28 
 
26 (61.9) 
9 (21.4) 
7 (16.7) 
 
8 (33.3) 
8 (33.3) 
8 (33.3) 
 
 
0.08 
 
Remission status 
at CBT 
CR 
Active disease 
 
 
28 (65.1) 
15 (34.9) 
 
 
13 (56.5) 
10 (43.5) 
 
 
0.59 
 
 
23 (54.8) 
18 (45.2) 
 
 
18 (75.0) 
6 (25.0) 
 
 
0.12 
 
Conditioning 
Myeloablative 
Non- 
 
31 (72.1) 
12 (27.9 
 
16 (69.6) 
7 (30.4) 
 
1.0 
 
29 (69.0) 
13 (31.0) 
 
18 (75.0) 
6 (25.0) 
 
0.78 
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I next addressed whether the NKG2C gene copy number of the dominant CB 
unit had any influence on the incidence of CMV reactivation..  Patients whose 
dominant CB unit was NKG2C w/d genotype had a significantly higher 
cumulative incidence of CMV reactivation than did the w/w groups. (HR 1.97 
[95% CI 1.05-3.71] vs 1.0, [P=0.036]). (Fig. 4.1a).  I then addressed if the same 
outcome was evident if the difference in NKG2C genotype was seen in the 
losing cord unit.  Similarly to the dominant cord, the presence of NKG2C w/d 
genotype in the losing cord unit was also associated with a significantly higher 
incidence of CMV reactivation than the w/w groups. (HR 2.09 [95% CI 1.11-3.94] 
vs 1.0, [P=0.026]). (Fig. 4.1b).  Thus our initial findings suggest that DUCBT 
recipients receiving a CB unit possessing a NKG2C w/d genotype in either one 
of the two CB units are at higher risk of experiencing CMV reactivation.   
 
Fig. 4.1 Presence of NKG2C w/d in either dominant or losing CB unit 
significantly increases risk of CMV reactivation.  Regardless of whether the 
CB unit is engrafted or not, the presence of NKG2C w/d gene possess a 
significant risk to CMV reactivation. a) Impact of NKG2C genotype in the 
dominant cord b) losing cord.  
myeloablative 
HLA match 
4/6 
5/6 
6/6 
 
16 (38) 
22 (52) 
4 (10) 
 
 
11 (48) 
10 (43 
2 (9) 
 
0.51 
 
22 (53) 
17 (40) 
3 (7) 
 
 
 
11 (46) 
11 (46) 
2 (8) 
 
 
 
0.81 
2 yr OS 26.1 (95% 
CI, 
13.5-44.5) 
40.2 (95% 
CI, 
22.2-61.2) 
0.97 28.1 (95% 
CI, 
15.8-44.8) 
47.3 (95% 
CI, 
26.9-68.6) 
 
0.31 
2 yr NRM 40.8 (95% 
CI, 
24.1-59.9) 
50.8 (95% 
CI, 
29.5-71.8) 
0.38 49.8 (95% 
CI, 
32.4-67.3) 
34.5 (95% 
CI, 
16.2-58.8) 
0.49 
2 yr relapse 28.5 (95% 
CI, 
16.6-44.5) 
29.1 (95% 
CI, 
12.9-53.2) 
0.34 37.2 (95% 
CI, 
22.9-54.2) 
20.7 (95% 
CI, 
8.3-42.3) 
0.14 
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The 72 study cohort (including the 6 patients with mixed chimerism) were then 
grouped into one of 3 possible CB unit combinations, 10 (14%) received two CB 
units with w/d genotype  (w/d-w/d), 30 (42%) received at least one CB unit with 
w/d genotype (w/d-w/w) and 32 (44%)  were transplanted with two CB units 
with the w/w genotype (w/w – w/w).   The cumulative incidence of CMV 
reactivation was highest in recipients of two CB units with the NKG2C w/d 
genotype (designated w/d-w/d), compared to only one (w/d-w/w) or none at all 
(w/w-w/w).  (HR 5.34 [95% CI 2.33-12.24] vs.1.39 [0.69-2.80] vs. 1 [P=0.001]).  
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(Fig. 4.2) Remarkably the cord blood NKG2C genotype combinations were the 
strongest determinant of CMV reactivation over any other predicting factors as 
illustrated in (Table. 4.3).  Collectively these results suggest that the 
susceptibility of DUCBT recipients to CMV reactivation is determined by the 
NKG2C content of the infused CB units.  
 
Fig. 4.2 NKG2C genotype combination of the two CB unit is a strong 
predictor of CMV reactivation.  Highest risk of CMV reactivation was 
observed when both CB units expressed the NKG2C w/d genotype.  The risk 
was significantly reduced with the presence of a w/w allele, and provided the 
lowest risk of CMV reactivation when both CB units expressed w/w. 
 
 
Table. 4.3 Univariate analysis of factors predicting for CMV reactivation 
Patient characteristics! Relative Risk (95% CI)! P!
Sex  !
Male!
female!
 
1!
1.18 (0.64-2.16)!
 
0.59!
Age (years)!
<40!
>40!
 
1!
1.59 (0.86-2.21)!
 
 
0.14!
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4.2.2 The frequencies of regenerating NKG2C-expressing NK cells are 
significantly lower in recipients of CB units with the NKG2C w/d genotype  
To address whether the increased risk of CMV reactivation in recipients of CB 
units with NKG2C w/d genotype could be related to deficiencies inNKG2C 
expressing NK cells in the NK cell repertoire after CBT, I used a 14-colour 
multiparameter flow cytometry approach for single-cell analysis of 
NKG2C-expressing NK cells in peripheral blood samples cryopreserved from 20 
patients at two post-CBT intervals (median 50.0 and 97.5 days post-CBT; 
designated T1 and T2 respectively).  A representative FACs plots for the 
surface markers tested are shown in Fig. 4.3.  The frequencies of 
Diagnosis!
AML/MDS!
ALL!
Lymphoma (NHL; HL)!
 
1!
1.35 (0.66-2.77)!
1.47 (0.69-3.16) !
 
0.53!
Remission status at CBT!
CR!
Active disease!
 
1!
0.89 (0.48-1.65)!
 
0.71!
 
Conditioning!
Myeloablative!
Non-myeloablative!
 
1!
1.29 (0.66-2.51)!
 
 
0.46!
HLA match (dominant CB 
unit)!
4/6!
5/6!
6/6!
 
1!
0.59 (0.28-1.26)!
0.84 (0.24-2.91)!
 
 
0.39!
 
HLA match (losing CB unit)!
4/6!
5/6!
6/6!
 
1!
0.85 (0.42-1.72)!
0.60 (0.14-2.58)!
 
 
0.75!
NKG2C genotype (dominant)!
W/W!
W/D!
 
1!
1.97 (1.05-3.71)!
0.036!
NKG2C genotype (losing)!
W/W!
W/D!
 
1!
2.09 (1.11-3.94)!
 
0.026!
CB1-CB2!
W/W-W/W!
W/D-W/W or W/W-W/D!
W/D-W/D!
 
1!
1.39 (0.69-2.80)!
5.34 (2.33-12.24)!
 
0.001!
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NKG2C+CD56+CD3- in recipients of CB units with the w/d genotype CB unit (as 
determined by chimerism) was significantly lower compared to CB unit with a 
w/w genotype (median 9.31% [interquartile range 2.39%-32%] vs. 17.46% 
[interquartile range 7.65%-32.7%]),P=0.008) at both time points T1 and T2. (Fig. 
4.4a,b).  These data demonstrate that the lack of NKG2C alleles correlates to 
an inherent reduction in NKG2C expressing NK cells post CBT, supporting the 
notion that these subsets are critical components in the control of CMV 
reactivation.  In both NKG2C w/w and w/d groups, early time point T1 post 
transplant was characterized by a high population of CD56bright NK cells (Fig. 
4.5), w/w = median 29.5%(20.9-59.7%) vs w/d median 
28%(21.4-55.9%)(P=0.7)) with a significant diminishment of this population by 
time point T2, w/w = median 20.5%(9.63-39.2%) vs w/d median 8.96% 
(19.6-37.2%)(P=0.902) inducing a proportional shift to CD56dim NK cells to 
predominate the NK population.  NKG2C w/w T1 vs T2 P= *0.0156, w/d T1 vs 
T2 P= *0.0313.  These results are consistent with previous findings that CD56 
bright NK cells are highly activated mature subsets of NK cells, which unlike 
peripheral blood CD56 bright subsets, posses both cytotoxic and cytokine 
producing phenotype.  They are the first subset of lymphocytes that 
reconstitute after allogeneic HSCT, where the early expansion of the 
cytokine-producing CD56bright NK cell subset is followed by the sequential 
expansion of an intermediate CD56brightCD16low subset, before the 
development of the dominant CD56dim subset, characterized by its higher 
cytotoxic activity.  High natural killer cell count at 3 month is associated with a 
lower incidence of chronic graft-versus-host disease. The expansion of these 
subsets are particularly profound in the absence of T cells due to less 
competition of high post-transplant level of IL-15 (194).  In this study, no 
significant difference was observed for the rate of CD56bright reconstitution or 
CD56dim maturation between NKG2C w/w and w/d groups. 
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Fig. 4.3 Representative FACS analysis of NK surface markers associated 
with CMV infection post HSCT/UCBT. Cryopreserved patient samples were 
thawed, rested and phenotyped for the CMV associated NK markers.  Gating 
strategy include gating on lymphocyte gate via SSCvsFSC, viable cell selection, 
gated on CD56+CD3 for NK cell then gated accordingly.  Representative FACS 
plot tested on PBMC; Gating strategy includes lymphocyte gate (SSC-A vs 
FSC-A) -> Singlet (SSC-A vs SSC-H) ->Live-> CD56+CD3-> CD56 vs Selected 
markers. 
 
 
 
Fig. 4.4 NKG2C genotype correlates to NKG2C surface expression on 
reconstituting NK cells post double cord blood transplant.  NK cells 
derived from NKG2C w/w CB units consistently displayed higher expression of 
NKG2C compared to w/d CB units throughout all timepoints. a) Representative 
FACS plot of NKG2C expression b) statistical significance between NKG2C w/w 
and w/d CB groups.  
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Fig. 4.5 Skewed subsets of CD56bright CD56dim ratio post DUCBT.  NK 
cell reconstitution at early timepoints (T1) are characterised by a high frequency 
of CD56 bright subset regardless of NKG2C genotype.  Significant reductions 
of these CD56bright NK subsets are observed by the second timepoint (T2), 
inversely proportional to an increase in CD56 dim subsets. 
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4.2.3 Reconstituting NKG2C-expressing NK cells from NKG2C w/d 
genotype CB units have a lower co-expression of critical NK receptors 
(NKRs) associated in CMV control 
NKG2C-expressing NK cells are conventionally known to have a biased surface 
expression of markers associated with adaptive or terminally differentiated 
phenotype (116, 195), hence I also assessed whether the influence of NKG2C 
allele deletion extends to the expression levels of other common NK receptors 
and co-receptors associated with NKG2C.  Our surface phenotyping panel 
adapted from previous studies (118, 132) included a wide array of activating and 
inhibitory NK receptors (Fig. 4.3).  Self-HLA Class I inhibitory receptors such as 
killer-cell immunoglobulin like receptors (KIRs), leukocyte Ig-like receptor 1 
(ILT2), and marker of terminal differentiation CD57 were included as 
NKG2C+NK cells represents a mature differentiated subset.  NKG2A, the 
dominant inhibitory counter part sharing the same ligand specificity with NKG2C, 
was included to precisely determine the functionally competent proportion of 
NKG2C+NK cells (i.e, to exclude NKG2C+NKG2A+ subsets which would be 
inhibited)(196, 197).  Sialic acid–binding immunoglobulin-like lectin 7 (Siglec-7) 
was also included as the decreased expression has been associated as an early 
indicator of NK functional dysregulation and high level viremia (198). 4-1BB 
(CD137), was included from the knowledge that EBV induces upregulation of 
this receptor and mediates survival signalling in T and NK cells(199).  Finally, 
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costimulatory activating receptors 2B4, DNAM-1 and NTB-A were included in the 
panel as they are potent enhancers of NK effector function, and also has been 
reported in several types of viral clearance (200-202).  Upon single-cell 
screening using our multi-parameter flow panel described, I identified two 
receptors which displayed distinct expression patterns between the NKG2C w/d 
and NKG2C w/w CB unit recipients.  One of which were the Pan-KIR receptors 
which include inhibitory receptors capable of recognizing self-HLA class I 
molecules, ultimately providing immune tolerance to self by establishing an 
activation threshold (203).  The Pan-KIR antibody used also detects activating 
KIRs, which some are suggested to recognize certain CMV virus induced 
peptides (204).  Acquisition of functional competence in reconstituting NK cells 
is dependent on the establishment of a functional KIR repertoire (205). I found 
that recipients of NKG2C w/d CB units result in lower median frequencies of 
NKG2C+KIR-expressing NK cells at 3.42% (interquartile range 0.04 -15.71%), 
compared to NKG2C w/w CB recipients with 10.20% (interquartile range 
0.21-20.90%)(P=0.036) throughout both timepoints (Fig. 4.6a,b).  The second 
receptor of interest was DNAM-1, an activation adhesion molecule involved in 
NK and T cell mediated cytotoxicity (206), which recently reported to be the 
dominant receptor involved in the lysis of CMV-infected myeloid dendritic cells 
(200).  NKG2C+DNAM-1 expressing NK cells were also found at a lower 
frequency in the NKG2C w/d CB recipients at 7.88% (interquartile range 2.02 
-29.15%) compared with that of the w/w group which displayed 14.73% 
(interquartile range 6.20-31.10%)(P=0.036) (Fig 4.7a,b).  The intrinsic 
mechanism of how the deletion of the NKG2C genotype affects the regulation of 
these activating receptors are unknown.  As briefly mentioned CMV infection 
induces the clonal expansion of NKG2C+NK cells which are known to have a 
skewed expression of KIRs.  Some studies have suggested that the 
upregulation of KIRs on the NKG2C+NK cells could be augmented through a 
NKG2C mediated signal (207), in which case NKG2C w/d recipients which are 
predisposed to a lower frequency of NKG2C+NK cells than the w/w recipients 
could suffer from delayed upregulation and/or lower frequency of KIRs.  Such 
differential KIR expression in the various NKG2C genotype has been reported in 
healthy individuals (208).  In CD8+ T cells, down regulation of positive 
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co-stimulatory pathways such as DNAM-1 is a hallmark of exhaustion through 
chronic viral infection as seen in HIV (209).  Perhaps a similar scenario is taking 
place here, where the impaired capacity to eradicate CMV in w/d recipients due 
to lower NKG2C+NK cells perpetuates viral spreading and replication, leading to 
progressive immune dysfunction and impairment in the form of DNAM-1 down 
regulation.  Several mechanisms could account for the down regulation of 
these activating receptors, but these data collectively suggest KIRs and DNAM-1 
to be an important component in controlling CMV reactivation.  There was no 
significant difference observed in any of the other NKG2C associated phenotype 
markers between the two genotype groups.  Surprisingly, no significant 
differences were observed in the frequencies of reconstituting NKG2C+ cells 
co-expressing CD57, 2B4, NTB-A, ILT-2, 4-1BB and siglec-7 between w/d and 
w/d CB recipients (Fig. 4.8), which have previously been reported to be 
preferentially expressed on NKG2C+ NK cells in CMV seropositive individuals.  
With reference to Fig. 4.8, median frequencies for the individual receptors 
between the two genotype groups are as follows; 2B4; 
w/w=15.92%(9.65-28.87%) vs w/d 16.75%(6.28-30.11%)(P=0.074), CD57; 
w/w=10.97%(1.56-20.20%) vs w/d 9.73%(3.48-15.6%)(P=0.692), NTB-A; 
w/w=19.83%(9.71-31.65%) vs w/d 17.71%(7.15-30.91%)(P=0.11), ILT-2; 
w/w=9.93% (5.97-20.08%) vs w/d 8.6%(4.2-18.4%)(P=0.158), 4-1BB; w/w = 
10.81%(5.08-21.12%) vs w/d 9.45%(5.83-11.43%)(P=0.822), siglec-7; 
w/w=42.9%(25.08-53.46%) vs w/d 36.9%(20.09-44.6%)(P=0.119). 
 
Fig. 4.6 Reconstituting NKG2C+ cells co-expressing PAN-KIR marker is 
significantly lower in w/d CB units compared to w/w/ CB units.  When the 
frequency of NKG2C+PAN-KIR+ NK cells were compared between the two 
genotype groups, w/d expressed a significantly lower co-expression of PAN-KIR 
amongst the NKG2C subset.  Representative FACs plot. 
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Fig. 4.7 Reconstituting NKG2C+ cells co-expressing DNAM-1 receptor is 
significantly lower in w/d CB units compared to w/w CB units.  When the 
frequency of NKG2C+DNAM-1+ NK cells were compared between the two 
genotype groups, w/d expressed a significantly lower co-expression of DNAM-1 
amongst the NKG2C subset.  Representative FACs plot.
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Fig. 4.8 NKG2C associated NK receptors show no differential expression 
between NKG2C w/w and w/d groups.   
 
4.2.4 Susceptibility of w/d CB group to CMV reactivation is likely due to 
quantitative differences in functional NKG2C+ subset. 
To assess whether the NKG2C-expressing NK cells represent a functional 
population during CMV reactivation, I measured the level of degranulation and 
cytokine response towards an HLA-E expressing target, in an attempt to 
recapitulate the physiological cellular target during CMV reactivation.  6 of the 
20 cryopreserved patients used in the phenotyping study was available for 
functional assessment, in order to evaluate any intrinsic defect in the 
functionality of the NK cells from w/d genotype group.  These 6 samples 
consisted of 4 w/w CB group and 2 w/d CB group, hence no statistical analysis 
was possible.  Nevertheless, functional comparison was attempted. 
CD56+CD3-NKG2C+NKG2A- subsets were specifically gated as the functional 
subsets towards HLA-E exressing target cells.  This is to remove any 
NKG2C+NKG2A+ co-expressing subsets which would be inhibited by the 
inhibitory NKG2A receptor (which share the same ligand as NKG2C at a higher 
affinity).  When comparing the NK cell functional output of NKG2C+NK cells 
between w/d and w/w recipients as illustrated in (Fig. 4.9), functional response 
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towards the 721.221-AEH (HLA-E) cell line appeared to be relatively similar in 
terms of CD107a degranulation, IFN-γ and TNFα production.  These results 
suggest that NKG2C+NK cells reconstituting from both w/d and w/w CB 
recipients are equally functional towards their NKG2C ligand expressing targets, 
which is in accord with previous studies reporting functional assessment of 
NKG2C+NK cells derived from various NKG2C genotype background (189, 208).  
Collectively with the data indicating that w/d recipients are susceptible to a lower 
frequency of NKG2C+NK cells, and w/d CB recipients are predisposed to a 
higher risk of CMV reactivation due to quantittive disadvantage for functional 
NKG2C+ NK cells, with majority of the NK cells being subsequently 
dysfunctional on a per cell basis.   
 
Fig. 4.9 Functional comparison between NK cells reconstituting from the 
NKG2C w/d and w/w groups suggest quantitative differences in functional 
response towards HLA-E.  Similar functional output were observed in the 
CD107a degranulation, IFNand TNFproduction between the two genotypes, 
suggesting the higher risk of CMV reactivation in NKG2C w/d to be caused by 
quantitative differences.  Gated on functional CD56+CD3-NKG2C+NKG2A- 
subsets. 
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4.2.5 The distinct outcomes between NKG2C genotype subgroups are 
independent of T cell responses 
The expression of the NKG2C activating receptor is not restricted to NK cells 
and is also detected on T cells, especially in CMV-seropositive individuals.  
Although CB grafts lack CMV-specific T cells due to their naïve status, 
emergence of NKG2C-expressing T cells post CBT in response to CMV 
reactivation may also potentially  contribute to the immunesurveillance of 
virus-infected cells.  Hence I investigated whether  NKG2C expression on 
reconstituting T cells post CBT is influenced by the NKG2C genetic contents of 
the CB units as was the case for NK cells.  Phenotyping of the reconstituting 
lymphocytes revealed the frequency of NKG2C-expressing CD3 T cells at T1 
and T2 post CBT to be extremely low in both genotype groups.  The frequency 
of NKG2C-expressing T cells was 2.468% in w/w (interquartile range 
0.32-3.85%) and 1.7% in w/d (interquartile range 0.43-3.51%), (P = 0.72). (Fig. 
4.10).  These results suggest that the NKG2C genotype background of the CB 
units does not influence NKG2C expression on T cells reconstituting post CBT 
and that the distinct outcome seen between NKG2C genotype subgroup is solely 
a NK cell driven response. 
 
Fig. 4.10 Protective influence of NKG2C genotype is independent of CD3+ 
T cells.  Single cell expression of NKG2C receptor was extended to CD3 T 
cells and compared between the two NKG2C genotype CB units.  In contrast to 
the NK cells, no significant differences were observed between the two genotype 
groups, both characterized by an extremely low frequency of NKG2C+ CD3+. 
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4.3 Discussion 
Cord blood transplant recipients are at increased risk for CMV reactivation due 
the naïve T cell repertoire of the cord blood unit and delayed recovery of 
CMV-specific memory CD8+ T cells.  While effective anti-CMV agents are 
available, they carry significant toxicity such as graft suppression or renal failure.  
Our data provide novel insights into the potential risks of CMV reactivation in the 
setting of DUCBT.  I report for the first time that the NKG2C zygosity of the CB 
graft was an important predictor of CMV reactivation post-CBT.  Remarkably, 
nearly all patients who received two CB graft with the NKG2C w/d genotype 
developed CMV reactivation after DUCBT, compared to patients receiving only 
one CB graft with this genotype having a lower risk of progression and patients 
receiving two grafts with the NKG2C w/w genotype had the lowest risk (HR 5.34 
[95% CI 2.33-12.24] vs.1.39 [0.69-2.80] vs. 1 [P=0.001]).  Parallel phenotypic 
and functional studies revealed that reconstituting NK cells from an NKG2C w/d 
cord blood graft had a much lower frequency of the immunocompetent NKG2C+ 
population, with significantly fewer DNAM-1 or KIR co-expressing NKG2C+NK 
cells, in addition to NKG2C w/d group most likely being at a quantitative 
disadvantage in potentially CMV-specific NKG2C+ functional subset.  DNAM-1 
has been reported to be a critical activating receptor in the control of CMV 
infected cells (210).  Although NKG2C receptors are capable of being triggered 
individually in both NK cells and T cells the true effector potential of NK cells are 
achieved through the synergistic activation of signals from multiple activating 
receptors (43).  Although this has not been verified, the crucial requirement for 
DNAM-1 by NKG2C+ NK cells strongly suggest that the combination of DNAM-1 
and NKG2C ligation induces a potent synergistic activating signal.  Moreover, 
DNAM-1 appears to be essential for the optimal differentiation and 
establishment of memory NK cells in mice (211).  CMV is equipped with 
viral-encoded peptides that can specifically target and downregulate DNAM-1 
ligands on infected cells, (212) further underscoring the importance of DNAM-1 
receptor-ligand interaction in controlling CMV infection.  Whether the lower 
expression of DNAM-1 on NKG2C-expressing NK cells in patients receiving 
NKG2C w/d CB grafts is directly influenced at the by the NKG2C copy number at 
the transcriptional level or whether it is an indirect effect caused by the failure of 
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controlling CMV infection in NKG2C w/d CB grafts, is unknown and would 
require further evaluation.  DNAM-1 down modulation have been reported in 
NK cells isolated from AML and ovarian carcinoma patients, suggested to be a 
result of chronic exposure and ligation of DNAM-1 ligands expressed on the 
leukemic blasts at a high frequency, which was demonstrated to be contact 
dependent (213-215).   
Similar mechanisms have been proposed for the loss of DNAM-1 on CD8+ T 
cells in chronic HIV infection, where the T cells are exposed to infected cells 
expressing DNAM-1 ligands, ultimately inducing T cells into an exhausted state 
(209).   
Down regulation of PAN-KIR, the other receptor which displayed differential 
expression between the two NKG2C genotype group, have also been reported 
in cases of chronic exposure to ligand, i.e. HLA class I(216).  However, CMV 
immune evasion mechanisms involves the down modulation of HLA class I in an 
attempt to escape T cell mediated immunity (217), hence this hypothesis is 
unlikely.  Alternatively, this difference in KIR expression and NKG2C 
expression may be due to a delayed maturation in the NKG2C w/d group, 
although CMV infection is conventionally known to induce rapid maturation of 
NK cells post HSCT regardless of NKG2C genotype (124).  In this study, CD57 
expression was not found to be significant between the two genotype groups, 
which further suggests that the differential KIR expression was not due to a 
difference in rate of NK cell maturation.  Comparison of the influence of NKG2C 
zygosity on NK cell compartment, namely receptor expression post CMV 
infection has revealed that NKG2C d/d groups had a lower KIR expression than 
the w/w group amongst healthy HCMV-seropositive individuals, hence the 
deletion allele may have an intrinsic effect on KIR expression (208).  KIR 
expression correlates to functional competence, and comparison of KIR+ and 
KIR- analysis have revealed that KIR expressing subsets express higher levels 
of anti-apoptotic genes such as BCL2 and BCLX (218).  Hence even under 
proliferative conditions in response to CMV reactivation, NKG2C w/w derived NK 
cells with a higher co expression of KIRs would be at a functional advantage with 
the ability to be prevalent until viral clearance is achieved, whilst the NK cells 
from the w/d group maybe be susceptible to diminish faster.  With regards to 
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the other receptors known to be associated with the memory NKG2C+ NK cell 
phenotype, namely siglec-7, 4-1BB and ILT-2 showed no significant difference 
between the two genotype groups, which was unexpected with reference to 
previous studies.  Loss of siglec-7 and 4-1BB is often associated with viral 
replication and was expected to be dramatically down-regulated in the NKG2C+ 
expressing NK cells, whilst ILT-2 is a self-inhibitory receptor and was expected 
to show similar trends to KIR expression and be higher in the NKG2C w/w group.  
Although none of our patients received a CB graft with the NKG2C d/d genotype, 
NKG2C heterozygosity is not uncommon (1 in 5 CB units), and our data highlight 
the importance of NKG2C typing in determining the risk of CMV reactivation after 
DUCBT.  NKG2C+ NK cells have been suggested to be crucial in the resolution 
of CMV episodes post allo-HSCT(219), although there has been only one study 
investigating the impact of NKG2C zygosity in cord blood reconstitution and the 
study had limitations due to relatively small cohort size (192).  Our analysis 
includes all possible combination outcomes of NKG2C w/d in the dominant or 
losing CB unit, where it was revealed that the engraftment status of CB unit was 
irrelevant but more with the gene content of the graft.  With increasing 
emphasis being placed on strategies to employ knowledge gained from 
immunogenetics such as KIR/HLA typing in the selection of donor grafts to 
reduce the risk of relapse and post-transplant, combined with our findings in 
chapter 3 of this thesis NKG2C genotype score may be an additional criteria 
expected to significantly improve outcome whilst minimizing CMV associated 
complications.  To elucidate the optimal ‘gold standard’ for cord blood graft 
characteristics, future studies should aim to compare NK cells derived from 
various NKG2C and activating KIR genotype background, combined with 
single-cell expression levels and functional validations demonstrating the ideal 
combination.  The determinants for a winning cord unit which ultimately 
dominates post double cord blood transplant remains to be unknown, however 
this discovery of the presence of single NKG2C deletion allele in either one of 
the cord unit posing a significant risk to CMV incidence regardless of whether its 
is the dominant or losing unit, should potentially have major clinical implications.  
Such genotype based protection would be particularly important in cord blood 
transplant settings, as in contrast to conventional cases of BM transplantation 
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where CMV sero-positivity of donor is important, CMV infection post CB 
transplant have been shown to have no association with donor serology (ie, the 
maternal CMV antibody status)(220, 221).   With this current perspective of 
donor maternal CMV serology being a poor predictor of CMV reactivation in CB 
transplantation, our proposed genotype based prediction of clinical outcome 
would be a promising alternative.   
Future work should involve comparing CB NK differentiation of different NKG2C 
genotype background in vitro to further validate the findings in this chapter.  
Also, the unresolved obstacle remains to be associated with the functional 
aspects of NKG2C+ NK cells as the NKG2C ligands speculated to be expressed 
on CMV-infected cells are yet to be identified.  Advancements in this field would 
also be a critical requirement in the further development of potential cellular 
therapies.  Previous studies have been restricted to the use of HLA-E 
expressing targets, as they are the only known ligand for NKG2C to induce 
functional response from NKG2C+ subsets (118), as I have here.  Such 
elucidation of the physiological target of NKG2C would greatly advance the 
understanding of NKG2C+ biology. 
As for exploiting these findings to envisage a potential NK cell therapy, 
strategies to expand these NKG2C+ adaptive NK cells are expected to 
significantly improve immune reconstitution after HCT and decrease CMV 
reactivation associated morbidity.  Such application would not be restricted to 
settings of hematological malignancies but would also have major impacts on 
other solid-organ trasnplants where CMV affects upto 75% of the recipients 
(222).  Hence future investigations should also aim to develop cell-based 
intervention strategies targeting these unique NKG2C+ NK cells from cord blood 
which are most likely to become effective than current strategies in tumor 
specific memory CD8+ T cells.  Now with a defined pathway established for the 
generation of memory NK cells in mouse models (223), homologous signaling 
pathways should be investigated to see if the similar results could be reproduced 
in human NK cells.  The proposed developmental pathway of NK memory cells 
by O’Sullivan et al suggest the requirement of a primary signal which recognizes 
the pathogen specific antigen signal, in humans speculated to be through 
NKG2C.  The requirement of co-receptor signaling through DNAM-1 have been 
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demonstrated to be essential for the initial lineage commitment into the memory 
subset in the early phase, but also for the optimal expansion in the later phase of 
pathogenesis (211).  Efficient expansion and survival of the memory subsets 
require intact IL-12 signaling and relied on functional STAT4 (Fig. 4.11) (224).  
 
Fig. 4.11  Proposed developmental requirements for the generation of 
memory NK cells in mice.  Differentiation of NK cells into the memory subset 
is proposed to follow a similar pathway analogous to T cell memory formation, 
involving 3 independent coordinated signals leading to expansion followed by 
contraction and long-term prevalence.  Initial stimulus include; CMV specific 
target antigen m157 signalling through Ly49H, mouse equivalent of NKG2C 
(signal 1), DNAM-1 co-stimulation (signal 2) and proinflammatory cytokine 
signaling mediated through IL-12/STAT4 signalling (signal 3). 
 
 Adapted from O’Sullivan et al., 2015 (223) 
Promising results have been reported in a human system using CMV infected 
monocytes, which supported the expansion of NKG2C+ NK cells through 
producing IL-12 and displayed specific involvement of HLA-E(225, 226).  If the 
proposed signaling and developmental pathway applies also to human NK cells, 
then theoretically NK cells could be manipulated and harnessed towards a 
variety of pathogens.  However, despite this unique adaptive NKG2C+ subsets 
being reported in a various other herpes virus (117-119, 132), the 
pre-requirement was that they were all sero-positive for CMV.  It is currently 
speculated that the initial expansion of NKG2C+ NK cells requires “priming” by 
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CMV, which suggest an evolution driven specificity to CMV.  Such specificity 
has been elegantly demonstrated by Hendricks et al. (227), whereby they 
attempted to induce the expansion of NKG2C+ NK cells from a cohort of CMV 
sero-positive and sero-negative individuals with an acute infection of EBV, being 
the most well characterized example of ubiquitous human viruses (228).  Only 
the CMV sero-positive group displayed a development in NKG2C+ NK cell 
subsets, and similar observation have been reported in a larger scale 
epidemiological study (229).  In addition to this, expansion of NKG2C+ NK cells 
post HCT show differential requirements depending on the donor graft source 
(230).  Miller et al compared recipients of allogeneic sibling and cord blood 
donors and discovered that whilst non-replicating persistent CMV was sufficient 
to induce NKG2C+ expansion in mature cells from the sibling graft, UCB grafts 
required sufficient reactivation to observe an increase in NKG2C+ subset.  
Although their study did not distinguish the NKG2C genotype as done here, such 
data suggest a fundamental difference in developmental requirement for 
NKG2C+ from CB NK cells.  In addition to CMV sero-positivity, other crucial 
variables such as viral load, virus/host genetics, magnitude and frequency of 
viral reactivation determine the development of adaptive NK compartment.  The 
previous monocyte based ex vivo expansion protocols also emphasize the use 
of live virus stock, as NKG2C+ expansion was diminished when UV-inactivated 
virus or an HCMV deletion mutant deficient for the gene region US2-11 
(regulating the generation of high density of surface MHC class I molecules), 
were used.   These observation collectively suggest that the signaling 
interaction cannot simply be achieved through a receptor-ligand approach, 
requiring dynamic interactions and would be a practical challenge with the use of 
CB NK cells in order to achieve without the actual induction of CMV disease. 
Hence identifying and establishing a physiological system recapitulating these 
other requirements ex vivo would be the main challenge for the therapeutic 
strategy to generate memory NK cells.  A more comprehensive understanding 
of the development of memory NK cell would ultimately inspire a new generation 
of adoptive NK cell therapies potentially towards a wider array of tumors and 
infections agents.  Finally, although in this study the role of total CD3 T cells did 
not appear to be significant in CMV clearance post UCBT, it cannot be excluded 
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that specific rare T cell populations may be contributing to CMV resistance, 
namely gamma/delta (γδ)T cells.  γδ T cells have been recognized for their 
protective role against CMV infection, and an increased frequency of these 
subsets are becoming a reliable prognosis factor for predicting the resolution of 
CMV infection (231).  Recent studies have established that it is the Vδ2 
negative γδ T cells that display a long-term expansion amongst HSCT patients 
experiencing CMV reactivation(232, 233).  Like the effector memory CD8+ T 
cells, NKG2C expression has also been reported on γδT cells (234), although 
the data on differential expression of NKG2C receptor amongst the γδT subsets 
are undefined.  Further studies investigating the possible synergistic roles 
between NK cells and γδT cells in CMV reactivated UCBT patients would be 
greatly beneficial.  
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CHAPTER 5 Expanding on the current perspectives of NK licensing 
 
5.1 Introduction 
 
The previous two chapters have emphasized the importance of donor KIR/HLA 
genetics and their influence on licensing and potentially memory NK 
establishment after CBT. However, in order to fully exploit their anti-leukaemic 
response after transplant, a better understanding of how NK cells become 
functionally competent is urgently required.  As a follow-up to my clinical 
findings summarized in the previous sections, this chapter focuses on an in vitro 
approach to dissect these observations mechanistically.   
 
5.2 Aims 
 
1.Study the different developmental phases of cord blood NK cells and their 
relationship to licensing/education. 
 
2. Determine if unique NK cell markers can define the licensing or education 
status of NK cells. 
 
5.3 Results 
 
5.3.1 Licensed and unlicensed NK cells express a comparable level of NK 
activating receptors. 
NK cell activation is ultimately determined by the quantitative imbalance of 
inhibitory and activating signals, however expression of activation receptor alone 
on NK cells is not sufficient to reverse the functional constraints set by the 
licensing process(14, 140).  Indeed, no surface phenotype marker has been 
identified to date that can distinguish the licensing status of NK cells, making the 
evaluation difficult.  In contrast, the expression of NK receptors such as killer 
immunoglobulin receptors (KIRs) or CD57 is often associated with a successful 
progression to effector or memory status in T cells (37, 38, 235).  Hence, I first 
attempted to identify differences in the expression of selected activating NK 
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receptors including the three natural cytotoxicity receptors (NCR) NKp30, NKp44, 
NKp46 and the C-type lectin activating receptor NKG2D using the antibody 
panel described in Table. 2.1.  NK cells expressing self-inhibitory receptors are 
deemed functionally competent (licensed), with their responsiveness increasing 
with the strength and number of self-inhibitory receptor engaged, whilst those 
expressing non-self inhibitory receptors or no inhibitory receptors at all are 
deemed hyporesponsive (unlicensed)(236, 237).  Therefore following this 
concept,  in this panel total inhibitory receptor positive (PAN KIR+) NK cells 
were classified as functionally differentiated and licensed, whilst inhibitory 
receptor negative (PAN KIR-) NK cells were deemed as unlicensed.  Although 
this does not distinguish self and non-self KIRs, previous studies have utilized 
such broad classification to distinguish licensed vs. unlicensed NK cells (133).  
As illustrated in fig.5.1, no differential expression of activating receptors was 
observed between licensed and unlicensed NK cells (p values; NKp30=0.360, 
Nkp44=0.8135, NKp46=0.8135, NKG2D=0.621).  The low expression of NKp44 
can be explained by the fact that this receptor is usually upregulated upon 
activation with cytokines. These results are in accordance with previous findings 
that licensed NK cells do not display a biased repertoire of activating receptors.  
As extensively studied by Freud et al(22), many of the activating NK receptors 
are acquired as early as stage 4, which is before the expression of KIR and 
hence considered pre-licensing.   
     Although more recent studies reported that activating receptors 
may contribute to NK licensing (131, 238), many of the adaptor molecules 
involved in signaling of activating receptors such as DAP10, DAP12, FcεRIγ and 
CD3ζ are not required for NK maturation and licensing (140).  Moreover, the 
absence of a biased NK cell repertoire or higher expression of activating 
receptors on licensed vs. unlicensed NK cells suggest that acquisition of 
activating NK receptors is independent of subsequent licensing, and that the 
enhanced functionality of licensed NK cells is not related to higher expression of 
activating receptors. 
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Fig. 5.1. The expression of activating receptors on licensed vs unlicensed 
NK cells is comparable.  Activating NK receptor expression was evaluated on 
PAN KIR+ (functional/licensed subset) and PAN KIR- 
(hyporesponsive/unlicensed subset), whereby no significant differences were 
observed in the expression levels of activating receptors (NKp30, NKp44, 
NKp46 and NKG2D) in the two subsets.  Based on these findings, I propose 
that activating NK receptors cannot be used as a marker of licensing and that 
differences in functional competence between licensed and unlicensed subsets 
are likely not due to differential expression of activating NKRs.   
 
5.3.2   Licensed and unlicensed NK cells respond to stimulation with 
PMA/Ionomycin at a comparable level. 
             Whilst resting unlicensed NK cells are known to be 
hyporesponsive, ‘priming’ these subsets with cytokines such as IL-2 can 
override the thresholds for activation to render them responsive, suggesting the 
existence of several activation pathways (239).  These observations were 
initially made using NK cells derived from TAP-deficient human patients, in 
whom IL-2 stimulation was able to break self-tolerance and increase NK effector 
function(240).  Physiologically this mechanism does make sense, as the 
presence of type 1 cytokines in the inflammatory environment should be 
perceived as indicative of a flight response by innate cells, hence resulting in the 
breach of safety thresholds in effectors such as NK cells.  Such alternative 
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licensing or activation pathways suggest the existence of redundancy in the 
activation pathways, whilst also supporting a defective activation pathway in 
unlicensed NK cells.   With this concept in mind, I designed functional assays 
to evaluate the differential functional response between licensed and unlicensed 
NK cells (by CD107a, IFNγ and TNFα detection) towards cellular targets.  
PMA/Ionomycin was selected as a positive control.  Phorbol esters such as 
PMA are potent activators of the protein kinase C (PKC) pathway, which, in 
combination with ionomycin, rapidly increases the influx of Ca2+ in NK cells.  
Such events induce downstream phosphorylation of adaptor molecules, 
ultimately initiating the activation cascade.  As illustrated in fig. 5.2, I found no 
significant difference in the functional response licensed compared to unlicensed 
NK cells post PMA/Ionomycin stimulation (p-values; CD107a=0.4611, 
IFNγ=0.8762, TNFα= 0.4).  As PMA/Ionomycin bypasses all NK 
receptor-mediated target recognition and directly activates PKC, my 
observations suggest that both licensed and unlicensed NK cells are equally 
functionally competent downstream of the PKC activation pathway.  Hence the 
defective activation signaling observed in unlicensed NK cells likely affects the 
earlier stages of activation signaling, specifically upstream of PKC. 
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Fig.5.2 PMA and ionomycin stimulation induces functional responses in 
both licensed and unlicensed NK cell subsets.  The combination of 
PMA/ionomycin induces rapid Ca2+ influx by bypassing all receptor 
engagement requirements and directly activating protein kinase C (PKC).  
Virtually all NK cells were stimulated regardless of their licensed or unlicensed 
state, suggesting that any modulation induced by the licensing process is taking 
place upstream of PKC. a) Representative FACs plots of PMA ionomycin 
stimulation b) comparison of licensed vs unlicensed NK cell effector output post 
PMA ionomycin stimulation. n=10. 
a)     b) 
 
 
5.3.3    NKG2A co-expression compensates for the lack of licensing and 
can render hyporesponsive and unlicensed NK cells functional. 
             For functional studies, I selected the K562 cell line, an MHC-class 
I deficient cell line commonly used in NK cell assays, as a target cell for my 
functional assays. In order to accurately monitor the differential response of NK 
cell subsets, I used primary cells in the absence of exogenous cytokines.  
Following stimulation with K562, single-KIR+ NK cells were identified by 
applying the gating strategy illustrated in figure 5.3a.  Initially the gating 
population was set to CD56+CD3- and KIR+ cells of interest, whilst excluding 
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KIR+ NK cells that were not of interest; e.g. to identify single 
KIR2DL1-expressing NK cells, I gated on 
CD56+CD3-KIR2DL1+KIR2DL3-KIR3DL1-.  However, I found no significant 
differences in the functional output of licensed vs. unlicensed NK cells using the 
gating strategy above.  After careful evaluation, I discovered that the 
co-expression of NKG2A can significantly enhance the functional output of 
unlicensed NK cells (Fig. 5.3).  Comparing total licensed and unlicensed NK 
cells revealed that there were no significant differences in all three functional 
outputs measured; CD107a (P=0.187), IFN (0.134), TNF  (P= 0.186). 
Subdividing the unlicensed population into NKG2A+ and NKG2A- revealed 2 
functionally distinct populations, where the NKG2A- subsets expressed 
significantly diminished functional output compared to the NKG2A+ counterparts  
(P=<0.0001).  In contrast, licensed NK cells showed no significant differences 
in functional output were observed when comparing the NKG2A+ and NKG2A- 
subset for CD107a, IFNand TNF(P=0.372, 0.679, 0.288 respectively), 
suggesting that the licensed NK cells are functionally competent regardless of 
NKG2A coexpression (fig.5.3b).  To support this, comparing NKG2A- subsets 
of licensed and unlicensed NK cells for CD107a, IFNand TNF revealed 
statistical significance (P=0.372, 0.679, 0.288 respectively), These data are in 
accordance with previous studies, reporting that NKG2A can act as a broadly 
specific inhibitory receptor and compensate for the lack of input from inhibitory 
KIRs during development, (14, 236).  As NKG2A precedes KIR expression 
during development, it can provide a similar qualitative inhibitory input as KIRs. 
Thus, NKG2A co-expression on KIR- as well as non-self KIR+ NK cells can 
compensate for the lack of self-inhibitory receptors and render KIR-NKG2A+  
functional.  Hence the ultimate hierarchy of NK responses are KIR+NKG2A+ 
>KIR+NKG2A- >KIR-NKG2A+ >KIR-NKG2A- in a missing self setting towards 
cellular targets.  Hence, to identify NK cells as truly expressing self-KIRs and to 
eliminate any contribution of NKG2A co-expression to NK cell function, single 
KIR+NKG2A- subsets were gated as described in Fig. 5.3a for all further 
functional analysis in my experiments.   
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Figure 5.3.  NKG2A co-expression compensates for the lack of 
functionality of unlicensed self-inhibitory KIR receptors in NK cells.  a) 
Representative FACs plot for single KIR+NKG2A- PBMC NK functional analysis. 
b) Statistical comparison of functional response between licensed vs unlicensed 
NK cells based on NKG2A co-expression.  
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5.3.4   Licensed single-KIR expressing NK cells display a significantly 
higher level of degranulation and pro-inflammatory cytokine production 
than unlicensed single-KIR expressing and hyporesponsive KIR-ve NK 
cells.  
            With a gating strategy capable of identifying licensed single-KIR+ 
NK cells established combined with HLA-typing data, functional analysis towards 
the K562 cell lines were extended in 25 healthy controls and grouped 
accordingly by genotype, into HLA-C1/C1, C2/C2 and C1/C2 donors.  
Figure 5.4a represents functional results from C1/C1 donors, whereby the 
licensed NK cells were considered as those expressing single-KIR2DL2/3+ and 
highlighted by the blue bars, where by red/green bars are unlicensed 
(single-KIR2DL1+ and single-KIR3DL1+ accordingly) and white bars are KIR- 
hyporesponsive subsets.  Single-KIR2DL2/3+ NK cells displayed a median 
functional output of 10.2% CD107a, 9.53% IFNand  8.7% TNF , in contrast 
to median 4.34% CD107a, 3.79 % IFNand 3.44% TNF of unlicensed single 
KIR2DL1+ subsets.   Licensed single-KIR2L2/3+ NK cells were significantly 
more functional compared to their unlicensed counterparts when taken from 
C1/C1 donors; vs unlicensed KIR2DL1+; CD107a (P= **0.0053) IFN(P= 
**0.0052)   TNF( P=* 0.0132).  Similarly, Figure 5.4b illustrates functional 
results collected from C2/C2 donors, where the licensed subsets were 
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represented by single-KIR2DL1+ NK cells in red bars.   Median functional 
readouts were 13.8% CD107a, 11.2% IFNand  9.1% TNF , in contrast to 
the unlicensed single-KIR2DL2/3+ subsets with median functional readouts of  
3.1% CD107a,  2.33 % IFNand  2.06% TNF.  Licensed single-KIR2DL1+ 
subsets were significantly more functional compared to the unlicensed single 
KIR2DL2/3+ when taken from a C2/C2 donor;  CD107a (P=**0.0036) IFN
(P=**0.0022 ) TNF( P=**0.0032).  Such interchanging functional dominance 
between the single-KIR2DL1+ and single-KIR2DL2/3+, which is dependent on 
the HLA background of the donors, are indicative of a self-ligand instructed 
licensing model consistent with previous studies (14, 129, 241, 242).  Figure 
5.4c illustrates functional results from C1/C2 donors, which provides a unique 
HLA environment as they posess both HLA-C1 and C2 alleles, hence are 
potentially capable of licensing both single-KIR2DL1+ and single-KIR2DL2/3.   
Analysis revealed both licensed single-KIR2DL1+ (red bars) and licensed single 
KIR2DL2/3+ (blue bars) express similarly high functional output; median 
single-KIR2DL1+ 15.6% CD107a,  9.67% IFN, 8.93% TNF, and median 
single KIR2DL2/3+ 12.4% CD107a,   9.45%  IFNand 7.33 % TNF             
Both licensed subsets were significantly more functional compared to their 
unlicensed counterparts; single-KIR2DL1+ vs unlicensed KIR3DL1+, CD107a 
(P= *0.0156) IFN(P= *0.0132)  TNF( P=*0.0234 ), single-KIR2DL2/3+ vs 
unlicensed KIR3DL1+, CD107a (P=* 0.0232) IFN(P=* 0.031) TNF( P= 
*0.035).  However, no statistical significance was observed in any of the 
functional parameters when licensed single-KIR2DL1+ and licensed 
single-KIR2DL2/3+ subsets were compared, indicating that both subsets are 
licensed to a similar level when taken from a C1/C2 heterozygous donor. 
CD107a (P= 0.072) IFN(P=0.054)   TNF( P= 0.13).  Hyporesponsive KIR- 
subsets had a median of 3.2% CD107a,  1.8% IFN, 0.88% TNF   and 
displayed high statistical significance when compared to the licensed subset in 
all cases, regardless of the HLA background of the donors. P=<0.0001 for  
CD107a, IFNand TNF respectively. 
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Figure 5.4. Comparison of functional response between licensed vs 
unlicensed NK cells towards various cell line targets in a) C1/C1 group b) 
C2/C2 group c) C1/C2 group 
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5.3.5 Licensed NK cells are specifically inhibited by HLA-class I 
expressing cell lines expressing their cognate ligands but not to irrelevant 
epitopes 
I next examined the specificity of KIR-inhibitory function using 721.221 cell lines 
expressing HLA-C, B and E alleles, where in the presence of a cognate 
interaction a suppressive response would be expected.  The wild type 721.221 
cell lines were used as the control, as they are HLA-class I negative and showed 
no significant different to K562 in terms of inducing NK functional output.  As 
illustrated in figure 5.4, conditions K562 and 721.221 display similar functional 
output of NK cell CD107a degranulation (p= 0.86), IFN(p=0.13) and TNF
(p=0.67), whilst the significant differences between licensed and unlicensed 
subsets were also observable in a similar manner to K562 in the 721.221 cell 
lines.      
In the C1/C1 donor groups (figure. 5.4a), licensed single-KIR2DL2/3+ NK cells 
were significantly inhibited at all 3 levels of functional output only when 
challenged with the cognate HLA-C1 ligand expressing cell lines. CD107a 
(P=***0.00012) IFN (P= ***0.00038  )   TNF ( P=**0.0025). Median 
suppression relative to wildtype 721.221=  78.9% CD107a,  82.6% IFNand          
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91.5% TNF .   No statistical significance in functional output were observed 
in the single-KIR2DL2/3+ NK cells under conditions with cell lines expressing 
HLA-C2,CD107a (P=  0.086) IFN(P= 0.14)   TNF( P= 0.092), HLA-Bw4, 
CD107a (P= 0.058) IFN(P=0.34)   TNF( P= 0.083), HLA-E, CD107a (P= 
0.14) IFN(P= 0.22)   TNF( P= 0.28).  
Similarly in the C2/C2 donor groups (figure 5.4b), licensed single-KIR2DL1+ NK 
cells were significantly inhibited towards cognate HLA-C2 expressing cell lines 
CD107a (P=***0.0004 ) IFN(P= ****<0.0001)   TNF( P=**0.0068), median 
suppression in comparison of wildtype 721.221=  74% CD107a,  78.1% IFN
and  74.1% TNF , whilst remained functionally competent towards other cell 
lines to a similar degree to the wild type control; HLA-C1 CD107a (P= 0.081) IFN
(P= 0.33)   TNF( P=0.19), HLA-Bw4, CD107a (P= 0.11 ) IFN(P= 0.094)   
TNF( P= 0.13). HLA-E CD107a (P=  0.35) IFN(P= 0.24)   TNF( P= 
0.12). 
 
For C1/C2 heterozygous donor groups (figure 5.4c), licensed single-KIR2DL1+ 
NK cells were only inhibited by cognate HLA-C2 cell lines CD107a (P= **0.0027) 
IFN(P= **0.0036)   TNF( P= **0.0031), median suppression in comparison 
of wildtype 721.221=  66.3% CD107a,  62.4% IFNand  68.89% TNF , 
whilst licensed single-KIR2DL2/3+ were also inhibited only by cognate HLA-C1 
cell lines. CD107a (P=  **0.0044) IFN(P= **0.0052)   TNF( P= **0.0015), 
median suppression in comparison of wildtype 721.221=  91.23% CD107a,  
87.84% IFN and   94.2% TNF  .  Licensed single-KIR2DL1+ were 
unaffected by other cell lines including the HLA-C1 expressing cell lines CD107a 
(P=  0.4) IFN(P= 0.55)   TNF( P= 0.61),  and likewise single KIR2DL3+ 
were unaffected by other cell lines including HLA-C2 cell lines. CD107a (P=  
0.08) IFN (P= 0.74)   TNF ( P= 0.88).   These results showing the 
susceptibility of non-self HLA expressing cells in a missing-ligand manner, yet 
displaying selective protectivity in self-HLA expressing cells from NK lysis 
recapitulates the setting of NK cell alloreactivity in HLA-mismatched HSCT 
illustrating how the donor KIR and recipient HLA type can significantly affect the 
clinical outcome. 
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5.3.6  Cord blood NK cells have a post-licensed status but require IL-2 
activation for optimal functional response 
               Despite the current understandings of NK licensing in 
peripheral blood NK cells, data on cord blood NK cell licensing and functional 
competence is scarce (107).  Cord blood functional studies are often 
challenging due to the low or absence of NK cell response to stimulation.  
Schonberg et al. used IL-2 to enhance the functionality of cord blood NK cells in 
vitro to overcome NK cell tolerance as described previously (102, 239, 243).  
They confirmed a differential functional output based on self-KIR and non-self 
KIR expression, in keeping with the concept of licensing, although the only 
functional parameter they measured was CD107a degranulation.   With the 
licensing assay successfully demonstrated in adult PBMC NK cells, the assay 
was repeated to assess functional properties of cord blood NK cells.  Resting 
cord blood NK cells towards K562 cells was found to be extremely low as 
described previously, with median readouts of 2.45% CD107a, 1.33 % IFNand 
0.87 % TNF . To study CB-NK cell licensing more comprehensively, I adapted 
the protocol from Schonberg et al. by pre-stimulating cord blood NK cells 
overnight with IL-2.  As illustrated in figure 5.5a, cord blood NK cells were 
characterized by lower KIR expression in comparison to PBMC NK cells, and 
also the majority of KIR expressing NK cells co-expressed NKG2A, suggesting 
that CB-NK cell are developmentally less differentiated in comparison to PBMC 
NK (figure.5.5a).  Despite having a higher functional output compared to the 
adult PBMC NK cells (due to the IL-2 prestimulation) with median readouts of  
36.8% CD107a, 18.7% IFN and 14.6% TNF  , analysis revealed that 
functional competence was indeed intact in a self-ligand dependent manner, 
similar to the results observed with PBMC NK cells.    Figure 5.5b represents 
functional readouts from cord blood unit with  a C1/C1 genotype,  where 
functional output are dominated by licensed single-KIR2L2/3+ NK cells with 
significantly enhanced response compared to their unlicensed counterparts; 
licensed single KIR2DL2/3+ vs unlicensed KIR2DL1+; CD107a (P=  *0.0134) 
IFN(P= *0.023) TNF( P= *0.025).    
             Figure 5.5c illustrates functional results from C2/C2 cord blood 
units, where the licensed single-KIR2DL1+ NK cells in red bars are significantly 
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more functional compared to the unlicensed single KIR2DL2/3+;  CD107a (P= 
**0.0067) IFN(P=* 0.023   )   TNF( P= *0.032).    Finally figure 5.5d 
representing cord blood unit with a C1/C2 heterozygous background, resulted in 
significantly more functional output in both licensed single KIR2DL1+ and single 
KIR2DL2/3+ subsets compared to their unlicensed KIR3DL1+ counterparts; 
single-KIR2DL1+ vs unlicensed KIR3DL1+, CD107a (P= **0.0056) IFN
(P=**0.0078)   TNF ( P= **0.0051), single-KIR2DL2/3+ vs unlicensed 
KIR3DL1+, CD107a (P= **0.0091) IFN(P= **0.0083)   TNF( P= * 0.023).   
             Response of cord blood NK cells towards the various HLA-class I 
ligand expressing cell lines demonstrated similar trends as with adult PBMC NK 
cells, where NK cells were selectively inhibited in cases only where target cell 
lines were expressing cognate ligands for the licensing KIRs.   However, in 
addition to being inhibited by the cognate cell lines, licensed subsets were also 
significantly inhibited by the HLA-E expressing cell lines regardless of the cord 
blood unit genotype. In the C1/C1 CB unit, functional response of licensed 
single-KIR2DL2/3+ NK cells were significantly inhibited when challenged with 
the cognate HLA-C1 ligand expressing cell lines. CD107a (P= **0.0034) IFN
(P=**0.0089)   TNF( P=** 0.0045). Median suppression relative to wildtype 
721.221=  85.6% CD107a,         72.3% IFNand    67.8% TNF  .   
No statistical significance in functional output were observed in the 
single-KIR2DL2/3+ NK cells under conditions with cell lines expressing 
HLA-C2,CD107a (P= 0.076) IFN(P= 0.44)   TNF( P=0.35), HLA-Bw4, 
CD107a (P=  0.13) IFN(P=0.42)   TNF( P= 0.38), but was significantly 
inhibited when challenged with cell lines expressing HLA-E, CD107a (P= 
****<0.0001) IFN(P=  = ****<0.0001 )   TNF( P= = ****<0.0001)  Similarly 
in the C2/C2 unit, licensed single-KIR2DL1+ NK cells were significantly 
inhibiteded towards cognate HLA-C2 expressing cell lines CD107a (P= 
***0.00067) IFN(P= ** 0.0014)   TNF( P= ***0.0008), median suppression 
in comparison of wildtype 721.221=  88.1% CD107a,   83.2 % IFNand  
75.5% TNF , and remained functionally competent towards other cell lines to a 
similar degree to the wild type control; HLA-C1 CD107a (P=  0.74) IFN(P= 
0.8)   TNF( P= 0.09), HLA-Bw4, CD107a (P= 0.08) IFN(P= 0.28)   TNF
( P= 0.42), but was significantly inhibited when challenged with HLA-E CD107a 
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(P= = ****<0.0001) IFN (P== ****<0.0001)   TNF ( P= = ****<0.0001).  
C1/C2 heterozygous CB units demonstrated both licensed single-KIR2DL1+ and 
licensed single-KIR2DL2/3 NK cells to be selectively inhibited by cognate 
HLA-C2 cell lines CD107a (P= ***0.0002) IFN (P= **0.007)   TNF
( P=***0.0004) (median suppression in comparison of wildtype 721.221= 85.5% 
CD107a,  73.2% IFNand    62.9% TNF ), and cognate HLA-C1 cell lines. 
CD107a (P=***0.0003) IFN (P=**0.006)   TNF ( P= **0.004) (median 
suppression in comparison of wildtype 721.221=  89.4% CD107a,  71.5% IFN
and 64.8% TNF ), but also towards HLA-E expressing cell line CD107a (P= 
****<0.0001) IFN (P= ****<0.0001)   TNF ( P= ****<0.0001), median 
suppression in comparison of wildtype 721.221= 88.5% CD107a,  91.2 % IFN
and   84.5% TNF .  These results indicate the dependence of the cord 
blood NK cells on NKG2A expression for functional competence despite 
showing trends of self-ligand induced licensing.  These extra requirement of 
self-protection/tolerance provided by the broadly specific NKG2A inhibitory 
receptor may reflect on the immunologically  naïve and functional immaturity of 
the cord blood NK cells.  Collectively these data suggests that cord blood NK 
cells are indeed, at least in part, appear to be a post licensed population but may 
also represent unique developmental intermediates in progress of licensing. 
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Figure 5.5. a) Representative gating strategy and FACs plots for 
single-KIR+ cord blood NK cell functional analysis.  b) Comparison of 
functional response between licensed vs unlicensed NK cells towards 
various cell line targets; C1/C1 unit  c) C2/C2 unit d) C1/C2 unit. 
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5.3.7 Licensed and unlicensed NK cells display no significant differences 
in transcriptional signatures 
Like all lymphoctyes, NK cells transit through multiple developmental stages and 
checkpoints which are strictly regulated by epigenetic mechanisms.  Early 
stages of NK cell development is similar to that of T cells and B cells, and follows 
a common lymphoid progenitor fate. Once differentiated and committed to a NK 
precursor (NKP), sequential progression through each developmental 
intermediate stages is regulated by a series of transcriptional events.  In order 
to identify differential expression in developmental transcription factors between 
licensed and unlicensed NK cells, candidate markers were screened.  I 
restricted my analysis to transcription factors associated with post stage 4 NK 
cell developmental statge/CD56 bright NK phenotype, as the process of 
licensing is believed to take place beyond this stage of development.  Of the 
sophisticated network of transcription factors which work in conjunction to 
maintain NK cell fate, two transcription factors, namely the T-box family, T-bet 
and Eomesodermin, were studied.  These transcription factors are essential 
components of NK cell development and for maintenance of mature attributes 
post lineage commitment (134, 135, 244).  Eomes and T-bet are both critical in 
the regulation of NK cell function, and reduction in these transcription factors 
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lead to functional impairment and an exhausted phenotype (245).  Hence, I 
identifed licensed and unlicensed KIRs through single-KIR+ NK cells, and 
measured intracellular levels of Eomes and T-bet by flow analysis, both before 
and after stimulation with K562 target cells.  Both licensed and unlicensed NK 
cells displayed high and stable expression of T-bet and Eomesodermin 
regardless of the stimulus as illustrated in (figure 5.6).  These data suggest that 
licensed and unlicensed NK cells follow identical developmental pathways up to 
the point of Eomes and T-bet acquisition.  My results are in keeping with the 
only study to investigate the effect of NK licensing on transcriptional program 
using pan-genomic microarray analysis, where minimal differences were found 
in the transcriptional signatures(246).  These data collectively suggest that 
licensed and unlicensed NK cells are regulated beyond mere quantitative 
differences in transcription factors and currently no detectable differences in 
transcriptional signatures are identified.    
 
Figure 5.6. a) Representative expression of the transcription factors T-bet 
and Eomesodermin in licensed vs unlicensed NK cells.  b) Comparison 
of T-bet and eomesodermin in licensed vs unlicensed NK cells from 7 
healthy controls. 
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5.3.8 Unlicensed NK cells express low level of adhesion molecules upon 
stimulation which is partially reversible by IL-2 activation  
 
LFA-1 is a member of the β2 integrin family and is used by cytotoxic T cells and 
NK cells to promote adhesion to target cells, allowing for stable immunological 
synapse formation and enhanced killing.  Particularly in NK cells, the initial 
establishment of LFA-1 interaction with its ligand ICAM1 is a critical step for 
initiating the polarization of NK cell lytic granules toward target cells (247, 248).  
NK cell activation can be broadly distinguished into early actin-independent and 
actin dependent steps, and it is of note that LFA-1 displays unique signalling 
properties in NK cells distinct from T cells, which makes them highly efficient as 
an early responsive receptor.  LFA-1 can be expressed on the cell surface as a 
closed low affinity form or a high affinity active form with an open conformation 
(249).  Whilst T cells require activation before subsequent LFA-1 signalling, 
LFA-1 can transmit its own inside-out signalling in NK cells, providing early 
activation of Vav1 and the MAP kinase pathway independently of actin 
polymerization.  This initial early activation signal promotes the actin dependent 
phase, allowing lateral movement of activation receptors into a concentrated 
cluster of lipid raft, synergizing the activation signals which further amplifies the 
inside-out signal and ultimately overcome the activation threshold whilst forming 
a stable and strong immunological synapse.  LFA-1 has been examined in 
previous studies when screening for licensed and unlicensed NK cell markers, 
however all previous studies use the common CD18 antibody which does not 
detect the CD11a subunit of the active form of LFA-1.  Hence, whether licensed 
and unlicensed NK cells display inherent differences in their adhesive 
capabilities to target cells remains unclear.  Recently, Long et al elegantly 
demonstrated that upon stimulation with target cells, licensed NK cells express 
much higher levels of the active form of LFA-1, and in combination with ICAM 
binding studies identified that this differential response is specifically related to a 
defective inside-out signalling by the unlicensed NK cells (133).  Thus, I aimed 
to further expand on this concept and investigate the individual inside-out 
signalling capacities amongst single-KIR+ NK cells.  Results illustrated in 
Figure 5.7 are in keeping with Thompson et al.’s findings that licensed single 
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KIR+ NK cells have a higher expression of the active form of LFA-1 in 
comparison to their unlicensed counterparts when encountering cellular targets.  
The differential inside-out signalling appears to be NKG2A independent, as the 
co-expression of NKG2A did not appear to compensate for the lack of 
KIR-mediated licensing, in contrast to earlier functional data (figure 5.5).  
Similarly to IL-12, IL-15 and IL-18, IL-2 induces cytokine production but not 
degranulation of NK cells alone.  NK cells stimulated with IL-2 become ‘primed’ 
and will display an enhanced functional response compared to unstimulated, but 
still requires encounter with a cellular target or antibody stimulation where 
activating signals through receptor ligation or loss of inhibitory signal (through 
encounter with an HLA-class I deficient target) is induced.  Hence there is no 
significant difference in high affinity LFA-1 expression between licensed and 
unlicensed subsets when no target is added regardless of addition of IL-2.  
However, interestingly the lower expression of the active form of LFA-1, an 
indication for defective inside-out signalling, was partially reversed by overnight 
stimulation with IL-2 (figure 5.7).   These results are also in keeping with 
previous studies where IL-2 stimulation successfully allowed unlicensed NK cells 
to overcome their functional constraints.  Hence this breaking of self-tolerance 
could be partially explained by the reversal of inside-out signalling.   
   
Figure 5.7. High-affinity LFA-1 expression is differentially expressed on 
licensed vs unlicensed NK cells. Statistical analysis of high-affinity LFA-1 
expression in licensed vs unlicensed subsets, resting vs IL-2 stimulated 
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5.3.9 Differential responsiveness between licensed and unlicensed NK 
cells is not related to differential co-activation signaling  
 
NK cells need an activating signals in the absence of an inhibitory signals in 
order to become activated.  However the activation of NK cells is regulated in 
multiple steps, each specific aspect is regulated by distinct signals that induce 
degranulation and granule polarization.  Ligation of a single activation receptor 
is insufficient to induce killing and cytokine secretory responses, and NK cells 
overcome these activation thresholds by synergizing two or more multiple 
activating signals (42, 250).  CD16, a low affinity Fc receptor that facilitates 
antibody-dependent cellular cytotoxicity, is the sole exception in that the 
activation threshold can be overcome by the ligation of this receptor alone (43).   
In vitro cytotoxicity assays often use cell lines, which inherently express multiple 
ligands for activating signals. However, in antibody cross-linking experiments, 
where the activity of a single activating receptor such as NKp46 or NKG2D is 
examined, the recently established concept of NK receptor synergy is missed.  
Cross-linking of single activating receptor produces a sub-optimal response and 
makes the assessment of the extent of NK licensing very difficult.  Moreover, as 
illustrated by data here and by others, if licensing indeed influences the efficient 
production of inside-out signals (to induce conformational change of LFA-1 to 
active form), it is possible that other inherent differences exist in signalling 
between licensed and unlicensed NK cells.  Hence, I hypothesized that the 
hyporesponsiveness in unlicensed NK cells may be the result of defective 
transduction of co-stimulating signals or a failure of the signals to synergize 
rather than a primary defect in the activating signal itself.  Indeed IL-2-activated 
human NK cells have been shown to induce cell lysis even with the engagement 
of a single activating receptor (251, 252), indicating that activation with IL-2 can 
overcome these activation threshold without the stringent requirement for 
synergy. Bryceson et al extensively studied NK receptor/co-receptor 
combinations and the pair-wise combinations that were compatible or 
non-compatible in promoting a synergistic NK cell response (43).  In this thesis, 
I selected to study the combination of NKp46 and 2B4, as they displayed the 
strongest functional output and hence, the difference between single receptor 
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and dual-receptor cross-linking was most significant.  2B4 is one of the best 
characterized NK coreceptors and is unique in that it displays phase-wise 
transition from an inhibitory status to activating status during NK development.  
Early in NK cell development, 2B4 couples with SHP1, inducing and inhibitory 
signal and suppressed NK cell function during early NK precursor stages. As NK 
cells developmentally mature, SHP1 is replaced by SAP, which when coupled 
with 2B4 transmits an activating signal (39).  One could speculate that licensing 
induces the correct recruitment of SAP to the intracellular domain and a 
functionally mature  2B4 receptor, whilst 2B4 on unlicensed NK cells remains 
coupled to SHP1 and induces hyporesponsiveness.  Therefore, I compared the 
functional output of licensed and unlicensed NK cells after cross-linking with 
NKp46 alone, 2B4 alone or the combination of NKp46 and 2B4 (figure 5.8a).  
The presence of effective co-activation signalling was confirmed as evident from 
the significant increase in degranulation and effector cytokine production by 
NKp46/2B4 synergy signalling compared to 2B4 or NKp46 alone (figure 5.8b). I 
found no significant differences in the strength of the co-activation signals in 
licensed vs. unlicensed NK cells, indicating that. licensing does not alter the 
degree of co-activation signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 169 
Figure 5.8. a) Representative FACs plots for functional induction through 
receptor cross-linking. b) Comparison of functional output in licensed vs 
unlicensed NK cells post receptor cross-linking 
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5.3.10 The adaptor protein CrkL is differentially phosphorylated in 
licensed vs. unlicensed NK cells 
 
In continuation of the signalling work in section 5.3.8 and 5.3.9, the final section 
of this chapter attempts to elaborate the intrinsic differences between licensed 
and unlicensed NK cells at the signalling level.  Identifying the signalling events 
responsible for inducing NK licensing and hence the acquisition of functional 
competence has been an on-going challenge since the concept of licensing was 
first established in 2005.  Studies by Kim et al identified that the ITIM domain of 
the self-inhibitory KIRs are the critical components for NK licensing (140).  They 
also attempted to investigate the signalling molecules that bind to the 
phosphorylated domains upon KIR ligation, which lead to activation of the 
SH2-domain containing protein tyrosine phosphatase-1 (SHP1).  
Disappointingly mouse models with defective SHP1 were found to have normal 
levels of functionally competent NK cells that were comparable to wild type mice, 
suggesting that SHP1 is dispensable for NK licensing (140).  However, the 
motheaten viable mice (mev/mev mice) which was used in this particular model 
had several limitations in the sense that although defective, it contains residual 
levels of SHP1 activity which brought into question the conclusion that 
licensing/education in this model was truly SHP1 independent.  Indeed in a 
previous study using mice displaying complete abolishment of SHP1 activity 
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(achieved by a trans-dominant negative mutation making the SHP1 catalytically 
inactive) NK cells showed decreased response towards MHC class I-deficient 
target cells (253).  Hence, whether SHP1 is truly dispensable for NK licensing 
remained a controversial matter.  Today, nearly after a decade since the first 
report, Viver et al demonstrated in a mouse model with selective deletion of 
SHP1, that NK cells and the NK receptor expressing ILCs are rendered 
hyporesponsive, re-introducing the importance of SHP1 in tolerance 
maintenance and licensing (254).  When the role of SHP1 in licensing was 
originally dismissed by the studies of Kim et al(140), SHIP1 was considered as 
the most likely alternative signalling pathway responsible for NK licensing.  
SHIP1 is a phosphatase that is functionally homologous to SHP1, is recruited to 
the ITIMs and is capable of arresting the activating signaling events through the 
dephosphorylation of Vav1 (255). Until recently, this concept proved practically 
difficult to demonstrate.  More recently, using an NK cell specific SHIP1 
deletion mouse model, SHIP was also shown to play an important role in NK cell 
licensing (256, 257).  However, SHIP1 is also expressed in all hematopoietic 
lineages and it was difficult to test in the germline SHIP1 deficienct mouse 
whether the effect SHIP1 deletion on NK licensing was intrinsic to NK cells alone 
or related to cell-extrinsic effects (e.g altered phenotypes in T, B, DC and other 
sentinel cells).  Now, with the establishment of the new mouse model with NK 
specific deletion of SHIP, the intrinsic importance of SHIP1 in NK cell licensing 
has been confirmed (258). Interestingly, this study by Kerr et al also suggests 
that SHIP1 also influences the development of the NK antigen-specific recall 
response, which is one of the proposed adaptive qualities in NK cells.  
Nevertheless, the current knowledge on the developmental signaling events 
responsible for NK licensing had been restricted to these ITIM associated 
phosphatases as no other inhibitory signaling pathway has been shown to be 
activated following the ligation of inhibitory KIRs.  Dephosphorylation of Vav1 
has also been conventionally studied as the most likely pathway driving the 
licensing process (259).  However, over the recent years, two additional 
inhibitory signaling pathways downstream of KIR ligation that take place in 
parallel to the conventional recruitment of phosphatases to the ITIMs have been 
identified (141),  These novel pathways involve the disruption of the signaling 
 173 
complex consisting of an adaptor protein Crk, guanine exchange factor C3G and 
the E3 ubiquitin ligase c-Cbl.  This cCbl-Crkl-C3G complex in its active form 
plays a role in propagating activation signals downstream of the activating 
signaling pathway.  However upon ligation of ITIM-containing receptors, 
tyrosine kinase ABL1 phosphorylates one of the molecules of this component 
Crk, causing the active complex to dissociate.  Crk forms a complex with ABL1, 
(Crk-ABL) leaving the dissociated complex inactive and the activation signals 
downstream is again disrupted.  In addition to this, the free cCbl which 
dissociates from the complex can also act directly and continuously inhibit the 
phosphorylated Vav1.   
 
Fig.  5.9   Multiple inhibitory signaling pathways are induced by the 
ligation self-inhibitory receptor ligation with MHC class I.  In addition to the 
conventional inhibitory pathway involved in the recruitment of tyrosine 
phosphatase SHP1 to the ITIM domain and subsequent abrogation of Vav1 
mediated activation (Pathway 1), recent studies have revealed two additional 
pathways that are involved in addition to pathway 1.  Tyrosine-protein kinase 
ABL1 phosphorylates Crk, which forms part of the critical signaling complex 
comprising cCbl-Crk-C3G.  Phosphorylation of Crk ultimately causes the 
molecule to dissociate from the signaling complex rendering them inactive and 
no longer able to propagate activation signals (Pathway 2).  In addition to this, 
the cCbl domain of the disrupted complex is also capable of interfering with Vav1 
mediated activation signals (Pathway 3).   
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        Illustration adapted from Hoglund and Brodin., 2010.(13) 
 
Hence the identification of these additional layers of inhibitory influence in 
ITIM-containing receptors expands the possibility of signaling pathway that may 
be involved in NK licensing.  As all three signaling pathways described in Fig.   
5.9 ultimately lead to the termination of common activation signals downstream, 
suggesting that perhaps these molecules function in an integrated manner and 
that the impairment of any single arm may lead to diminished licensing.  The 
previous SHP1 and SHIP1 studies support the concept of integration, rather 
than a process of complementing or redundancy, as the impairment of either 
one of the phosphatases led to significantly compromised functional 
competence (253, 254, 257).  Therefore, in the next set of experiments, I 
focussed on these novel arms of inhibitory signaling, specifically investigating 
the intrinsic role of the adaptor protein CrkL in NK licensing.  Peterson et al. first 
reported phosphorylation of Crk proteins in YTS NK cell lines upon KIR ligation 
with ligand-expressing target cells (141). This work was validated in primary NK 
cells using confocal imaging, whereby using a combination of lipid bilayers and 
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target cell lines expressing HLA-E ligands, they elegantly demonstrated the 
specific accumulation of phosphorylated Crk (dissociated from complex form) at 
the HLA-E/NKG2A inhibitory synapse and also their role in actin-remodelling.  
These observations inspired us to study the differential levels of phosphorylated 
Crk between licensed and unlicensed NK subsets.  I hypothesized that 
quantifying the level of the phosphorylated form of Crk, which indicates the 
dissociation of the cCbl-Crk-C3G complex, should correlate with the degree of 
inhibitory signaling.  Although Long et al demonstrated the phosphorylation of 
Crk through KIR ligation in cell lines, they did not distinguish their licensing 
status, and whilst their imaging studies revealed additional roles for Crk, their 
study only looked at the interaction between NKG2A and HLA-E.  In order to 
distinguish the licensed and unlicensed NK cells I developed a multiparameter 
flow panel in combination with phosflow, assay since obtaining sufficient 
numbers of single-KIR+ cells for western blotting was not feasible), As this was a 
very novel approach to studying NK licensing and no previous data were 
available, a significant fraction of this section was invested in assay 
development and optimization.  I successfully designed a seven-colour flow 
panel that combined surface phenotyping for individual KIRs with phosflow 
assay as described in chapter 2.  
I first focused on the phosphorylation of CrkL amongst the licensed and 
unlicensed (non-self single KIR+ and KIR-) NK cells, by gating on NK cells 
expressing exclusively the KIR of interest.  Regardless of their license status of 
KIR-expressing NK cells, NKG2A+ cells displayed an identical degree of CrkL 
phosphorylation in licensed vs. unlicensed KIR+ NK cells post NKG2A ligation.   
This is consistent with the functional data (Figure. 5.4), whereby all 
NKG2Aexpressing NK cells are significantly inhibited upon co-culture with 
HLA-E expressing cell lines regardless of the license status of KIR+NK cells. 
Specificity of the assay, specific target receptor phosphorylation was validated 
as no increase in pCrkL was seen in NKG2A- NK cells.  Physiologically, these 
data indicate that NK cell function is tightly, such that all functional NK cells have 
at least one inhibitory receptor capable of recognizing self.  As HLA-E displays 
limited polymorphism and is a broadly expressed inhibitory ligand, it is not 
surprising that a similar strength of signaling also derives from the inhibitory 
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NKG2A receptor. NK cells gain functional competence during development 
through the common NKG2A receptor, which in turn becomes fine tuned into 
unique individual KIR-expressing repertoires based on the HLA-type (C1, C2, 
Bw4)(97, 260).  As expected, NKG2A- NK cells did not display an increase in 
phospho-CrkL, meaning these subsets are incapable of receiving inhibitory 
signals.  In combination with the functional data, my data are consistent with 
previous findings that cells lacking self-inhibitory receptors maintain tolerance 
and are hyporesponsive.  In addition to this, phospho-CrkL levels in total 
NKG2A+ NK cells were comparable to the levels found in single-KIR+NKG2A+ 
NK cells..  This indicates a level of redundancy provided by NKG2A, in which 
regardless of the co-expression of other self or non-self KIRs, the signaling 
intensity through NKG2A remains the same (i.e, presence of self or non-self 
KIRs does not enhance or diminish the strength of NKG2A signaling). We then 
proceeded to look at the signaling capacity of each individual KIRs by 
cross-linking with specific KIR mAB..    When KIR-mediated inhibitory 
signaling was artificially induced by antibody cross-linking of individual KIRs in 
PBMC samples, licensed self-KIRs were capable of inducing a stronger signal 
compared to the unlicensed non self KIRs based on phospho-CrkL levels.  
(Figure 10 c. licensed vs unlicensed phospho CrkL p =** 0.0008, 0.0013, 
0.0015, respectively for KIR2DL1, KIR2DL2/L3, KIR3DL1).  The data on 
differential phosphorylation of CrkL amongst self and non-self KIR+ subsets 
were very exciting and support a possible role for CrkL in KIR  licensing.  A 
notable trend was that although the absolute frequency of phospho-CrkL+ NK 
cells varied throughout individuals, there was a notable trend that 
self-KIR2DL2/L3/S3 expressing NK cells appeared to display higher 
phospho-CrkL compared to the self-KIR2DL1 expressing NK cells.  The highest 
phospho-CrkL was seen amongst self-KIR3DL1 expressing cells although with 
significant variation amongst different individuals. 
Such differential inhibitory signaling among different KIR-expressing NK subsets 
is interesting although the data must be interpreted with caution as it cannot 
simply be translated to licensed NK cells being more capable of inducing a 
stronger inhibitory signal.  Indeed it has been suggested that the signaling 
pathway and thresholds required for inhibition of effector function and licensing 
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are very distinct and independent pathways, in which case this experiment only 
confirms the differential signaling in the functional inhibition that KIR2DL2/3 can 
induce a stronger inhibitory signal than KIR2DL1.  Indeed the functional data 
show that licensed single-KIR2DL1 expressing NK cells exhibit higher functional 
output (CD107a, IFNγ and TNFα) compared to licensed single-KIR2DL2/3 
expressing NK cells.  If the functional output (strength of licensing) directly 
correlates to the phosphorylation of CrkL, the results should have been opposite 
and KIR2DL2/3 should have mediated higher functional response than 
KIR2DL1-expressing NK cells. Yawata et al(9) tested various KIR-ligand 
combinations in primary NK cells and established a hierarchy of KIR-ligand 
combinations according to the strength of NK cell licensing.  Here, KIR2DL3+ 
NK cells from C1 individuals displayed a greater missing-self response 
compared to KIR2DL1+ NK cells from C2 individuals,  suggesting that 
KIR2DL3-mediated licensing by C1 allotypes is enhanced to a greater extent 
compared to that of KIR2DL1-mediated licensing by C2 allotypes , in which case 
my data supports this model.  Finally, the CrkL phosphorylation between 
licensed single-KIR+ NK cells and total licensed KIR+ NK cells were comparable, 
suggesting a redundancy amongst the cells similar to NK cells.  From the 
functional perspective NK cells expressing more self-reactive inhibitory 
receptors are known to have greater response potential, however my signaling 
data reveals that co-expression of other self or non-self KIRs does not raise the 
intrinsic level of phospho-CrkL upon stimulation, hence showing no direction 
correlation to function. 
Hence although the importance of CrkL signaling pathways in NK licensing 
would require further confirmation, the differential level of CrkL phosphorylation 
between licensed and unlicensed NK cells strongly support a role for the adaptor 
protein Crk in establishing NK licensing. Long et al demonstrated in silencing 
experiments that Crk was indeed also required for activation playing a role in 
F-actin remodeling for the establishment of activating synapse, and they also 
support the model in which such inherent differences in Crk availability could 
ultimately lead to differences in effector output.  Such hypothesis strongly 
supports my findings regarding higher frequency of active form LFA-1 on 
licensed NK cells (Section 5.3.8), as LFA-1 dependent adhesion is promoted by 
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the small GTPase Rap1, which requires activation by the guanine exchange 
factor component C3G of the cCbl-Crk-C3G complex (261, 262).  
 
Figure. 5.10 a) Representative gating strategy for the detection of 
phosphor-CrkL amongst single-KIR+ NK cells b) Statistical comparison of 
differential phosphorylation of CrkL between self and non-self KIRs 
a) Representative FACs plot demonstrating the exclusion gating strategy 
for identification of single KIRs. 
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b)  Self KIRs induced a greater increase in PhosphoCrkL.  This was 
licensing dependent, as the same KIRs within the population showed 
differential level of CrkL phosphorylation depending on the presence of 
self vs. non-self KIR.   
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5.4 Discussion 
 
       In this chapter I studied the intrinsic mechanisms that 
differentially regulate licensing in NK cells. I showed that in spite of similarities in 
their developmental pathwa with CD8 cytotoxic T cells, NK cells are very distinct 
in terms of their effector phenotype and expression of unique markers such as 
activating receptors and their transcriptional signatures.  Licensing is also 
distinct from maturation/differentiation, and hence cannot be defined based on 
markers of maturation/differentiation (e.g. CD57)(263).  In my experiments, I 
successfully demonstrated that cord blood NK cells are licensed based on 
self-KIR and cognate HLA-class I expression; these data support my hypothesis 
and the clinical data presented in chapters 3 and 4.  My results also extend on 
those of Uhrberg et al (107) and includes additional information on cytokine 
production, revealing that cord blood NK cells are licensed with a dependency 
on NKG2A co-expression. Peripheral blood NK cells initially acquire functional 
competence through the broadly expressed NKG2A receptor, followed by self 
specific KIRs which fine-tunes the degree of functional competence in a more 
unique manner to the individual(264, 265).  As NKG2A down regulation occurs 
in parallel to KIR up regulation, creating a gradual shift from non-specific to the 
more self-specific receptor and ultimately KIR+NKG2A- NK cells dominate the 
repertoire in PB with loss of dependence for NKG2A.  However, the data from 
this chapter suggest that cord blood NK functions are still highly dependent on 
NKG2A+ co-expression.  Although single-KIR+ NKG2A- subsets were 
identified within the cord blood population, these were extremely low in numbers 
and displayed extremely low functionality, particularly with regards to cytokine 
production. This is in contrast to PB NK cells that are NKG2A independent.  
Hence although cord blood NK cells appear post-licensed and are inhibited upon 
encounter with their cognate ligand, it cannot be ruled out that cord blood NK 
cells follows a distinct developmental pathway and hence the developmental 
intermediates represented based on KIR and NKG2A expression could be very 
different to ,their PB equivalent.   
This chapter also shed light on the possible differential signals regulating 
licensed and unlicensed NK cells, particularly regarding their adhesion 
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properties and the possible role of CrkL .  Initially, CrkL was reported to have a 
central role in functional inhibition of NK cells. However, my data point to a 
potential role of CrkL in the developmental calibration and functional 
competence of NK cells.  Additional studies are needed to define a signalling 
phenotype for licensed vs. unlicensed NK cells.  In summary, despite 
advancements in clinical applications of NK cells in the treatment of cancer, our 
fundamental understanding of NK cell development and mechanisms of 
licensing remain greatly unexplored.  In order to develop novel NK cell 
immunotherapy for the treatment of cancer, it is imperative to fully elucidate the 
functional properties of licensed and unlicensed NK cells and mechanisms that 
regulate their function.  
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CHAPTER 6 Conclusions and Future work 
 
6.1 Conclusions  
 
A number of epidemiological studies have explored the association between 
KIR/HLA genotype and disease outcome(33, 158, 266-268). However, these 
studies are limited by a lack of plausible mechanistic information for the reported 
observations. The data presented in my thesis attempts to address some of 
these deficiencies by combining large KIR/HLA association studies in the setting 
of double cord blood transplantation with extensive phenotypic and functional 
characterization of the reconstituting alloreactive NK cell repertoire capable of 
mediating potent GvL at the single cell level with the use of multiparameter flow 
cytometry.  In summary, the achievements and novel findings demonstrated in 
this thesis are as follows. 
 
1. In chapter 3 I determined the size of the alloreactive NK cell pool 
reconstituting in recipients following double cord blood transplant.  
Recipients were stratified into 2 groups based on their HLA-C allotype. I 
showed that HLA-C2/C2 homozygous groups were particularly susceptible 
to increased risk of relapse, with the probability of relapse free survival 
improved with the presence of HLA-C1 allele, regardless of copy number 
(HLA-C1 homozygous and heterozygous displayed comparable protection).   
Relapse-free survival was further improved when patients received a graft 
with the combination of a licensed KIR2DL2/3 and the corresponding 
activating KIR2DS2/3 genes.  These differential outcomes were revealed to 
be due to the earlier acquisition of KIR2DL2/3 expression on the surface of 
NK cells, permitting HLA-C1/C1 recipients to a more enhanced 
reconstitution of quantitatively and qualitatively competent NK population. 
 
2. In chapter 4, I characterized the CMV associated NKG2C+ NK cells in 
patients post DUCBT.  Lower incidence of CMV reactivation positively 
correlated with the presence of NKG2C gene in the cord graft in a dose 
dependent manner, which also correlated directly to the expression levels of 
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NKG2C receptor on the surface of NK cells.  NKG2C w/w homozygous 
recipients displayed a lower incident rate of CMV reactivation compared to 
w/d heterozygous recipients respectively.   
 
3. In chapter 5, I explored defined novel attributes of NK cell 
licensing/educations in peripheral blood and cord blood NK cells.  My 
studies revealed that cord blood NK cells have already undergone the 
process of licensing/education.  Licensed and unlicensed PBMC NK cells 
were unable to be distinguished at the level of surface markers and 
transcriptional signatures, in conjuction with current perspecitves of NK 
development.  Licensed and unlicensed subsets were only distinguishable 
through differences in conventional functional output (measuring 
degranulation and cytokine production) but also revealed novel differences 
in adhesion properties.  The chapter also opened possibilities for adaptor 
protein CrkL to be a promising candidate partially responsible in providing 
the potential transient signal in NK licensing.  Phosphorylated CrkL 
molecules plays an inhibitory role by disrupting actin-dependent activation 
signaling pathways, but are also known to assist activating receptor 
realigning and hence enhance activation capacity.  Phospho-CrkL 
signaling during early NK cell development may set an inhibitory threshold 
and predisposes NK cells to respond more efficiently when the inhibition is 
removed.  Removal of inhibition under ‘missing self’ conditions would allow 
efficient rearrangement and engagement of activation receptors in licensed 
self-KIR expressing NK cells, whilst unlicensed NK cells will remain 
hyporesponsive with low CrkL recruitment (due to lack of KIR ligation).   
Such regulation of signaling may be responsible for differential functional 
output between licensed and unlicensed NK cell subsets. 
 
With the concept of NK licensing beginning to be appreciated considerably in the 
outcome of transplant settings, it is expected that increasing number of trials will 
explore the use NK cell immunotherapy.  
The results generated in chapter 3 have defined the mechanisms underlying the 
observed effects of different KIR-HLA combinations on clinical outcome in 
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patients after CBT. This achievement will empower us to move forward with 
clinical interventions such as infusing NK cells post-CBT and could shift the 
paradigm in constructing algorithms for the selection of the best available CB 
unit for transplantation to include the specific pattern of expression of KIR-HLA 
genes and its prediction of NK cell activity against leukemic targets. The 
demonstration of delayed recovery of C2-specific (KIR2DL1+ve) NK cells in 
patients homozygous for HLA-C group 2 will compel us to develop a clinical trial 
to expand and infuse activated mature CB-NK cells, expressing the C2-specific 
NK receptor KIR2DL1, into HLA group C2 patients in the peritransplant or 
immediate post-CBT period, using currently available robust, GMP-compliant, 
clinical-scale expansion procedures.  
Based on results in chapter 4, we also propose that NKG2C genotype of the CB 
units to be a reliable biomarker in predicting incidence of CMV reactivation in the 
double UCBT settings, and anticipate that the implementation of NKG2C 
genotype in the CB unit selection process may provide beneficial clinical 
outcomes. 
 
I propose that future studies should also focus on the role of HLA and KIR 
polymorphisms, since specific allotypes may display differences in their surface 
expression levels and ligation capacity, which in turn could greatly alter the 
degree of NK licensing.  This would be an additional concept further 
complicating the prediction of NK cell licensing.  Not only should the HLA-KIR 
pair be considered, but also taking into account the polymorphism of HLA alleles 
which could lead to differential licensing, similarly to TCR binding (weak, optimal 
and excessive).  Currently it is becoming apparent that different allotypes of the 
same HLA class display differing specificity towards their cognate KIR, resulting 
in a hierarchy in the strength of NK cell licensing/education (most well studied 
example being the combination of KIR2DL3 and HLA-Cw*07 which provides the 
strongest licensing effect, followed by Cw*12 and B*46)(9, 269).  Simiarly, even 
in HLA-E molecules which display minimal polymorphism, the HLA-E*01:03 
variant is found to have a significantly higher surface expression and stronger 
peptide binding to NKG2C, which is ultimately associated with protection from 
chronic autoimmune disorders such as psoriasis development(270).  Therefore, 
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the future of NK cell studies in the translational settings requires a wider concept 
of awareness, taking into account HLA-KIR mismatch and also polymorphisms 
of both receptor and ligand to accurately interpret the data generated. 
 
6.2 FUTURE WORK 
 
Improved methods for the ex vivo expansion/activation of NK cells and the 
selection of donors based on KIR-ligand mismatch have led to increased interest 
in exploring the potential of NK cells in clinical therapies, particularly in 
hemato-oncology. Most studies of NK cell recovery after transplantation are 
limited to the enumeration of NK cells, and even if phenotyped the concept of NK 
cell licensing/education is very rarely taken into account.  I would like to 
continue to challenge this misconception by addressing the importance of NK 
cell regulation at the early stages of development and maturation, providing 
insights into NK licensing/education of CB and PB NK cells.  Up until recently, 
classical NK licensing studies have been restricted to the use of direct cellular 
cytotoxicity and cytokine production using isolated NK cells (14, 129, 140).  The 
ability of NK cells to cross-talk with other cells such as dendritic cells, neutrophils, 
T cells has been described by many in the field (271-274); however, information 
on the influence of NK licensing in this setting is very limited.  As NK cells play a 
critical role in bridging the innate and adaptive arm, providing insights into the 
strict and detailed regulation of these interactions would greatly be beneficial in 
harnessing the full potential of immune responses.   
My future plans are to investigate the impact of NK cell licensing/education on 
the NK cell cross-talk with other cells.  I hypothesize that NK 
licensing/education could have a profound influence on the ability of NK cells to 
communicate and thus, regulate cells in the same niche rather than have a 
restricted influence on only itself, which would be biologically inefficient.  Indeed 
there have been recent reports demonstrating the differential capacities of NK 
cells to cross-talk with other cell types depending on their license/education 
status.  Cook et al reported that dendritic cell activation is strictly regulated by 
licensed but not unlicensed NK cells in a TNFSF14/LIGHT dependent manner, 
which is a TNF 14 superfamily axis involved in the co-stimulation to induce DC 
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maturation (275).  I am also interested in exploring the role of NK cells in 
autoimmunity; specifically, the involvement of NK cell licensing in T cell 
differentiation.  A study performed in a cohort of Crohn’s disease patients, 
reported that licensed and unlicensed NK cells have a differential cytokine profile, 
with licensed NK cells being better producers of cytokines which induces Th17 
skewing (276).  This study was unique in the sense that their investigation went 
beyond studying the orthodox functional properties of NK cells and instead, 
linked NK licensing to the involvement of specific T cell lineage, namely Th17 
cells.  Th17 cells represent a pathogenic subset of CD4 T cells that have been 
reported to be involved in the pathogenesis of a number of rheumatological and 
orthopaedic disorders. Thus, studying the contribution of NK cell licensing to the 
pathogenesis of autoimmune disease may provide mechanistic information on 
NK-Th17 cross talk and their role in autoimmunity. 
 
Fig. 6.1 Licensed NK cells promotes naïve CD4+ activation and augments 
the differentiation into Th17 lineage.  Microfluidic analysis of licensed and 
unlicensed NK cells revealed licensed NK cells to be producing a significantly 
wider variety of cytokines including that of Th17 skewing potential (IFN, TNF, 
IL-6)(a).  Supernatants collected from licensed NK cell cultures augmented T 
cell proliferation and polarized differentiation to a IL-17/IL-22 producing Th17 
axis ex vivo (b).  Such observation was absent in supernatants collected from 
unlicensed NK cells.   
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     Adapted from Lin et al., 2014(276) 
 
In addition, the study of NK cross-talk could ultimately lead to the discovery of 
the cell types responsible for the NK licensing/education process, which is one of 
the major questions that remain unanswered by NK researchers.  Although it 
has been demonstrated that NK cells could indeed be licensed by the relevant  
HLA-class I epitopes expressed on themselves, both cis and trans manner(20), 
myeloid cells and neutrophils have been shown to play a significant role in NK 
licensing, as shown by recent data that depletion of these subsets results in a 
significant impairment in NK development and functional competence (277-280).   
 
Secondly, I would like to consider the possibility that perhaps licensing may also 
extend to other cellular processes which have not yet been considered, and I 
hypothesize that trogocytosis may be affected by licesning.  Trogocytosis, an 
acquisition mechanism utilized by NK cells to transfer membrane components 
from neighbouring target cells, is a critical process which allows the alteration of 
phenotypic and migratory properties of NK cells (281).  It is now becoming 
apparent that this exchange is strictly regulated by the specific interaction 
between KIRs on NK cells and the corresponding HLA-class I on the target 
proximal cell.  Marcenaro et al reported that CD56dim NK cells expressing 
inhibitory KIRs had significantly less trogocytosis capacity, thus preventing the 
interaction and acquisition of CCR7 from CCR7+ cells (282).  Such properties 
observed strongly suggests an involvement of licensing/education in regulating 
trogocytosis.  Theoretically, it is possible that CD56dim NK cells lacking 
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self-inhibitory KIRs and hence lacking inhibition should be promoted to acquire 
CCR7; thus, enabling them to migrate in response to chemokines.  As 
unlicensed NK cells are already known to respond to cytokines more readily 
than their licensed counterparts, this property of selective recruitment through 
enhanced trogocytosis to cytokine rich secondary lymphoid organs could 
perhaps explain their physiological purpose.  Perhaps functionally competent 
licensed NK cells are selectively programmed to remain in the periphery for 
surveillance, whilst unlicensed NK cells (KIR negative) are susceptible to lymph 
node homing which may permit over-riding of hyporesponsive state through 
cytokine activation.  A more precise understanding of the mechanism and 
induction of trogocytosis can have clinical benefits and novel approaches to 
laboratory protocols, such as the acquisition of chimeric antigen receptor 
through manipulation of the process as Cho et al demonstrated (283).  Other 
possible cellular processes which might display differential patterns between 
licensed and unlicensed subsets could be the degree of metabolic regulation 
such as aerobic glycolysis.  In T-cells, an efficient differentiation of memory T 
cells involves a transition of metabolic regulation, namely a switch from 
glycolysis to fatty-acid metabolism (284).  Metabolic pathways in NK cell 
maturation and function has not been extensively studied.  Moreover, whether 
licensing is an energy consuming process requiring biosynthetic precursors are 
not known.  Perhaps a similar differential metabolic phenotype is apparent 
between NK licensing and unlicensed subsets.  
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Fig. 6.2 Metabolic differences between effector, Tregs and memory T cells.  
T cell cycle involves a dramatic remodelling of the metabolic pathways during 
development, where metabolic phenotypes ultimately integrate with T cell 
function and differentiation.  Upon stimulation, CD4+ and CD8+ effector T cells 
upregulate glucose uptake and glycolysis to meet the high demands for growth 
and proliferation. Metabollic transition is observed in Tregs and CD8+ memory 
cells which burn lipids through b-oxidation (b-ox) in the mitochondria and 
generate ATP through electron transport and oxidative phosphorylation 
(ET/OXPHOS) instead.  Such posttranslational and epigenetic remodelling may 
also exist between licensed and unlicensed NK cells. 
 
             Adapted from Gerriets et al., 2012(284) 
 
Finally, I would like to continue my pursuit in identifying the key signalling events 
leading to NK licensing/education.  In keeping with the data reported by Guia et 
al where pan-genomic microarray analysis showed minimal differences in 
transcriptional factors in licensed vs. unlicensed NK cells (246), the data from 
chapter 5 of this thesis strongly suggest that NK licensing is likely modulated by 
transient signals as proposed by Long et al., making NK cells susceptible to 
further modulation in an altered HLA-class I environment.  Such tuneable 
modulation has been reported in mouse models, where transfer of dysfunctional 
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NK cells from an MHC deficient mouse in to a wild type mouse (MHC positive 
environment) demonstrated a gain in functional competence (17).  Another 
independent study challenged the concept in the opposite direction, where the 
transfer of functionally competent NK cells from a wild type mouse into an MHC 
deificient model resulted in the NK cells losing functional competence (18).  
Hence current perspectives of NK licensing/education strongly suggest that the 
molecular differences between licensed and unlicensed subsets must be 
investigated beyond simple expressions of transcription factors displaying 
comparable levels, and instead extended to studies of epigenetic mechanisms 
and chromatin modifications.  This thesis attempted to dissect one possible 
modification mechanism, phosphorylation, focusing on the candidate adaptor 
protein CrkL and its differential phosphorylation response between licensed and 
unlicensed NK cells, but there are many other possibilities. Phosphorylation 
provides much finer temporal and spatial regulation than merely the presence or 
absence of a molecule: Local Crk phosphorylation may disrupt F-actin at the 
center of the inhibitory synapse, while allowing formation of a peripheral F-actin 
ring (285).  Repressive modifications at the epigenetic level are critical 
mechanisms in maintaining cellular integrity in T cells (286), where 
lineage-promiscuous genes are decorated with histone methyltransferases in a 
repressive manner (repression of IL4 gene in Th1 cells, Ifnγ gene in Th2 
accordingly)(287).   Similarly, it is reasonable to speculate that transcription 
factors of licensed NK cells may have intrinsic differences in modification 
patterns, at the level of various histone modifications; namely, methylation, 
acetylation and ubiquitination which could be associated with both induction or 
repression of certain genes.   
Recent data suggest licensed and unlicensed NK cells have specific roles at 
different phases of immune response (171, 288, 289).  At the early stages of 
infection, licensed cytotoxic NK cells play a predominant role in eliminating 
infected cells at the sites of infection, while unlicensed cells commit to the 
promotion of DC expansion in the lymph nodes to enhance antigen-specific T 
cell responses. In contrast, at the late stages of infection licensed NK cells 
extends to an immunoregulatory role by lysing antigen-specific T cells at both 
the site of infection and the lymph nodes, while unlicensed NK cells migrate to 
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the sites of tissue damage to aid IL-22 mediated tissue repair. These 
observations by Sunger et al. collectively suggest that licensed NK cells have an 
effector/suppressor function while the unlicensed NK cells function as the 
helper/repair population.  Recognizing beyond the conventional CD56+CD3- 
bulk NK phenotype and harnessing the distinct effector properties of licensed 
and unlicensed NK cells as two independent populations could have significant 
impact as a ‘tailored’ immunotherapy.  Specific subsets can either adoptively be 
transferred or therapeutically targeted clinically to aid in different stages of 
immunological response, including viral infection, transplantation associated 
complications such as GvHD, and even for tissue repair and regeneration. 
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